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ABSTRACT
The SL 12 murine T-lymphoma cell line established by M acLeod et. al., has 
two sister clones SL 12.3 and SL 12.4. These two cell lines with similar 
amount o f DNA have been shown to have different surface antigens, 
tumourigenicity and pattern o f metastasis. This was thought to be due to 
differential expression of genes, either repressed or activated, by the two cell 
lines.
This study has re-established the SL 12.3 and SL 12.4 cell lines, hi tissue 
culture, both cell lines grow well in suspension in modified Dulbecco 
medium (DMEM). SL 12.4 cells grow in clumps whereas SL 12.3 cells 
grow diffusely in vitro. Growth curves of SL 12.3 and SL 12.4 cell lines 
over five days show similar characteristics but with wide variation in 
SL 12.4 cell counts resulting in large standai*d error of mean. Clmnping of 
SL 12.4 cells may be responsible for this variation due to cell counting 
difficulties. Therefore, although growth curves between the two cell lines are 
shown to be similai; it is not possible to conclude that the growth rates and 
cell doubling times are identical.
In macroscopic studies, mice injected with 10^ SL 12.3 cells via the tail vein 
deteriorate over a median of 17 days (range 11 to 24 days). All mice (100%) 
have huge hepatosplenomegaly. On the other hand, only one mouse (9.1%) 
injected with similar number of SL 12.4 cells deteriorated with métastasés at 
22 days. When the inoculum o f SL 12.4 cells was increased to 10^ cells, 
78.5% o f mice developed metastasis over a median of 48 days (range 31-56
days). M étastasés were seen in ovaries, kidneys and lymph nodes 
macroscopically in contrast to SL 12.3 cells. Microscopically, it was found 
that both SL 12.3 and SL 12.4 cells were similarly distributed in various 
organs that were not involved macroscopically indicating that the observed 
differing pattern of metastasis is more likely to be due to differential Tn- 
organ’ gi'owth rates rather than cells homing to a particular site after 
injection.
This hypothesis was Jhirther investigated by in vivo cellular tracking studies 
using ^^^lUDR labelled cells. The mean number of SL 12.4 cells per gi'am of 
wet tissue was foiuid to be higher in ovarian tissues at 60 minutes post 
injection but after 3 hours post injection, both cell lines showed no 
significant differences in tissue distribution. This again suggested no 
evidence of a Tioming' phenomenon. However, the highest possible mean 
percentage of incorporation of radioactive label into these cell lines was 
6.9% for SL 12.3 cells aiid 4,8% for SL 12.4 cells at 2.0 ).iCi/ml o f ‘^ ^lUDR. 
The percentage of incorporation was poorly reproducible and this maikedly 
reduced the sensitivity of tire study producing wide variation making the 
data interpretation difficult and therefore, conclusion based in the data non- 
valid.
Molecular characterisation of the two cell lines was performed using the 
teclmique of Differential Display to further investigate the possibility of 
differential gene expression or repression that could be responsible for the 
differing in vivo growth rates. Three cDNAs band of interests were isolated 
from the two cell lines. Bands A and C were exclusively expressed in
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SL 12,4 cells and SL 12.3 cells respectively. Band D is expressed more in 
SL 12.4 cells.
To fLirther characterise these thi'ee cDNAs, reamplification was attempted 
using the TA cloning system. Despite changing parameters such as 
vector/insert ratios and PCR cycles, it was not possible to amplify these 
clones using this technique as multiple attempts repeatedly produced false 
positive colonies with bhmt ligation at the plasmid ECoRI sites. The tliree 
cDNAs (bands A, C and D) were finally reamplified directly using PCR 
with extended primers.
Comparing with available genetic databases (Embank and Genbanlc), Band 
A has weak homology to tyrosine kinase gene in Elydra vulgaris (66.7 % 
identity with 63 nucleotide overlap) and ERCC2/XPD gene in Xiphophoriis 
maculatus (55.9 % identity with 128 nucleotide overlap). Both these genes 
are important in cancer as mutation in tyrosme kinase and the ERCC genes 
can result in uncontrolled cellular proliferation (Cadena, 1992) and impaired 
DNA repair (Weeda, 1997) respectively. Band C has weak homology to 
transforming protein gene in Caenorhabditis elegans (56.9 % identity with 
102 nucleotide overlap). The expressed proteins of these mutated genes are 
able to interact with other cellular proteins to transform the cells to become 
cancerous (Darnell, 1990). Lastly Band D has weak homology to the gene 
for proliferin related protem (59.7 % identity with 159 nucleotide overlap). 
This protein is known to be homologous to the prolactin growth family and 
is expressed by several murine cell lines and placenta (Linzer, 1985). Their 
function is luiknown but their association with the prolactin growth family 
suggests their importance in cancer (Reynolds, 1997).
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These tliree sequences are now available for further studies, initially by 
Northern blotting to confirm differential expression and subsequently, used 
to further probe the mouse cDNA libraries to identify the complete gene 
sequence which then would allow characterisation of their protein fmiction 
using tecliniques such as transfection studies and 'knock-out' transgenic 
mouse models. The teclmique established in this thesis o f differential display 
and direct sequencing can be extended to investigate human tumour models 
to isolate cDNAs that are responsible for the tumour pattern of metastasis 
and tumourigenicity.
QUOTATION
When a plant goes to seed, 
its seeds are carried in all directions; 
but they can only live and grow  
i f  they fa ll on congenial soil "
(Mr. Stephen Paget, Lancet 1889)
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X V I
Chapter I Metastasis: The Process
In troduction
The word 'M etastasis' is Greek in origin and is defined by The Borland's 
Medical Dictionary as the transfer o f disease from one organ or a part to 
another not directly connected to it and the transfer could be of pathogenic 
micro-organism (as in tubercle bacilli) or cells (as in malignant tumours) 
(Borland 1981). It was initially used by Reclaimer in 1829 (Reclaimer 1829) 
when he applied it to a growth in the brain of a patient who also had breast 
carcinoma.
In 1903, Schmidt (Schmidt 1903) studied the process in detail and clearly 
described all its morphological aspects including cellular invasion, 
intravasation, arrest, extravasation and formation of secondary growths in 
new sites. Today, from reconstruction o f surgical biopsies and post mortem 
specimens, we believe metastasis to be a complex multistep cascade process 
with potentially rate Ihniting steps. Tumour cells have to complete all steps 
in order to metastasise and failing in any of them will eliminate the process 
(Liotta 1985). M etastasis is, therefore, not an adaptive process but appears 
to involve selection o f pre-existent tumour cells with higher metastatic 
potential that could complete all steps (Nicholson 1982; Talmadge 1982). 
The outcome o f the event also depends on factors such as the host's immune 
response and the compatibility o f the new site.
The clinical significance of metastasis
A review on six hundred and forty-five colorectal carcinoma cases by 
McArdle et al showed that one quarter o f patients presenting with colorectal 
carcinoma for the first time already had distant métastasés (McArdle 1990) 
and one half o f patients with tumours showed some signs o f tumour fixity at 
their first presentation. The overall five year survival rate for colorectal 
cai'cinomas is about 25-30 % after surgery (Nigam 1994) and the five-year 
survival rate for 'curative' surgical resection is no more than 50 %. If  liver 
métastasés are present, the median survival is about six months (Nigam 
1994) and only about 1-3 % of all colorectal carcinoma patients benefits 
fiom hepatectomy for liver metastasis (Scheele 1993).
Furthennore, results fiom other alternative treatments such as regional or 
systemic chemotherapy for métastasés are also poor with only about 15-20% 
of colorectal car cinomas responding to systemic chemotherapy with 
marginal benefits in terms o f survival (Nigam 1994).
Such poor response to available therapy is not surprising as it has been 
estimated that by the time visceral métastasés are diagnosed, these lesions 
are about one cubic centimetre containing about a billion cells. Any therapy 
that could destroy 99.9 % of these cells is, therefore, not sufficient to 
produce a cure as it still leave a million cells to proliferate and generate 
farther variant resistant cells (Fidler 1985). As a result, most deaths fiom 
cancer are due to the uncontrolled growth of métastasés resistant to therapy 
(Poste 1980; Fidler 1985).
The mechanism of metastasis
The process o f metastasis involves eight distinct steps: cellular separation, 
local invasion, angiogenesis, mtravasation, distribution, lodgement, 
extravasation and seeding (Liotta 1985; Fidler 1988; Fidler 1990; Kerb el 
1990). These steps are not mutually exclusive to each other and do not 
necessarily have to occur in the order as described. However, a cell has to 
complete all steps before it can metastasise (Liotta 1985; Fidler 1990).
Metastatic cells detach themselves from the tumour mass and invade 
surrounding parenchyma, blood and lymphatic vessels. During this time, 
new and abnormal blood vessels are developing, feeding the expanding 
tumour. The metastatic cells then mtravasate mto blood or lymphatic vessels 
and are carried to all organs. At the new site, the cells lodge, extravasate and 
hivade the surrounding parenchyma. N ew  deposits begin to grow and later 
the whole metastatic process can be repeated: metastasis'from métastasés 
(Figure 1.1).
Figure 1.1 The metastatic process
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(1) Cellular separation
Normally cells, excepting haemopoietic cells, are bound tightly to each other 
by cellular surface proteins resulting in little or no movement possible 
between them. Malignant cells, on the other hand, have weaker intercellular 
binding and a lesser force is required to separate one malignant cell from 
another (Coman 1944). This weakness in intercellulai’ binding is important 
as it directly relates to the number o f cells that are able to separate from the 
main tumour mass (Elvin 1982). For example, it has been shown 
experimentally that trauma or even just massage to a tumour mass can lead
to an increase in the release o f tumour cells into the venous outflow (Liotta 
1974). Recent studies have shown that adhesion molecules, such as 
E-Cadlierm, play an important role in maintaining this intercellular binding 
and a decreased in E-Cadherin expression has been associated with an 
increased metastatic potential (Jiang 1994).
(2) Local invasion
The process o f local mvasion by tumour cells depends on eellular growth, 
motility and tissue destruction (Evans 1991). During this period, tumour 
cells proliferate rapidly resulting in an expanding mass that exerts local 
pressure on surroimdmg tissue. Unlike benign tumours (e.g., fibroadenoma 
o f the breast) which stop at this stage, malignant tumours continue to 
expand. The mechanical pressure, produced by the rapid expansion, forces 
finger-like cords o f tumour cells along the lines o f least resistance (Fidler 
1987).
Invasion is also an active process of tissue destruction involving degi adative 
enzymes such as proteases. These proteolytic enzymes hydrolyse peptide 
bonds of connective tissues, thus, facilitating local invasion into sun'ounding 
tissues. Tumour cells pass tlrrough the basement membrane, eventually 
makmg their way to blood or lymphatic vessels. It is now believed that 
tmnour cell invasion is not solely due to the deregulated production of 
proteases but also to an unpaired balance between local concentration of 
active proteases and the levels o f their inhibitors, the tissue inliibitors of 
metalloproteinase (TIME) (Waxman 1992). -
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Four major classes o f proteases have been described namely Aspartic,
Serine, Cysteine and Metalloproteinase. The important proteases involved 
principally in tumour invasion are serine protease plasminogen activator 
(Ossowski 1983b), cysteine protease catliepsinB (Sloane 1986) and the 
metalloproteinase collagenases (Liotta 1979).
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Plasminogen activator (PA)
Plasminogen activator may also have a role m the degradation of basement 
membrane both directly and indirectly (Figure 1.2). Directly, it degrades 
various glycoprotein and proteoglycan components o f basement membranes. 
Indirectly, it converts plasmmogen to plasmin, which in turn activates latent 
type IV collagenase activity that also results in the degradation of basement 
membrane (Evans 1991).
The important role o f plasminogen activator in local invasion is ftirther 
supported by studies on the mvasion o f human amnion by B16-BL6 murine 
melanoma cells. Invasion is inhibited with anti-urokinase antibodies, 
plasmin inhibitors and collagenase inhibitors (Mignatti 1986). In addition, 
plasmin also causes degradation of fibrin and the resulting fibrinolytic 
activity correlates with the experimental potential of B16 mouse muiine 
melanoma cells to metastasise (Wang 1980).
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Figure 1.2 The role of plasminogen activator in the degradation of plasma membrane
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Degradation of basement membrane
Cathepsin B
This cysteine protease is foimd normally in lysosomes but is also secreted in 
large amount by tumour cells. Cathepsin B functions optimally at pH 7.0 and 
degrades basement membrane components such as glycoproteins, 
proteoglycans and collagen type HIV. It also appears to be able to activate 
latent procollagenase (Evans 1991). Cathepsin B-like activity has also been 
correlated with metastatic potential in B16 melanoma cells (Sloane 1984).
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Metalloproteinases
The Metalloproteinases are a group of multidomain, zinc binding and calcium 
dependent lytic enzymes which cleave tissue coUagens (Types I, H, III, IV 
and V), gelatin, fibronectin, laminin and proteoglycans (Nagase 1992; 
Yoneda 1994) imder normal conditions of body pH and temperatrue. hi local 
invasion, metalloproteinases also promote cellular separation from the primary 
tumour'. The classification of metalloproteinases is based on thefr substrate 
specificity. Two collagenases, two gelatinases, three stromelysins and 
matrilysin have been described (Nagase 1992; Yoneda 1994).
Interstitial collagenases degrade collagens type I, II and III, gelatinases 
degiade gelatin and type IV collagen and stromelysins degrade 
proteoglycans and collagen type IV (Hart 1992). Besides playing an 
important role in tumour invasion, metalloproteinases have also been 
associated with normal physiological processes such as morphogenesis, 
angiogenesis, uterine involution and cervical softening (Waxman 1992)
Increased in tissue concentration of metalloproteinase messenger RNA or 
immimoreactivity has been described in cancer o f the skin, blood, 
endometrium, ovaries, stomach, colon, prostate, breast, lung, thyroid, head 
and neck (Yoneda 1994), In these cancers, the mcreased concentration of 
metalloproteinases is found to correlate with their mvasiveness and their 
metastatic state (Waxman 1992).
8
(3) Angiogenesis
Angiogenesis or the formation o f new blood vessels is one o f the commonest 
physiological responses o f tissues to injury and is seen classically in 
granulation tissue. In tumour growth angiogenesis is required if the tumour 
mass were to grow beyond two millimetres in diameter as the transport of 
nutrients and waste products is not efficient enough beyond this distance by 
difhision alone (Hart 1989; Hart 1992). This neovascularisation process is 
induced either directly by tumours releasing angiogenic factors (Folkman 
1989) or by the tumour stimulating h o sf  s cells such as macrophages to 
release the angiogenic factors.
Angiogenic Factors
Regulation of angiogenesis is a balance between the effects o f a number of 
angiogenic factors. Vascular endothelial cells growth factor or VEGF is a 
known angiogenic inducer in several in vivo systems (Alessandro 1995) and 
has been shown to be overexpressed hi human tumours such as colon, 
breast, Imig and bladder cancer (Alessandro 1995). hitraperitoneal injection 
of anti-VEGF antibodies inhibited growth of liver metastasis of a human 
colon carcinoma model (Wan'en 1995).
The major groups of angiogenic peptides that have been isolated are 
fibroblast growth factor (FGF) (Sliing 1984; Shing 1985), low molecular 
weight products such as nicotmamide (Kull 1987), platelet derived 
endothelial cell growtli factor (PD-ECGF) (Ishikawa 1989),
9
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epidermal growth factor (EGF) and transforming growth factor - a  (TGF- a )  
(Evans 1991).
10
1
f i .SJ-
(4) Distribution
M etastatic cells can be distributed to distant tissues by direct extension, 
lymphatics or the haematogenous route (Willis 1973). It is widely 
recognised that certain tumours (such as sarcomas) prefer to spread by the 
haematogenous route whereas other tumours such as carcinomas spread by 
the lymphatic route. However, tliis is not necessary true as there is 
substantial evidence showing that malignant cells pass freely between 
lymphatics and other vessels (Poste 1980; Fidler 1987).
Direct extension
In this process, tumour cells extend directly and progiessively from the 
primary tumour mass to mfiltrate distant tissues via natural routes, fascial 
planes and neural sheaths (Poste 1980). In body cavities, they may seed 
directly onto cellular surfaces such as pleural and peritoneal membranes 
(Poste 1980). Common examples o f such transcoelomic spread are often 
seen m gastric and ovarian tumours.
Spread via lymphatics
III this process, invading tumonr cells mteract with the exterior surface of the 
endothelium lining lymphatics (DeBryun 1979; W arren 1980). As 
lymphatics are thin walled structures, they offer relatively little mechanical 
resistance to penetration by tumour cells (Poste 1980). Once within the 
lymphatic system, tumour cells are filtered by groups of mtervening nodes. 
Tumour emboli could either be trapped by the lymph nodes or evade the 
filtering mechanism and metastasise to distant organs, the '‘skip'' metastasis 
(Fidler 1987). Eventually, the cells are drained into the systemic circulation.
The lymphatic system m general and lymph nodes in particular, play an 
important role in controlling metastasis. Lymph nodes are immunologically 
reactive in patients with neoplasm and usually become clinically enlarged 
and palpable (Fidler 1987). Unlike angiogenesis, no factors have been 
described which induce the formation of new lymphatic chamiels.
(5) Intravasation
In this process, invading tumour cells attach themselves to the collagen Type
IV and proteoglycan components o f the basement membrane of venules and 
capillaries. Entry mto the circulation is then facilitated by the release of lytic 
enzymes such as collagenase and hepai anase to produce degradation of the 
basement membrane (DeBryun 1979; Warren 1980). Ultrastructural studies 
have shown that endothelium of tumour-associated blood vessels are usually
11
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defective and as such are susceptible to tumour cell penetration (Poste
1980).
After intravasation, tumour cells are either carried away passively or may 
stay at the site o f penetration and continue to shed emboli into circulation 
(Poste 1980). Shedding of emboli is also exacerbated by intermittent 
changes m venous pressure, by turbulent alteration m blood flow and by 
movement or manipulation of the neoplasm during diagnostic tests or 
surgery (Poste 1980).
Circulating tumour cells must be able to lodge at the capillary level before 
extravasating into distant organs and therefore, any factors which encourage
and the interactions o f tmnour cells with each other and with circulating host 
cells to create multicellular emboli are hnportant in the lodgement o f tumour 
cells in capillaries (Poste 1980).
(6) Lodgement
I
the process o f lodgement, such as endothelial damage, will promote 
metastasis (Cotmore 1973). M echanical factors such as size and 
defonnability o f tumour cells, the diameter and distensibility o f capillaries
I
Circulating tumour cells interact with endothelial cells both directly and 
mdirectly. It has been proposed that tumour cells are able to lodge in 
capillaries by mechanical interlocking directly witli the vessel surfaces 
(Weiss 1994). On the other hand, tumoui* cells may also interact indirectly, 
by initially bmding to normal blood cells such as platelets. When circulating
12
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platelets attach themselves to exposed basement membrane and damaged 
endothelium lining, they degranulate. This process recruits more platelet to 
tire damaged endothelium and eventually a platelet aggregation is fom ed. 
Such platelet aggregation can in turn entrap circulating tumour cells, thus, 
increasmg the chances for tumour cell interaction with the endothelium and 
basement membrane (Evans 1991).
Coagulability o f blood
Size o f tumour embolus :
Circulating tumour cells that are in aggregation (i.e., larger tumour emboli) 
have a higher chance to wedge and lodge at capillary level than those that do 
not aggregate. Even though the presence of tumour cells in circulation does 
not guarantee metastasis fonnation (Salsbury 1975; Fidler 1977), there is a 
good correlation between the size o f tumour cell clump, rate of arrest and 
likelihood of secondary tumour foimation (Fidler 1973b; Liotta 1974).
Studies have shown that certain tmnours are associated with higher levels of 
thromboplastin and procoagulant-A activity (Fidler 1988). Pro coagulant-A 
directly activates factor X  o f the clotting cascade, thus, increasing the chance 
of coagulation at the capillary level. As a result, tumoui' cells are slowed 
down m circulation and become entrapped within small capillaries, 
increasing the chances of lodgement (Fidler 1987). On the contrary, it has 
also been shown that some metastatic cells are associated with mcreased 
fibrinolysis and plasminogen activator production, thus, they may decrease
13
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the coagulability o f blood. Tliis is believed to reduce the likelihood of 
tumour cells becoming enmeshed m a fibrin network, hence, facilitating 
metastasis (Chew 1976; Donati 1980; Gastpar 1982). In reality, both 
processes probably happen.
In addition to passive flow and tumour clump size which aid lodgement, 
tumour cells are also able to recognise and bind specifically to endothelium 
or basement membrane receptors (Zetter 1990). After lodgement at the 
capillary bed, four possible outcomes for tumour cells have been suggested 
(Figure 1.3). Firstly, the cell may lodge and fonn a metastasis. Secondly, 
cells may lodge but become dormant. Thirdly, cells may lodge but do not 
survive. Finally, cells may fail to lodge. Little is known about tumour 
dormancy. In normal cells a form o f dormancy has been reported. Wlien 
thyroid cells were injected mtravenously, they lodge in the limg and 
remained dormant until the host animal becomes thyroxine deficient 
(Taptiklis 1968; Taptiklis 1969). It has been shown that only 1 % tumour 
cells in circulation survive to develop métastasés. This could be due to the 
expression of incompatible growth factors or that the cells are destroyed by 
the host hnmune system I
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Figure 1.3 Lodgement at capillary
CELL LODGES BUT STAY DORMANT
CELL LODGES BUT DIES CELL UNABLE 
TO
RECOGNISE 
AND BIND
CELL BINDS TO BASEMENT MEMBRANE 
AND EXTRAVASATE
(7) Extravasation
Extravasation is the process where tumour cells leave the circulation and 
pass into surroundrug tissue. It is usually preceded by cellular lodgement 
except in those rare situations where haemorrhage has occurred. The 
mechanism o f extravasation is similar to the process o f intravasation but in 
reverse and mvolves cellular motility and enzymatic degiadation of 
intercellular structure.
Extravasation can be broadly divided into two main processes. Fhstly, 
tumour cells divide withm the lumen and invade outwards en masse (Chew 
1976). This usually means that tumour cells extravasate by destruction of 
capillaries rather than by active migration. In the second process tumour 
cells move actively between endothelial cells and degrade intercellular
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matrix and basement membrane using lytic enzymes such as the matrix 
metalloproteinases (Dingermans and Weerman 1980).
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Having extravasated, tumour cells begin to invade the extracellular matrix. A 
tliree-step hypothesis o f extracellular matrix invasion by tumour cells has 
been described (Liotta 1986). Firstly, tumour cells bmd specifically to 
exposed extracellular matrix via cell surface receptors (Attachment). The 
anchored cells then secrete hydrolytic enzymes that can locally degrade the 
matrix (Dissolution). Finally, tumour cells relocate into the region o f the 
matrix by proteolysis (Locomotion).
(8) Further development of métastasés
i
I
The ability o f tumour cells to grow in the new environment depends on the 
capability o f the cells to evade the host hnmune system and to express 
appropriate matrix metalloproteinases and angiogenic factors. In addition, 
the cells must also express appropriate growth factor receptors. Under 
favourable conditions, tumour cells proliferate, invade and eventually, 
metastasise to other organs.
Ii
H o s f  s defence system
It is becoming increasmgly realised that cellulai’ immimity is an important 
factor in the prevention of métastasés. It is well loiown that when host 
immunity is reduced by either T-lymphocyte depletion or by bone marrow 
ablation, the metastatic potential o f certain tumour cell lines is greatly
iI
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mcreased (Alexander 1976; Frost 1983; Schirrmacher 1985). In vivo, clones 
of tiunonrs known to vary in their metastatic capacity, metastasise equally in 
nude or irradiated mice (Eisenbach 1985).
In circulation, the host's defence system consists o f the non-immune and the 
immune defence system. The non-immune system is non specific and 
includes phenomena such as intravascular turbulence which can be traumatic 
enough to accoimt for rapid tumour cell death. Tumour cells may overcome 
tliis phenomenon by clumping with each other (homotypic aggregation) or 
with host's cells such as platelets and lymphocytes (heterotypic aggregation) 
to form multicellular emboli.
On the other hand, the immune defence system is more complicated and can 
be subdivided broadly mto specific (lymphocytes and antibodies) and non 
specific (for example, natural killer cells and macrophages) elements. The 
mechanism o f immune surveillance for metastatic cells is similar to that 
responsible for graft rejection.
Both the Natural killer cells (NK) and macrophages play hnportant role in 
preventing metastasis. Natural killer cells inhibit tumour colony formation 
(Hanna 1982a) and tlieir absence is related to increased colony formation. 
For example, in vivo, tumour cells that were unable to form colonies in the 
spleens o f healthy mice were able to do so if the mouse was pre-treated with 
anti-NK cell antibodies. Furthermore, when NIC cells are inactivated with 
cyclophosphamide, marked enliancement o f both lung and extrapulmonary 
colonies were observed but these effects could be reversed by the transfer of 
normal spleen cells to cyclophosphamide treated mice (Hanna 1980).
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The effects of NK cells on the pm nary tumour have been observed to be 
different from that on metastatic lesions. It is believed that metastatic lesions 
which are more resistant to the effects o f NK cells may have different 
surface antigens from the primary tumour (Fogel 1979).
Macrophages are important m the inunune system as the absence of an intact 
macrophage system is lethal (Fidler 1985). These cells are able to recognise 
and discriminate between “s e l f  from “n o n se lf  and they phagocytose and 
desti'oy any effete cells and foreign invaders. Frequently, macrophages 
provide the first line o f defence against microbial infections and parasite 
infestations (Fidler 1987). Wlien activated by lymphokmes such as IFN-y, 
macrophages are capable o f lysing virus-hifected or tumourigenic cells and 
not normal cells (Fidler 1985). It has been shown that macrophages 
activated by intravenous admhiistration of lymphokines encapsulated with 
liposomes can enhance the host destruction o f métastasés (Fidler 1985). I
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In spite of a competent immune system, some tumour cells manage to 
complete the metastatic process by escaping the iinmmie system. One 
possible explanation is that higlily metastatic cells are able to shed off 
surface antigens compared to poorly metastatic cells. Shed antigens may 
then inhibit lymphocyte mediated cytotoxicity (Alexander 1974; Currie 
1974; Kim 1975).
Chapter 2 Metastasis: The Pattern
Introduction
The distribution of metastatic tumours has always fascinated clinicians and 
pathologists. It has been observed that some organs, such as the liver, lung 
and bone, are more involved in metastasis than others (Paget 1889). The 
liver, for example, is a common site for metastasis for a luunber o f cancers. 
Some arise from nearby tissue such as colonic carcinoma while other distant 
cancer such as choroidal melanoma bypass several organs to metastasise to 
the liver. On the other hand, well vascularised organs such as the heart, skin 
and muscles are unfavourable sites for metastasis (Zetter 1990; Miyasaka 
1995).
The interest in metastatic pattern began at the end o f the nineteen century. 
Studies attempted to answer questions such as “ What is it that decides 
what organs shall suffer m a case o f disseminated? " asked by clinicians 
such as Langenbeck and Billroth (Paget 1889). In 1882, Fuch proposed the 
'Theory of Predisposition’ claiming tliat certain organs maybe more 
predisposed to growth o f secondary cancers than others. Fuch observed that 
in choroidal sarcoma, sarcomatous elements were found in the capillary 
vessels of the retina and métastasés developed as far afield as the liver and 
spleen but not in nearby retinal tissue (Paget 1889).
This was followed by Paget in 1889, who performed necropsies in 735 cases 
of breast cancer, 244 cases o f uterine cancer and 340 cases of pyaemia. He
19
I . .  .' . _____________________________________________________   '
■a
noted that out o f 735 cases o f breast carcinoma at post mortem, secondary 
disease was found in the liver in 241 patients, in spleen in only 17 patients 
and in the renais and suprarenals m 30 patients (Table 2.1). Despite equally 
good blood supply to both liver and spleen, the spleen appeared to be a less 
favourable site for metastasis. Comparmg to cases of pyaemia, Paget found 
that secondary abscesses were foimd in almost equal porportion in both liver 
and spleen. He then proposed the ‘Seed and Soil Hypothesis’ drawing the 
analogy that when the plant (the primary tumour) goes to seeds (métastasés), 
its seed are carried in all directions (disseminations); but they can only live 
and grow if  they fall on congenial soil (predisposed organ) (Paget 1889).
Table 2.1. Autopsies performed by Paget {Paget 1889) showing the disproportionate
distribution of métastasés between spleen and liver in breast and uterine tumour 
cases compared with cases of pyaemia
AUTOPSIES LIVER SPLEEN KIDNEYS AND 
SUPRARENALS
LUNGS
735 BREAST 
CARCINOMA
241 (32.7%) 17 (2.3 %) 30 (4 %) 70 (9.5 %)
244 UTERINE 
CARCINOMA
35 (14.3 %) 1 (0.4 %) 6 (2.5 %) 8 ( 3 . 3 %)
340 PYAEMIA 66 (27.1 %) 39 (16 %)
H alf a century later, Ewing proposed a second model for the metastatic 
pattern on tlie basis of circulatory anatomy. His concept formed the basis of 
the ‘Mechanical Hypothesis’ o f metastasis. In this hypothesis, the pattern of 
tumour spread is entirely due to the route of blood flow and that various 
tissues are passive receptacles for tumour cells. The ability of cells to grow
20
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ill an organ depends on the number o f viable cells delivered to it (Ewing 
1928; Coman 1953).
Evidence for ‘Seed and SoiT Hypothesis
make-up and the compatibility of the new tissue enviromnent. Evidence
(b) Tissues specificity shown by tumour cells
I
In the ‘Seed and Soil’ hypothesis, metastasis is a non-random process and 
each cancer has its own specific metastatic pattern. The growth of 
métastasés in target organ depends on both the cellular intrinsic genetic I
supporting this hypothesis falls into the following observations:
(a) Discrepancies between the relative blood supply and the relative :
incidence o f métastasés in various organs
If  tumour emboli are disseminated in tlie blood stream, then they should be 
distributed to the different viscera in proportion to their relative blood 
supply. Thus, one should expect richly vascular tissues be in involved in 
métastasés more frequently than poorly vascular ones. However, this is not 
so as organs with the richest vascular supply such as adrenals, thyroid, 
gastrointestinal tract, skeletal muscles and spleen are infrequent sites of 
metastasis compared to the liver, lung and bone (Fidler 1987).
i
Certain primary tumours such as lung, prostate, breast and kidneys 
frequently metastasise specifically only to bone bypassing other organs. 
Studies have suggested that such tissue specificity could be due to soluble
2,
growth factors released by cells o f the target organs allowing specific 
tmnour cells to proliferate and grow (Horak 1986; Nicholson 1986; Naito 
1987). For example, mouse mammary tumour cells that normally foiin 
pulmonary métastasés are unable to survive m medium enriched with liver or 
thyroid extract. However, when the same tumour cells ar e cocultured with 
pieces o f lung, they survive and adliere to the substratum. These effects can 
be transferred from one culture to another with cell-free media ‘conditioned’ 
by the organ (Horak 1986).
Furthermore, when B 16 melanoma cells were injected into C57BL/6 mice, 
métastasés were found in fr agments o f pulmonary or ovarian tissue 
implanted intramuscularly. In contrast, metastatic lesions did not develop in 
renal tissue implanted mtramuscularly as ‘control’ or within the scar (Hart
1981). The same author also showed that extracts taken from mouse lung 
stimulated growth o f lung-colonismg tumour cells whereas extracts from 
other organs inhibited their growth. Similar results were obtained using 
extracts or conditioned medium from mouse ovary, lung, brain, liver and 
thyroid (Hart 1982). Another reason for such tissue specificity may lie in the 
ability o f tumour cells to ‘hom e’ to various target organs. This phenomenon 
will be discussed later under ‘Homing’.
The “Seed and Soil” hypothesis therefore assumes that tissues provide 
optimal chemical and metabolic conditions for tlie growth o f particular 
secondary tumours and that different tumours may have differing optimal 
requirements. Hence, each tumour has its own preferential sites of 
metastasis. Different “seeds'’ require different “soils” and in poor “soil” 
the “seeds” fa il to germinate.
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Evidence for the ‘Mechanical Hypothesis’
1"
The mechanical hypothesis proposes that the development o f secondary 
tmnours m common sites such as the lung, liver and bone is non random and 
can be explained by a combination of blood flow and the nmnber o f viable
tumour cells reaching these sites via venous and arterial channels (Coman 
1953). Having ‘escaped’ from the primary tumour, tumour cells gam access 
to either lymphatic and/or venous system. They then travel to various organs
via different routes.
Both the liver and lung are organs that are frequently involved with 
.metastasis as they receive venous drainage from the portal system and the 
caval system respectively. In addition, the liver and lung might also receive 
tumom’ emboli through the hepatic and bronchial arteries respectively 
(Coman 1953). In the limg, tumour cells could either enter the puhnonary 
vehis or the pulmonary arteriovenous anastomosis to enter the arterial 
circulation (Coman 1953; Sugarbaker 1981) to metastasise to organs such as
:kidneys, adrenals, spleen and muscle.
Tumour cells could reach the skull and axial bones via the communications 
between vertebral venous system o f Batson and systemic venous system.
Vertebral veins form an extensive system from the pelvis to skull 
anastomosing freely with the caval system at each segmental level providing 
an explanation for the spread o f breast, thyroid and prostatic cancers to the 
axial bones bypassing other organs (Batson 1940; Coman 1953).
Furthermore, the mammary veins communicate with the vertebral system
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through the intercostal and subclavian veins providmg a route for the spread 
o f breast cancer to the vertebrae (Coman 1953).
Lastly, tumour cells that gained excess to the lymphatic chamiels form 
métastasés in the lymph nodes that they encountered. From there, tumour 
cells could join the venous system via lymphaticovenous channels or the 
thoracic duct that drains into the main systemic venous system (Sugarbalcer
1981)
The mechanical hypothesis was supported by Coman hi 1951 and 1953 
when he injected suspension of rabbit V2 carcinoma cells (a tumour that 
rarely produces spontaneous métastasés in organs other than lungs) into the 
left ventricle of a rabbit. He found that tumour cells ‘appeared and grew in 
virtually all organs’. He concluded that the reason métastasés failed to 
develop widely was not due to tlie various organs offering an unfavourable 
chemical environment but because inadequate number o f cells did not reach 
those organs that did not develop métastasés (Coman 1951; Coman 1953).
The mechanical hypothesis was ftirther supported by the observation made 
by Weiss. He found that when 4 X 1 0 ^  Walker 256 tumour cells were 
injected into the rats via the tail vein, 90 % of the rats had secondaries in 
their limgs but only 10% of them had extrapulmonary tissues métastasés, 
mainly in the liver. However, when he repeated the experhnent by injecting 
1 X 1 0 ^  W alker 256 tumour cells mto the rats via intrahepatic/portal vein, he 
found that 90% of the rats had liver métastasés. Using radiolabelled cells, 
Weiss was able to showed that tumour cells, after tail vein injection, reached 
the liver after being filtered by the hmgs and came to the conclusion that the
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liver is not an unfavourable soil for tumour cells to grow but most cells 
reaching it were dead (Hart 1982; Weiss 1985).
'Seed and Soil’ Vs ‘Mechanicaf hypothesis
In the mechanical hypothesis, the development o f metastasis is dependent 
solely upon the dose o f viable tumour cells delivered to the appropriate 
organs but these anatomical and haemodynamic considerations do not 
explain all the metastatic patterns o f spontaneous tumours (Poste 1980;
Fidler 1987; Pauli 1988; Fidler 1990). Moreover, the mere presence of
viable tumour cells does not predict that the cells will proliferate to produce III
métastasés (Fidler 1970; Fidler 1990).
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A  review by Sugarbaker suggested that the two hypothesis are both active 
and can be reconciled if  due consideration is paid to the manner in which the 
data to support these hypothesis have been obtained (Sugarbaker 1981 ; Hart
1982). For early-stage tumours of moderate and low metastatic potential, the 
initial sites o f metastasis are almost exclusively determined by the 
mechanical hypothesis. Once generalised metastasis has occurred, the i
autopsy pattern o f metastasis indicates that for a given loistological primary 
tumour, organ specificity can be demonstrated. On the other hand, tumours 
with high potential tliat metastasise rapidly to all organs by the time of 
clmical diagnosis and treatment, no apparent seed and soil mechanisms are 
apparent (Sugarbaker 1981). ■!ï
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T um our H eterogen eity
Cancers were once thought to be monoclonal in nature: ‘Tumour cells 
simply bred true and a monoclonal tumour grew into a bigger version of 
itse lf (Dexter 1982). However, in 1977, Fidler and Kripke provided the first 
experimental demonstration of the metastatic heterogeneity o f neoplasm 
using B 16 melanoma cells. Using a modification o f the fluctuation assay 
devised by Luria and Delbmck in 1943 for analysmg the origin o f microbial 
mutants, Fidler and Kripke were able to show that individual cells from the 
parent tumour varied dramatically in their ability to metastasise and that 
subpopulations of tmnour cells o f differing metastatic potential existed 
within the parent tumom (Fidler and Kripke 1977).
It is now widely accepted that both human and annual tumours are 
heterogeneous in nature containing subpopulations of cells with different 
phenotypes (Evans 1991; Dexter 1982; Heppner 1984). Such heterogeneity 
is not confined to cells in the primary tumours and is equally prominent 
among cells populating métastasés (Fidler 1985). These subpopulations of 
cells within a single neoplasm or metastatic lesion may vary in their 
metastatic potential, surface antigens, morphology, immunological 
properties, growth rates, metabolic characteristics, hormone receptors, 
radiosensitivity and susceptibility to cytotoxic drugs (Heppner 1984; 
MacLeod 1985; Fidler 1990).
In vivo, the tumomigenicity and the metastatic potential may vary between 
clones fi'om a same tumom mass. For example, clones isolated from murine 
melanoma model K1735 differed greatly from each other and from the
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parent tumour in their ability to produce lung métastasés (Fidler 1980). 
Similarly, clones from the SL 12 murine lymphoma model, despite equal 
DNA content confirmed by flow cytometry, vary in their surface antigens, 
tumourigenicity and metastatic patterns (MacLeod 1984; M acLeod 1985). 
Such biological heterogeneity exhibited by both primary and secondary 
tumours forms a major barrier in the treatment of cancer resulting in poor 
response of cancers to current therapies (Heppner 1984; Fidler 1990, Dexter 
982).
The mechanism of tumour heterogeneity
The mechanism o f how a single tumour mass achieve its heterogeneity 
would be easier to understand if  tumours were multicellular in origin. 
However, not all tumours are multicellular in origin (Heppner 1984) and it is 
more difficult to perceive the source o f heterogeneity m neoplasms that are 
unicellular' in origin (Fidler 1987).
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Foulds introduced the ‘Theory o f Progression’ to try to explain the 
progression of premalignant to malignant lesions in the breast (Foulds 1975; 
W eiss 1985). Extensive studies on the progression of mouse mammary 
tumours led Foulds to believe that tumours undergo a series o f permanent 
and irreversible changes during the course o f the disease (Nicholson 1982; 
Fidler 1987). Ulthnately, this results in a heterogeneous tumour mass with 
subpopulations o f cancer cells that are related but not identical. According to 
Foulds, the ‘neoplasia tends to go from bad to w orse’ (Foulds 1949; Foulds 
1969).
■,4
Fould’s theory of progression was further refined by Nowell in 1976, who 
suggested that tumour progression results from genetic instability such as 
point mutations, genomic rearrangements, cliromosome losses and gene 
amplification. As a result, emerging variants with increasing genetic 
instability are produced in an expanding tumour (Nowell 1976; Fidler 1978; 
Heppner 1984). This model of tumour evolution was further supported by an 
observation that clones o f highly metastatic mmme fibrosarcoma are more 
unstable with a significantly higher rate of spontaneous mutation compared 
to poorly metastatic potential clones (Evans 1991; Cifone 1981; Dexter
1982).
It is also possible to isolate one or more clones of high grade metastatic 
potential from a tumour using single cell-cloning methods if  the frequency of 
metastatic variants is high enough (Fidler 1977; Kerbel 1990). However, in 
some cases, initially highly metastatic clones become phenotypically 
unstable and tend to revert to the less metastatic parental wild-type after 
weeks to months in culture. Such behavioural trait of tumour cell clones in 
vitro is sometimes referred as “phenotypic drift” . This phenomenon can be 
explamed by heritable (but unstable) epigenetic events such as DNA 
méthylation, transcriptional and translational control processes (Evans 1991; 
Neri 1981; Kerbel 1990).
Phenotypic differences between cells are not found only within the primary 
tumour but even with métastasés themselves, thus, explaining why multiple 
métastasés in the same patient, even within the same organ, show biological 
diversity (Dexter 1982; Fidler 1986; Kerbel 1990).
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H om ing
In 1960, Kinsey showed that when mice were injected intravascularly by 
either intravenous, mtra-arterial or intraventricular routes, with melanoma 
S91 Cloudman (a lung-homing melanoma tumour model), the S91 persisted 
its preference to metastasise to the host lung and also to ectopically 
transplanted lung tissue but not to other organs (Kinsey 1960; Zetter 1990). 
Such site specificity displayed by tumour cells is also observed clinically in 
patients who have peritoneovenous shimts for malignant ascites. These 
patients develop metastasis at specific sites and rarely witlhn the lung or
Mechanisms
Like leucocytes trafficking, circulating tumour cells are able to recognise 
and attached specifically to endothelial cells, basement membrane and
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cardiovascular system (Tarm; Price 1984b; Fidler 1990). Furthermore, when 
K-1735 murine melanoma cells and B-16 murine melanoma cells were 
mjected directly into the carotid artery o f mice, it was shown that K-1735 
cells metastasised to the brain parenchyma whereas B-16 cells only 
produced meningeal secondaries even tliough clmically they are both murine 
melanomas (Schackert 1988).
I
I'It is believed that tumour cells exliibit non-random metastatic patterns 
because they are able to ‘hom e’ to their target organs (Zetter 1990). Such 
homing processes are not unique to tumour cells alone as normal cells also 
display homing. For example in embryonic pattenhng and leucocyte 
traffickmg, cells travel selectively to distant tissues for fiirther growth, 
differentiation and maturation (Picker 1992).
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extracellular matrix. Having interacted, tumour cells begin to extravasate and 
invade with the help o f degradative enzymes. Their cellular motility is also 
influenced by motogens produced by the host tissue. Angiogenesis and host 
tissue factors facilitate further growth o f the cells at the new site (Jiang 
1994).
Selective recognition
The flow of circulating tumour cells slows down at the capillary level. As a 
result o f diminishing flow, it is believed that tumour cells lodge and arrest 
passively, an important event preceding potential extravasation. However, 
tliis non-specific mechanism is insufficient to explain why certain organs are 
bypassed and métastasés develop selectively in other sites downstream with 
similar sized capillary beds (Hart 1982). Fidler showed that only 1 % 
circulating cells after intravenous injection survived to form métastasés and 
that the first encountered organ was not necessary involved. Cells are also 
noticed to recirculate through organs without forming métastasés (Fidler 
1970; Fidler 1990). Therefore, more specific mechanisms must be involved.
In 1964, Greene and Harvey proposed tliat the localisation of tumour cells at 
target organs might involve formation o f an initial bond between tumour 
cells and the adliesion molecules on the luminal side of the vascular 
endotheliiun o f that organ. Furthermore, the strength of this adhesive bond 
varies with different tumours and also with the vascular endothelium at 
different sites (Greene 1964). Auerbach et ah, subsequently demonstrated 
that when tumour cells are incubated with cultured endothelial cells firom
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different organs, they stick selectively to the endothelial cells derived from 
their preferred secondary site (Auerbach 1987). When tumour cells are 
exposed to liistological sections, they also stick to sections prepared from 
their preferred site o f metastasis (Netland 1984).
Increasing evidence now suggests that adliesion molecules play an important 
role hi tumour cell liomhig (Zetter 1990; M iyasaka 1995). Similar to T- 
lymphocytes homhig to primary and secondary lymphoid organs for 
differentiation and maturation (Picker 1992), tumour cells have also been 
shown to express cell surface receptors or adhesion molecules that are able 
to recognise and interact specifically to their counterparts on endothelial 
cells, exposed basement membrane and extracellular matrix (Zetter 1990). 
Selective adhesion between these molecules allows tumour cells to bind 
firmly to the vascular endothelium, leading to specific entrapment and later 
site-specific métastasés. It has also been demonstrated that such firm binding 
can even protect tumour cells from cytotoxic T-cells and natural killer cells, 
thus, prolonging their half life and increasing their chances o f forming 
métastasés (Kaminski 1988).
Adhesion molecules
Adliesion molecules are cell surface receptors that mediate cell-cell and cell- 
extracellular matrix interactions (Nigam 1993). Recent studies have shown 
that adhesion molecules play hnportant roles in the metastatic cascades. 
Their down regulation allows cellular detachment from the prhnary and their 
upregulation allows specific recognition and attacliment to endothelial
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cellular ligands in target organs. Molecules that maybe involve in tumom 
cell homing are the integrins, tlie members of the immmioglobulin 
superfamily (VCAM, ICAM-1, ICAM-2, NOAM etc.,), CD44, selectins and 
addressing.
Figure 2.1 Major families of cellular adhesion molecules (Hynes 1992)
I
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Integrins
The integrin family is divided into at least tliree subfamilies, each consists of 
heterodimers with a common p subunit (90-110 kDa). The common p 
subunit is noncovalently associated with a specific group of a  subunits (120- 
180 kDa) as shown in Figuie 2.1 (Jiang 1994, Hynes 1992; Maemura 1994),
M ost p subunits can associate with several different a  subunits, whereas, a  
subunits usually bind to one particular p subunit (Roos 1991).
Integrms are transmembrane receptors expressed by most cells (Nigam
1994). They bind to ligands such as the immunoglobulin superfamily on the
endothelial surfaces (VCAM, ICAM  1 & 2), components o f basement
membrane (collagen IV and laininin) and extracellular matrix proteins found
during early development, inflammation and wound healing (fibronectin,
fibrinogen, vitronectin, thrombospondin and peptide sequence such as the
ROD sequence) (Hynes 1987; Hynes 1992; Albelda 1993). The RGD-
peptides sequence was originally identified as the cell attaclnnent promoting
sequence in fibronectin but now has been found in a number of matrix
proteins including fibrinogen, thrombospondin, vitronectin, laminin and type
I collagen (Hynes 1992; Maemura 1994). hi vitro, when integrin receptors
are blocked by synthetic RGD-peptides sequence (Arg-Gly-Asp), invasion of
.human melanoma cells across amniotic basement membranes is inhibited
. . .(Gehlsen 1988) and in vivo, coinjection of RGD-peptides sequence and 
BiôFio murine melanoma cells reduced the number o f metastatic hmg 
nodules in mice (Hmnpliries 1986). These studies suggest that RGD- 
peptides sequence act as ligand analogues, competing for adhesion receptor
;
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binding sites and thereby decreasmg the amount of integrin-mediated 
attachment between metastatic tumour cells and extracellular matrix 
(Maemura 1994).
In metastasis, integrins play an important role in tumour cell attaclnnent to 
extracellular matrix and invasion after extravasation as they provide a link 
between cytoskeleton and extracellular matrix (Maemura 1994). They are 
foimd to be expressed in tumours o f the breast, colon, pancreas, stomach, 
kidneys, prostate, lung and the skin (Nigam 1994).
subfamily
The pi subfamily contains 7 heterodimers (a iP i to agpi and avpi) and is the 
largest integrin subfamily (Maemura 1994). They are also known as the 
VLAs (Very late after activation) subfamily and its members are also called 
by their V LA -a subunit number (Hynes 1992; Miyasaka 1995). The ligands 
for the p 1 subfamily are extracellular matrix proteins such as laminin (VLA- 
1, -2, -3 and -6), collagen (VLA-1, -2 and -3) and fibronectin (VLA -3, -4, ~
5 and -v) (Maeimna 1994; M iyasaka 1995). Unlike VLA-1, - 2, -3 and -6 
which are expressed by most cells, VLA-5 (fibronectin receptor) is poorly 
expressed in most tissues.
I
Both VLA-5 and 6 are important in metastasis. VLA-5 is a fibronectin 
receptor and is responsible for migration of tumour cells whereas VLA-6 is a 
laminin receptor and adhesion to laminin, an important component of 
basement membrane, has been shown to be essential in metastasis (Roos 
1991). I
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Abnormal expression o f Pi has been correlated with increased metastatic 
ability o f tumour cells (Miyasaka 1995). For example, increased expression 
of VLA-2 has been associated with metastatic behaviour o f 
rhabdomyosarcoma cells and VLA-3 with melanoma progression. VLA-4, 
on the other hand, is expressed mainly by lymphoid and myeloid cells. 
Besides being a fibronectin receptor, VLA-4 also binds specifically to 
immunoglobulin VCAM-1 (Vascular adliesion molecule-1) (Miyasaka
1995).
p2  subfamily
The p2 integrins have three members, LFA-1 (GDI 1 a/CD 18), Mac-1 
(C D llb /C D 18) and gp 150/95 (CD 11 c/CD 18) wliich are expressed 
exclusively on white blood cells, thus, gaining the name “leucocyte 
integrins” (Roos 1991). Their primary role is in mtercellular adhesion such 
as leucocyte-leucocyte or leucocyte-endothelial cell interactions ” (Roos 
1991; Maemura 1994). h i addition to intercellular adhesion, Mac-1 and 
gp 150/95 maybe involved in adhesion to substrates as well.
LFA-1 (Lymphocyte functioning antiaen-1 or a M
LFA-1 is the most extensively characterised P% integrins. It is widely 
expressed by leucocytes and plays an essential role in inflaimnation (Roos 
1991). LFA-I binds to endothelial ligands of the immunoglobulin 
superfamily, ICAMs (Intercellular adhesion molecules), with a higher 
affinity for ICAM-1 than ICAM-2 (Roos 1991).
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p3  subfamily
LFA-1 is also expressed by many metastatic lymphomas. Adhesion and
consequently, invasion o f these lymphoma cells in hepatocyte and fibroblast L
11monolayers is inhibited by anti LFA-1 antibody, suggesting that LFA-1 is 
required for efficient metastasis formation (Roos 1991; Maemura 1994).
Furthermore, lymphoma cell variants deficient in LFA-1 are unable to invade 
.and metastasise in vivo (Roosien 1989), and in vitro, LFA-1 deficient mutant 
cells were less invasive than their parental cells in hepatocyte and fibroblast 
monolayers. Tins provides strong evidence for an essential role o f LFA-1 in 
metastasis o f these cells (Roos 1991; Maemura 1994).
Mac-1 (CD11b/CD18orauB.) a n d aDl50/95 (CD11c/CD18 or avB,))
I
Mac-1 and g p l50/95 expression is largely limited to myeloid cells and they Iappear to be involved in interaction with endothelial cells and extracellular |
matrix, thus, probably involved in extravasation. They probably play an 
important role in tumour formation for myeloid tumours (Roos 1991).
This subfamily has two members namely anbPs and aePs. The integrin
a
aiibp3, a fibrinogen receptor is expressed primarily by platelets and is 
involved in platelet aggregation (Albelda 1993). It is also found to be 
expressed by certain tumours and plays a caicial role in tumour cell-platelet- 
endothelial interactions. Such interactions could be reversed by antibodies to
.aiibPs- Tumour platelet aggregation helps in the lodgement and arrest of
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tumour cells at capillary levels, thus, facilitating metastasis (Maemura 1994; 
Tang 1994). On the other hand, induction of thrombocytopenia, is associated 
with a decrease o f metastasis (Albelda 1993).
Œvp3, on the other hand, is a vitronectin receptor (Maemura 1994) but is also 
foimd to bind fibronectin, fibrinogen, thrombospondin, osteopontin and von 
Willebrand factor (Garrod 1993). Both integrins have been found to be 
expressed in human melanoma cells but not in benign melanocytes. There 
seems to be a direct relationslhp between their expression and tumour 
metastasis (Maemura 1994; Tang 1994).
Immunoglobulin superfamily
hr this large family, all molecules shar e a common structural feature, the 
immunoglobulin homology unit (Figure 2.1) and they exhibit both 
haemophilic and heterophilic interactions.
VCAM-1 (Vascular cellular adhesion molecules-1) is expressed by 
endothelial cells that are activated by cytokines. It is a ligand for integrin 
VLA-4 (a 4 p i) . As a result, tumour cells such as melanoma (Albelda 1993) 
that expressed VLA-4 could bind specifically to activated endothelium via 
VLA-4/VCAM-1 interactions (Maemura 1994). Furthermore, VCAM-1 is 
also expressed by bone marrow stromal cells, thus, explaining the metastasis 
o f lymphoma cells to the bone marrow and the retention of leukaemia cells 
in the bone marrow (Jimeja 1993).
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ICAM-1 (intercellular adhésion molecules 1) contains 5 extracellular 
immunoglobulin-like domains and a short cytoplasmic tail. It has been 
recognised as an endothelial ligand for integrin, LFA-1 (lymphocyte 
functioning antigen-1) (Maemura 1994) but recently, has also been found to 
act as receptor for Mac-1 and rhinovirus (Miyasaka 1995). ICAM-1 is also 
expressed in non-endothelial cells such as in melanomas and squamous cell 
carcinoma (Maemura 1994; M iyasaka 1995). In melanoma, it correlates 
with tumour progression and increased risk of metastasis (Johnson 1989; 
Natali 1990; Maemura 1994). It has been speculated that melanoma cells 
which expressed ICAM-1 could bind to lymphocytes via LFA-1, thus, able 
to disseminate throughout the blood stream in analogy to lymphocytes 
(Maemura 1994).
Other important iimnunoglobulin superfamily includes NCAM , LI and CEA. 
NCAM  (Neural cell adhesion molecule) is a homophilic calcium-dependent 
cell-cell adliesion molecule that is expressed primarily in the nervous system 
(Albelda 1993). It has been found to be expressed in many neural and 
neuroendocrine tumours including W ilm’s tumour, pituitary adenomas, 
phaechromocytomas, small cell hmg carcinoma and frequently in bile duct 
cancer (Albelda 1993; M iyasaka 1995). Its circulating form may be a 
potential marker for small cell lung carcinoma (Jaques 1993) and there is 
also a correlation between its expression and neural mvasion of bile duct 
cancer (Seki 1993)
LI is also a homophilic neural adhesion molecule and is expressed by 
lymphomas. Its expression correlates negatively with metastatic capacity of 
lymphomas (Kowitz et al. 1993). CEA (carcinoembryonic antigen) was
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described as an oncofetal glycoprotein found in the serum o f patients with 
colonic carcinoma but was subsequently found to be associated with other 
tumours (Albelda 1993). Recently, CEA has been recognised to be a 
member of the immimoglobulin superfamily and function as a true cell 
adliesion molecule. It still remains unclear how the increased expression of 
CEA on tumour cells is related to the development of malignancy. One 
possible explanation is that the presence of excess CEA could interfere with 
the flmction of the normally present cell-cell adliesion molecules by 
downregulating integrin and cadherin molecule expression (Albelda 1993; 
Nigam 1994)
CD 44 (Hermes antigen, H-CAM, pgp-1 antigen)
1
CD 44 is a membrane glycoprotein (37-kD core protein) witli an amino-
terminal domain homologous to the cartilage link protein (Miyasaka 1995). If
It is present in many cell types including epithelial and haemopoietic cells I
■t(Guo 1994; M iyasaka 1995) and functions as a receptor mediating cell-cell 
and cell-matrix interactions by binding to ligands such as hyaluronic acid, 
collagen and fibronectin (Aruftb 1990; Lesley 1990; Underhill 1992). In
■n,lymphocyte trafficking, CD 44 behaves as a lymph node homing molecule
iby helping lymphocytes to bind selectively to high endothelial venules found i"Iin mucosal lymph node tissue (Maemura 1994; M iyasaka 1995). f;
I
At molecular level, the transcription of CD 44 is by alternative splicing, thus 
producing many variants and some o f these variants are important in tumour 
cell homing and invasion. Transfection studies showed that tumour cells
■f:Æ
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which acquire CD 44 variant cDNA increase their metastatic potential 
(Underhill 1980; Underhill 1981; Haynes 1983; Namec 1987; Horst 1990; 
Stamenkovic 1991; Dougherty 1992; Jalkanen 1992; Matsumura 1992; 
Albelda 1993). For example, Gunthert identified a variant, pMeta-1 cDNA, 
which is expressed in a highly metastatic pancreatic carcmoma cell line in 
rats but not m a poorly metastatic variant. Tins variant CD 44 contains an 
additional extracellular domain of 162 amino acids, probably introduced by 
alternative splicing (Albelda 1993). By transfecting this heavier cDNA to the 
non-metastasising cell line, the cells were able to express both the normal 
and variant CD 44 and became metastatic (Guntliert 1991). In vivo, 
antibodies against CD 44E were found to have inhibitory effects on tumour 
growth and metastasis (Seiter 1993) supporting the hypothesis proving that 
interactions between CD 44 variant and its ligands are important in 
metastasis.
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Evidence showed that the higher molecular weight o f CD 44 variant is a 
distinct form with different adhesion potential. It is possible that this higher 
weight form confers metastatic potential by allowing the cells to adhere 
strongly to hyaluronic acid, thus, aiding tumour implantation (Albelda 1993). 
Another explanation is that this additional extra extracellular domain could 
also be found in activated T-cells. Thus, expression o f this variant CD 44 
could act as a “molecular disguise” that helps the tumour cells to mimic 
circulating activated lymphocytes (Kalm 1992; Albelda 1993). Such 
molecular disguise or “wolves in lamb clothing” helps the tumour cells to 
evade immune system (Nigam 1994). For example, when tumour cells are 
transfected to overexpress the epithelial variant CD 44R1, they readily gain
access to lymph nodes and distant metastatic sites in animal models 
(Stamenkovic 1989; Tanabe 1993).
Selectins
The Selectms are adhesion molecules that share a common stmctiue 
characterised by an amino-terminal lectin domain area, an epidermal growth 
factor-like domain, a variable number of complement regulatory protein 
repeat sequences and a short cytoplasmic domain as shown in Figure 2.1. 
They bind to carbohydrate ligands and consist o f P-selectin (GMP140 or 
PADGEM), E-selectin (ELAM-1) and L-selectin (LECAM-1).
P-selectin is expressed on platelets and endothelial cells (Maemura 1994) 
and possibly play a role in tumour mvasiveness as it was found to bind to 
tumour sections o f the breast, colon and lung (Aruffo 1990; Albelda 1993; 
M iyasaka 1995).
E-selectin (Endothelial Leucocyte Adhesion Molecule 1 or ELAM-1) is 
found to be expressed by endothelium activated by interleukin-1 (IL-1), 
tiunour necrosis factor a  (TNF-a) and other cytokines and not in 
imstimulated endothelium. It binds to a carbohydrate ligand containing sialyl 
Lewis X (SLe^) or sialyl Lewis a (SLe^) stmcture on leucocytes. As several 
carcinoma cells also express sialyl Lewis x (SLe^), these malignant cells 
have the potential to bind to endothelial cells via E-selectin (Maemura 
1994). Antibodies against E-selectin has been shown to inliibit adhesion of 
seven colon carcinoma cell lines to activated endothelium (Lauri 1991)
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Selectins also play an important role in lymphocyte trafficking (Picker and 
Butcher 1992). L-selectin (Leucocyte adliesion molecule 1 or LECAM-1) is 
a lymph node homing receptor and helps lymphocytes to bind specifically to 
peripheral lymph node addressins (PNAd) expressed by the high endothelial 
venules o f lymph nodes (Bartgatze 1987; Picker 1992; Garrod 1993). It has 
also been suggested that L-selectin is a predictor of the haematogenous 
dissemination of murine lymphomas (Miyasaka 1995)
Cadherins
Cadlierins form a group o f cell-cell adliesion molecules which are calcimn- 
dependent transmembrane proteins. They mediate cell-cell adhesion mainly 
by homotypic interaction (Takeichi 1991; Jiang 1996) and are responsible 
for establishing and maintenance o f intercellular connections (Takeichi 
1991). There are four subclasses of Cadherins which share a common basic 
stmcture but display a imique tissue distribution pattern: E-cadherin 
(epithelial cadherin), P-cadherin (placenta cadlierin), N-cadherin (neural 
cadherin) and L-CAM  (liver cell adliesion molecule) (Takeichi 1991 ; 
M iyasaka 1995).
E-cadlierin (also known as uvomorulin, Arc-1 and cell-CAM 120/80), is one 
o f the best characterised cadherins. This 120-kDa transmembrane protein is 
confined to all epithelia originating from ectodermal, mesodermal and 
endodermal tissue (Behrens 1993; Jiang 1996). The intracellular domain of 
E-cadherm interacts with a group of cytoplasmic proteins called catenin, 
which consists o f alpha, beta and gamma subunits.
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Addressins
E-cadherin is a key intercellular adhesion molecule. Cells without E- 
cadherin / catenins do not aggregate or adhere to each other (Takeichi 1991) 
and this non-adhesive state could be reversed by transfecting E-cadherin 
negative cells with E-cadherin cDNA (Jiang 1996). Furthermore, a loss of E- 
cadlierin / catenins expression correlates with poorly differentiated and 
invasive malignant tumours (Takeichi 1991; Albelda 1993; Behrens 1993; 
Dorudi 1993; Garrod 1993; Kinsella 1993; M aemura 1994; Jiang 1996). 
E[ence, E-cadherin /  catenins have been regarded as a tumour suppressor 
(Jiang 1996).
Lymphocytes homing to different organs are regulated by adliesion 
molecules (homing receptors) recognising tissue specific vascular addressins 
on endothelium such as peripheral lymph node addressins (PNAd) and 
mucosal vascular addressins (Mad) (Picker 1992).
Peripheral lymph node addressin, a mixture o f glycoproteins, is group of 
adhesion molecule that is selectively expressed in the high endothelial
1?:'
venules (LEV) o f peripheral lymph node. They play an important role in the 
homing of lymphocytes to peripheral lymph nodes by bmding to LECAM-1, 
a selectin adhesion molecule on circulating lymphocytes. Antibodies to 
either LECAM-1 or PNAd markedly reduce lymphocyte binding in vitro to 
peripheral lymph node (Picker 1992)
M ucosal vascular addressin (Mad), on the other hand, is a group of adhesion 
molecule that is selectively expressed in the high endothelial venules (HEV) I 
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ill gut-associated lymphoid tissue (GALT) such as Peyer’s patches and 
appendix. They bind to mucosal-homing and not lymph node specific 
lymphocytes (Picker 1992).
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Table 2,2 A summary of adhesion molecules and their ligands
Adhesion molecule family Adhesion molecule Ligand
Integrin (a  and p subunits) Ig superfamily. Extracellular matrix 
proteins, Basement membrane
pi ; VLA-1 Laminin, Collagen
pi : VLA-2 Laminin, Collagen
Pi : VLA-3 Laminin, Collagen, Fibronectin
Pi ; VLA-4 VCAM -1, Fibronectin
Pi ; VLA-5 Fibronectin
pi : VLA-6 Laminin
p2 : LFA-1 lCAM-1; ROD sequence
P2 : MAC-1 lCAM-1
Immunoglobulin superfamily ICAM-1 LFA-1, MAC-1
VCAM-1 VLA-4
CD 44 Hyaluronic acid, Collagen, 
Fibronectin, MAd
Selectin L-selectin (LAM-1) Endothelium of lymph node, PNAd
E-selectin (ELAM-1) Carbohydrate, Sialyl Lewis x/a
P-selectin (PADGEM) Carbohydrate
Cadherins Cadherins (Homotypic)
P-cadherin (Placenta) P-cadherin (Placenta)
E-cadherin (Epithelial) E-cadherin (Epithelial)
N-cadherin (Nerve) N-cadherin (Nerve)
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Chapter 3 Models of metastasis
Various models o f metastasis have been described such as those used by 
Hart, Fidler, W ang and Mignatti as previously described (Wang 1980; Fidler 
1985; Mignatti 1986; Hart 1992).
h i 1984, M acLeod described a murine T-cell lymphoma model (MacLeod
1984).
T he SL 12 cell lines
AKR mice are an inbred strain that develop tliymic lymphomas at high 
frequency after six months o f age and usually die within two weeks after the 
clinical onset (Hays 1982). In this animal model, lymphoma originates in the 
thymus and then metastasise to liver, spleen, kidneys and lymph nodes.
In 1984, M acLeod et. al., were able to isolate and establish a T-lymphoma 
cell line (SL 12) from the femoral bone marrow of an eight month old female 
AKR mouse with disseminated spontaneous lymphoma. By using the 
technique of limiting dilution on the SL 12 cells in tissue culture, two cloned 
cell lines, SL 12.1 and SL 12.4, were hirther established. These cell lines 
were maintained with DM EM  supplemented with 10 % to 20 % Foetal calf 
serum, glutamine, penicillin and streptomycin (MacLeod 1984; MacLeod 
1985)
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SL 12.1 and SL 12.4 cells appeared to be less tiimourigenic than their 
parental SL 12 cells in vivo. W hen reinjected intravenously into AKR mice 
via the lateral tail vein, neither SL 12.1 nor SL 12.4 nor both cells at 
different mixed proportions produced the same rapid onset and progression 
of disease observed with the parental cell line SL 12 (MacLeod 1984). 
Subsequently, a further T-cell lymphoma clone, SL 12.3, was established 
from recultured cells from the spleen of a six week old AKR mouse six days 
after intravenous injection o f 10^ SL 12 cells followed by limiting dilution 
cloning.
In vivo characteristics ofSL 12.3 and SL 12.4 cell lines
"1.
%If'In vivo, the tumourigenicity o f SL 12.3 was foimd to be similar to the SL 12 
parent cell line. Compared with the SL 12.4 cell line, in studies by 
MacLeod, SL 12.3 produced tumours in all animals after inoculation of 10"^  
cells whereas only one-half o f the animals were affected after an inoculation 
of 10^ SL 12.4 cells (Table 3.1) (MacLeod 1985). The differences in 
tumourigenicity were not affected by the age and sex o f the recipient animal.
The difference in tumourigenicity and the latent period between inoculation 
and tumour formation between SL 12.3 and SL 12.4 cells was further 
demonstrated by intradermal inoculation (Table 3.2).
I#
If I"
:
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Table 3.1 Tumourigenicity of SL 12, SL 12.3 and SL 12.4 cells after intravenous inoculation 
(MacLeod. 1985)
S L  12 S L  1 2 .3 S L  1 2 .4
No. of cells % of Latency % of Latency % o f Latency
inoculated animals period animals period animals period
developed between developed between developed between
lymphoma inoculation lymphoma inoculation lymphoma inoculation
and disease and disease and disease
10^ 100 9-12 days 100 10-16 days 43.3 34-79 days
10^ 100 12-16 days 100 14-18 days 8.3 49 days
10^ 100 16-24 days 100 23-27 days 0 -
10^ 100 21-30 days 40 23-45 days 0 -
Table 3.2 Tumourigenicity of SL 12, SL 12.3 and SL 12.4 cells afier intradermal inoculation 
(MacLeod 1985)
S L  12 S L  1 2 .3 S L  12 .4
No. of cells 
inoculated
% o f
animals
developed
lymphoma
Latency
period
between
inoculation
and 2 mm
nodule
% o f
animals
developed
lymphoma
Latency
period
between
inoculation
and 2 mm
nodule
% of 
animals 
developed 
lymphoma
Latency
period
between
inoculation
and 2 mm
nodule
ï ÿ 100 4 days 100 5 days 100 8 days
10^ 100 5 days 100 9 days 0
........................
lO'^ 100 9 days 100 13 days 0
....................: .......................
10^ 100 11 days 50 - 0 :....................
1 ? ............... 100 14 days Not tested - 0
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Furthermore, the macroscopic pattern of metastasis m vivo also differ 
between the SL 12, SL 12.3 and SL 12.4 cell lines after intravenous 
inoculation of 10^ cells. SL 12.3 cell line produced difftise splenomegaly 
with occasional hepatomegaly whereas SL 12.4 cell Ime appeared to 
produce diffuse involvement of the liver (37 % of animals) and the spleen 
(58 % o f animals) (MacLeod 1985).
In addition to hepatosplenic involvement, SL 12.4 cell line has been shown 
to produce extranodal tumours which consisted of massive nodules in the 
kidneys, tumour mass in the thigh muscle and around the knee joint, 
subcutaneous tumour nodules, orbital and intracerebral tumours and massive 
bilateral ovarian tumours in about 95 % of animals (Table 3.3) (MacLeod
1985).
Table 3.3 Metastatic pattern of SL 12, SL 12.3 and SL 12.4 cell lines after intravenous 
inoculation of 10® cells
SL 12 SL 12.3 SL 12.4
Muscle 0% 0% 37%
Liver 100 % (diffuse) 87 % (diffuse) 37 % (difflise)
Spleen 100 % (diffuse) 100 % (diffuse) 58 % (diffuse)
Ovaries 0% 0% 95 % (>1 cm)
Mean latent period in days
_ I s
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Microscopically, all tumour cells had large and pleomoiphic nuclei but no 
detailed microscopic analysis o f individual organ was docmnented 
(MacLeod 1985).
In vitro characteristics ofSL 12.3 and SL 12.4 cell lines
In tissue culture both SL 12.3 and SL 12.4 cells grow in suspension. SL 12.3 
cells grow difflisely whereas SL 12.4 cells grow in clumps (MacLeod 1985).
The in vitro phenotypic characterisation of SL 12.3 and SL 12.4 cell lines 
has shown that both the cell lines differ in their expression o f inRNAs for 
several surface antigens. The SL 12.4 cell line expresses mRNAs for almost 
all the components o f TCR/CD3 complex. The TCR or T-cell receptor 
antigen is expressed in association with the CD3 complex proteins by all 
developing thymocytes in order to become ftmctional in the immune system. 
Furthermore, SL 12.4 cells also express surface antigen TdT, which is found 
in cortical thymocytes. SL 12.3 cell line, on the other hand, expresses very 
few of the genes required for T-cell flmction and does not express TdT 
(MacLeod 1990).
However, both cell lines were found to have no expression o f the suiTace 
antigens Lyt-1 (which is commonly found on cortical thymocytes) and Lyt-2 
(which is found on medullary thymocytes and on functional T-cells). These 
surface markers are known to be present in primary spontaneous lymphoma 
(Lyt-1) and virus accelerated lymphomas (Lyt-2).
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111 summary, SL 12.4 cell line appears to be the most differentiated and least 
tumourigenic clone with surface markers of immature cortical thymocytes. 
On the other hand, the SL 12.3 cell line appears to be the least differentiated 
and most tumourigenic clone with surface antigens of even more immature 
thymocytes (MacLeod 1985).
One of the most interesting aspects o f the SL 12.3 / SL 12.4 model o f
metastasis is that these two closely related clones appear to exhibit 
.completely different metastatie pattern in vivo. One clone, SL 12.3, 
producing diffusely hepatic involvement and SL 12.4 apparently producing
predominantly nodal disease and nodular deposits. Detailed microscopic 
analysis was not performed however in M acLeod’s initial studies but these 
two patterns o f metastasis are frequently seen in human tumours for 
example, metastatic adenocarcinoma of the colon.
This metastatic model was therefore chosen for further investigation and 
characterisation.
II"II
Chapter 4 Aims, Hypothesis & Overview of 
Studies Performed
Studies on the M olecu lar P ath ology  o f  M etastasis w ith  
particu lar reference to the SL 12 m urine lym phom a m odel
Aim :
Hypothesis :
Overview of the studies :
The study is divided into three 3 sections as shown in figure 4.1. In the first 
section, the SL 12.3 / SL12.4 model of metastasis was re-established in
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The aim of these studies is to investigate the molecular pathology of 
metastasis focusing on the homing phenomenon of tumour cells and the 
possible genes responsible in the metastatic process.
ii
Variation in metastatic potential between clones of the same tumour cell
population is due in part to the differentiation of genes, which after either
.being activated or repressed, favour the selective growth of the certain cells 
in organ specific environments. Furtlrermore, differences in gene expression 
may allow immune evasion, “homing” of particular clones to specific distant
tissues and favour implantation.
AKR mice. The growth rate in vitro, tumourigenicity, microscopic and 
macroscopic pattern o f metastasis of the SL 12.3 / SL 12.4 model was 
studied in detail in AKR mice.
In the second section, radiolabelled cells were used to study the metastatic 
pattern and the dissemination o f the two cell lines o f interest to different 
organs after intravenous injection.
In the tliird section, the teclmique of differential display was used to identify 
and isolate cDNAs expressed in one cell line and not in the other. This study 
then concludes with the amplification and comparison of cDNAs of interest 
with known sequences in gene databanks.
i
. V  I - ' .
Figure 4.1 Overview of the study
SL 12.3 & SL 12.4 cell lines re-established 
▼
Further definition of macroscopic and microscopic metastatic pattern
T
In vivo tracking of radiolabelled cells
M olecular studies o f differential gene expression 
between the two cell lines
T
Differential display ▼
Amplification cDNA of interest 
Sequencing 
Identification of cDNAs
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Chapter 5 Establishing the SL 12.3 and SL 12.4 Lymphoma model and in vitro growth rate comparison
The SL 12.3 and SL 12.4 cell lines were re-established in tissue culture from 
frozen storage supplied as a kind gift o f Professor M acLeod (UC, San 
Diego).
Both SL 12.3 and SL 12.4 cells were grown in Dulbecco's modified Eagle 
medium (DMEM, Imperial) supplemented with 10 % foetal calf serum 
{Imperial), L-glutamine (20 mis o f 200 inM/L of medimn. Sigma) penicillin 
(100,000 units/L o f medium, Sigma) and streptomycin (100 mg/L of 
medium. Sigma). The cells were cultured at 37”C with an atmosphere 
containing 5 % CO2.
10^ cells were initially transferred mto 6 mis o f supplemented DM EM  in 25 
cm^ tissue culture flasks {Costar). Subsequently, cells were recultured with 
passage of 1 ml of medium plus cells into 5 mis of fresh supplemented 
DM EM  every 48 to 72 hours.
In vitro grow th  characteristics  
Methods
2 X 10^ SL 12.3 and SL 12.4 cells were introduced into 75 cm^ tissue 
culture flask (Costar) witli 10 mis of DM EM  each. Each day 90 pis of cells
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was pipetted out and mixed with 10 pis o f 0.4 % Trypan Blue. 15 pis o f this 
mixture was used to fill two counting wells. Live cells were counted in 
duplicate from the 25 squares o f two counting chambers with a total volume 
of 0.1 mm^ or 10"^  ml (1 mm X 1 mm X 0.1 mm) each. The mean value of 
the two counts were multiplied by 10"^  (for a volume of 1 ml) and 10 (for 
1 Omis) to give the number of live cells per 10 mis of sample. This is then 
further corrected for the volume o f Trypan Blue that was 10 % of the total 
volume. No further medium was added after each daily count. Growth 
curves were estimated in triplicate.
Results:
SL 12.3 and SL 12.4 grow in suspension in supplemented DMEM. Unlike 
SL 12.3 cells, SL 12.4 cells tend to grow in clumps (Figure 5.1 and 5.2).
Figure 5.1: SL 12.3 cells grows diffusely
%
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Figure 5.2: SL 12.4 cells grows in clumps
I;' '  '
Daily cell counts (Table 5.1) and growth curves (Figure 5.3) for the SL 12.3 
and SL 12.4 showed that both the cell lines grow at a similar rate with cells 
reaching exponential growth rate between forty-eight to seventy-two hours 
before medium exhaustion. Doubling time for both cell lines is 
approximately sixty hours
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Table 5.1. Daily cell counts for SL 12.3 and SL 12.4 cells
S L  12 J
Days Study 1 Study 2 Study 3 Mean Standard error of mean
0 2610000 1770000 4000000 2793333 650239
1 1420000 654000 2620000 1564667 572126
2 2430000 1400000 4000000 2610000 755932
3 5410000 4820000 9950000 6726667 1620641
4 5300000 5090000 4350000 4913333 288116
5 4100000 6090000 5095000 995000
S L  12,4
Days Study 1 Study 2 Study 3 Mean Standard error of mean
0 2700000 2880000 1000000 2193333 598925
1 2450000 654000 425 0 00 0 2451333 1038076
2 2700000 864000 10900000 4821333 3085199
3 4170000 4280000 18500000 8983333 4758439
4 4770000 4770000 12700000 7413333 2643333
5 6990000 4830000 5910000 1080000
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The growth curve for SL 12.3 and SL 12.4 cell lines 
(Error bar = standard error of the mean)
Chart 5.1
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Chapter 6 Macroscopic and microscopic study of 
metastatic pattern
Introduction
Although earlier studies (MacLeod 1985; MacLeod 1990) demonstrated a 
difference in metastatic pattern, no microscopic analysis was performed.
The studies were not randomised and differing numbers o f cells were 
inoculated. The previous studies o f M acLeod were therefore expanded with 
frill macro and microscopic analysis.
Methods :
Either 10^ SL 12.3 or 10^ SL 12.4 cells was injected via the tail veins into 
twenty two 8-10 week old AKR mice. Subsequently the study was repeated 
using 14 AKR mice inoculated with 10^ SL 12.4 cells.
Injection o f cells into AKR mice
SL 12.3 and SL 12.4 cells during the exponential growth phase (48 to 72 
hours after starting culture) were pelleted and re-suspended in Phosphate 
Buffered Saline (PBS) at appropriate concentrations. The mouse was 
restrained in a bivalved 50 mis bladder syringe (Figure 6.1). 10^ SL 12.3 
cells, 10^ SL 12.4 cells or 10^ SL 12.4 cells in 200 pL of Phosphate
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Buffered Saline (PBS) were injected into the tail veins of 11, 11 and 14 
AKR female mice respectively. In the initial set of mice with 10^ SL 12.3 or 
SL 12.4 cells, the injection order was randomised to avoid bias due to errors 
in injection teclinique.
Figure 6.1; AKR mouse restrained for tail vein injection
BrVALVED CLAI^IP TO
TAIL
FOR
INJECTION
BLADDER HOLD
SYRINGE SYRINGE
\ A
PLUNGERAKR MOUSE
Post injection, the mice were kept on a standard diet, observed and weighed 
daily. Any mouse showing signs of distress (e.g., hunched and piloerection), 
losing more than 10% of their original weight or surviving beyond 8 weeks 
was euthanised and had an autopsy performed. Organs fi'om each mouse 
(i.e., liver, spleen, lymph node, ovaries, lungs, kidneys and brain) were 
weighed and their macroscopic appearances recorded before being fixed 
with acetic methanol (1:3) for 1 hour. All tissues were preserved with formal 
salme (Bancroft 1990) until further use.
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Microscopic study
Two sections of different plane (horizontal and vertical) of 3 to 5 inin thick 
were cut randomly from each organ. The specimens were dehydrated 
tlirough alcohol before being embedded into wax. Sections of 4 pm were cut 
with a standard microtome on each tissue biopsy and all specimens were 
stained with haematoxylin-eosin dye. The stained specimens were then 
analysed m conjunction with a consultant histo-pathologist. Sections were 
scored as either ‘definitely positive’, if there were groups of eight to nine 
large lymphoblasts seen infiltrating the tissue or as ‘definitely negative’ if 
there were none or less than five lymphoblasts. When there are any doubts 
about a slide, another random section was cut from tlie wax block and re­
analysed.
Results
Macroscopic analysis
The results of the macroscopic analysis on the metastatic patterns of SL 12,3 
and SL 12.4 within 8 weeks of injection are shown in Table 6.1a and b. 
Injecting 10^ SL 12.3 cells intravenously into each of the 11 AKR mice 
produced 100 % mcidence of métastasés. The mice deteriorated over 17 
days (median) with a range between 11 to 24 days. SL 12.3 cells appeared 
to produce métastasés mainly within the liver (100 %) and spleen (100 %) 
causing difhise organ enlargement as shown in Figure 6.2. Only 1 mouse
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(9.1 %) of this group had renal and subcutaneous secondaries. No mice had 
ovarian enlargement.
In contrast, 10^ SL 12.4 cells injected intravenously into each of 11 AKR 
mice only produced metastasis in one mouse only at 22 days. The remaining 
mice survived up to 8 weeks with no apparent distress when the study was 
terminated. On repeating this section of the study with 10^ SL 12.4 cells 
injected intravenously into 14 AKR mice, the incidence of metastasis 
increased to 78.5 % (11/14). Unlike SL 12.3 cells, mice developed large 
ovarian metastasis (greater than 1 cm in diameter) in one of the eleven mice 
following injection of 10^ SL 12.4 cells and in six out of fourteen mice 
following injection of 10^ SL 12.4 cells. The other major differences 
macroscopically were a higher mcidence of nodular renal metastasis (5/14, 
35.7 %) and also massive retroperitoneal lymph node involvement, (8/14, 
57.1 %) again followmg tlie injection of 10^ SL 12.4 cells. An example of 
the macroscopic findings in mice injected with SL 12.4 cells is shown in 
Figure 6.3. The involved ovaries were found to be enlarged, haemoniiagic 
and difhisely involved with métastasés. Gross hepatosplenomegaly after SL 
12.4 injection was not seen in contrast to SL 12.3 injection (figure 6.2).
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Table 6.1a, Macroscopic pattern of metastasis shown by 10  ^12.3 and 10® SL 12.4 ceils 
(p-value calculated using the Exact Probability Test)
( *** = p<0.001 )
Mouse SL 12.3 SL 12.4
Number of Cells 10^ 10^
Liver 11/11 
(100.0 %)
1/11
(9.1 %)
Spleen 11/11 
(100.0 %)
1/11 
(9.1 %)
Kidneys 1/11 
(9.1 %)
1/11
(9.1 %)
Ovaries 0/11 
(0.0 %)
1/11 
(9.1 %)
Lungs 0/11 
(0.0 %)
0/11 
(0.0 %)
Retroperitoneal lymph nodes 0/11 
(0.0 %)
1/11 
(9.1 %)
Brain 0/11 
(0.0 %)
0/11
(0.0 %)
Thymus 0/11 
(0.0 %)
0/11 
(0.0 %)
Subcutaneous metastasis 1/11 
(9.1 %)
0/11 
(0.0 %)
Median Latent Period days 
(Range)
17 days 
(11-24 days)
56 days 
(22-56 days)
(p-value for Median Latent Period was obtained using the Wilcoxon Rank Sum Test)
(## = p<0.01)
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Table 6.1b. Macroscopic pattern of metastasis shown by 10® 12.3 and 10  ^SL 12.4 cells 
(p-value calculated using the Exact Probability Test) 
f  ** = p<0.01, * = p<0.05)
Mouse SL 12.3 SL 12.4
Number of Cells 10^ 10?
Liver 11/11 
(100.0 %)
11/14 
(78.5 %)
Spleen 11/11 
(100.0 %)
11/14 
(78.5 %)
Kidneys 1/11 
(9.1 %)
5/14
(35.7 %)
Ovaries 0/11 
(0.0 %)
^6/14 
(42.9 %)
Lungs 0/11 
(0.0 %)
0/14 
(0.0 %)
Retroperitoneal lymph nodes 0/11 
(0.0 %)
**8/14 
(57.1 %)
Brain 0/11 
(0.0 %)
1/14 
(7.1 %)
Thymus 0/11 
(0.0 %)
0/14 
(0.0 %)
Subcutaneous metastasis 1/11 
(9.1 %)
2/14
(14.3 %)
Median Latent Period days 
(Range)
17 days 
(11-24 days)
^^48 days 
(31-56 days)
I
(p-value for Median Latent Period was obtained using the Wilcoxon Rank Sum Test)
(## = p<0.01)
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Figure 6.2 Example of findings on an abdominal examination on an AKR mouse 
injected with 10® SL 12.3 cells (median = 17 days; range = 11-24 days)
LIVER
SPLEEN
Figure 6.3 Example of findings on an abdominal examination on an AKR mouse
injected with 10  ^SL 12.4 cells (median = 48 days; range = 31-56 days)
LIVER
RIGHT
KIDNEY
RIGHT
OVARY
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The macroscopic differences between organs of mice injected with SL 12.3 
and SL 12.4 cells are also demonstrated when the mean percentage body 
weight o f individual organs are compared as shown in Table 6.2 and 
graphically in Chait 6.1
Table 6.2 The mean percentage of body weight (Standard Deviation) of organs in mice injected 
with SL 12.3 and SL 12.4 cells
Organs SL 12.3 (10® cells) SL 12.4(10® cells)
Liver **11.080 (3.246) 5.806 (0.508)
Spleen *2.237 (0.505) 0.513(0.598)
Right Kidney 0.838 (0.069) 0.775 (0.089)
Left Kidney 0.794 (0.055) 0.745 (0.058)
Right Lung 0.790 (0.241) 0.555 (0.170)
Left Lung 0.427 (0.184) 0.273 (0.078)
Right ovary 0.122 (0.044) 0.074 (0.026)
Left ovary 0.128 (0.048) 0.064 (0.018)
Organs SL 12.3 (10® ceils) SL 12.4(10" cells)
Liver **11.080 (3.246) 6.024(1.086)
Spleen **2.237 (0.505) 0.600 (0.418)
Right Kidney 0.838 (0.069) 0.786 (0.124)
Left Kidney 0.794 (0.055) 0.721 (0.084)
Right Lung **0.790 (0.241) 0.532 (0.165)
Left Lung 0.427 (0.184) 0.331 (0.130)
Right ovary 0.122 (0.044) 0.890 (1.367)
Left ovary 0.128 (0.048) 0.601 (0.820)
'^*=p<0.01 * = p<0.05
(p~values were obtained using the Wilcoxon Rank Sum Test)
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Chart 6.1 The comparison between mean percentage of body weight of organs in mice 
injected with 10« SL 12.3 ceiis, 10® SL 12,4 ceiis and 10? SL 12.4 ceils 
(arrows indicate significant differences between 10  ^SL 12.3 ceils and W  SL 12.4)
Mean percentage of total body weight
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Microscopic analysis
Microscopic analysis differs from the macroscopic pattern in certain organs 
(Table 6.3). Microscopic analysis confirmed the macroscopic appearance in 
liver and spleen involvement. Although renal tissue was not enlarged 
following SL 12.3 injection, microscopic métastasés were present in 7/11 
(63.6%) kidneys and in particular, although, the ovaries were not enlarged in 
SL 12.3 mice microscopic métastasés were present in all ovarian tissue 
examined. This is in contrast to the obvious massive involvement of ovarian 
tissue by SL 12.4 cells although in 5/14 no microscopic ovarian disease was 
detected. Similarly, microscopic infiltration was seen following SL 12.3 
injection in both lungs and retroperitoneal lymph nodes.
Furthermore, microscopic studies showed that the pattern of infiltration 
differs between organs. For example, in the lungs, tumour cells were found 
to be in the interstitial tissues and in the brain, the meninges were the site of 
involvement compared to parenchymal involvement in most organs.
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Table 6.3. Macroscopic and microscopic patterns of SL 12.3 and SL 12.4 cells
SL12.3 SL12.4 SL12.4
Cells 
(X 10")
1 1 10
Macro Micro Macro Micro Macro Micro
Liver 11/11
(100%)
9/11
(81.8%)
1/11
(9.1%)
1/11
(9.1%)
11/14
(78.5%)
10/14
(71.4%)
Spleen 11/11
(100%)
11/11
(100%)
1/11
(9.1%)
1/11
(9.1%)
11/14
(78.5%)
8/14
(57.1%)
Kidneys 1/11
(9.1%)
7/11
(63.6%)
1/11
(9.1%)
1/11
(9.1%)
5/14
(35.7%)
5/14
(35.7%)
Ovaries 2/11
(18.2%)
11/11
(100%)
1/11
(9.1%)
2/11
(18.2%)
6/14
(42.9%)
9/14
(64.3%)
Lungs 0/11
(0.0%)
11/11
(100%)
0/11
(0.0%)
0/11
(0.0%)
0/14 
(0.0 %)
8/14
(57.1%)
Retroperitoneal 
lymph nodes
0/11
(0.0%)
11/11
(100%)
1/11
(9.1%)
1/11
(9.1%)
8/14
(57.1%)
6/14
(42.9%)
Brain 0/11
(0.0%)
3/11
(27.3%)
0/11 
(0.0 %)
1/11
(9.1%)
1/14
(7.1%)
5/14
(35.7%)
Thymus 0/11
(0.0%)
5/11
(45.5%)
0/11
(0.0%)
0/11
(0.0%)
0/14
(0.0%)
6/14
(42.9%)
Subcutaneous
metastasis
1/11
(9.1%)
i / l l
(9.1%)
0/11
(0.0%)
0/11
(0.0%)
2/14
(14.3%)
2/14
(14.3%)
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Chapter 7 Cell tracking studies
Introduction
To study the distribution of SL 12.3/SL 12.4 cells after re-injection into 
AKR mice cell tracking studies were perfonned. The study o f cellular 
dissemination and arrest in metastasis requires a suitable teclinique that 
permits the identification and quantification of tumour-cell emboli. One 
method of doing this is to label living cells with radioisotopes as described 
by Tidier (Tidier 1970). Several criteria must be satisfied when 
radioisotopes are used for labelling living cells. Firstly, the radioactive label 
should bind finnly to the cells while they are still viable. Wlien labelled cells 
die, the isotope must not be re-utilised by other cells, but excreted rapidly. 
Secondly, the radioactive label must not alter the biological behaviour of the 
tumoui' cells when bound. Thirdly, the quantity of radioactive label used 
should be sufficient to allow a few cells to be detected sensitively in vivo but 
not to be in excess to kill botli the host and the tumom* cells.
^H-tliymidine, ^^Cr and 5-(^^I)odo-2'-deoxyuridine (^^^lUDR) have all been 
used in such studies. Results using ^H-thymidine and ^^Cr are controversial 
as they do not meet the ideal criteria. For example, when or ^^Cr are 
released from dead cells, they can be re-utilised by adjacent nonnal host 
stromal cells. Furthermore, the rate o f escape of ^ ^Cr from viable tumour 
cells is rapid and up to 60 % can be lost. ^^Cr can also be re-utilised and 
absorbed by the normal host’s cells within 24 hours. As a result, tissue
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counts may not represent the true number of viable circulating tumour cells 
(Fidler 1970).
5-(^^^I)odo-2-deoxyuridine (^^^lUDR), which has a half life o f 59.6 days, 
tends to fit the ideal selection criteria slightly better. Being an analogue of 
thymidine, ^^^lUDR is incorporated exclusively into DNA of actively 
dividing cells. When the cells die, unlike thymidine, ^^^lUDR is released and 
is not re-utilised by other cells. Released and unused ^^^lUDR is degraded 
quickly in the liver and the degradative products are largely excreted in the 
mine (Fidler 1970). Furthermore, is suitable for autoradiographic 
studies. This is useful when determining the quality of radiolabelling and the 
percentage of radiolabelled cells.
For each cell line studied in this manner, the optimiun concentration of the 
isotope must be determined and labelling efficiency checked by 
autoradiography. Subsequently tracking studies were performed following 
the inoculation of labelled cells into AKR mice.
D eterm ination  o f  the optim al concentration  o f  ^^^I-5-Iodo-2' 
deoxyiirid ine for labelling  SL 12.3 and SL 12.4 cells
Method
10 petri dishes containing 10^ SL 12.3 cells per 6 mis o f medium each and 
10 petri dishes containing 10^ SL 12.4 cells per 6 mis o f medium each were 
incubated at 37°C with 5 % carbon dioxide for 24 hours. ^^^I-5-lodo-2'-
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deoxyiiridine (^^^lUDR) was added to each of the petri dishes at the 
following concentrations: 0 (control), 0.5, 1.0, 2.0 and 5.0 pCi/ml in 
duplicate.
Incubation was continued and after 24 hours, the cells were pelleted and 
washed tliree times with phosphate buffered saline (PBS). The washed 
radiolabelled cells were then analysed by gamma coimter to determine the 
amount o f ^^^lUDR incorporation. The cells were then returned to normal 
medium before re-incubation and daily cell counts were performed to 
monitor cell viability and growth over a five-day period.
Results
The radiolabelled cells from each petri dishes containing either 10^ SL 12.3 
or 10^ SL 12.4 with varying concentration of ^^^1-5-Iodo-2'-deoxyuridine 
were analysed with the gamma counter. The percentage of incorporation of 
radioactivity was calculated using the foiimila:
% of incorporation = Counts per minute o f Washed Cells
Counts per minute of Unwashed Cells + Medium
The percentage of incorporation of ^^^lUDR by SL 12.3 and SL 12.4 cells 
are shown in Table 7.1 and graphically in Chart 7.1
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T able 7.1. Percentage of incorporation of radioactive labels by cells at different
concentration of l-5“lodo-2'-deoxyuridine
Petri dish 
(6 mis of 
medium)
Concentration
of
(^iCi/ml)
%
incorporation
%
incorporation
Mean Standard 
error of 
mean
SL 12.3 (SET 1) (SET 2)
0 0.00 0.00 0.00 0.00
0.5 2.43 6.24 4.34 1.91
1.0 2.85 8.47 5.66 2.81
2.0 4.04 9.72 6.88 2.84
5.0 6.28 9.43 7.86 1.57
SL 12.4 (S E T l) (SET 2)
0 0.00 0.00 0.00 0.00
0.5 5.22 2.99 4.11 1,12
1.0 6.08 4.38 5.23 0.85
2.0 5.61 4.04 4.83 0.78
5.0 6.35 5.97 6.16 0.19
a
"S.
Table 7.1a. p-values (determined with Student T-test) showed no significance statistically 
between the incorporation of different concentration of by SL 12.3 and 
SL 12.4 cells
:
Concentration of 
""TUDR (pCi/ml)
Mean % of 
incorporation for 
SL 12.3
Mean % of 
incorporation for 
SL 12.4
P value using Student 
T-test
0 0 0 -
0.5 4.34 4.11 0.9
1.0 5.66 5.23 0.9
2.0 6.88 3.83 0.6
5.0 7.86 6.16 0.4
I
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Chart 7.1 : Mean percentage (standard error of mean) of incorporation of radioactive labels
by SL 12.3 and SL12.4 cells at different concentration of i^M-5-lodo-2' 
deoxyuridine.
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Concentration of 125 lUDR
To check that ^^^lUDR incorporation did not affect cell growth rates, daily 
cell counts for 5 days were performed and the results are as shown in table 
7.2 and graphically in charts 7.2, 7.3, 7.4 and 7.5
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T able 7.2, Daily cell counts to check viability and growth of SL 12.3 and SL 12.4 cells
at varying concentration of ^^s|-5-lodo-2'-deoxyuridine
SL12.3 (SET 1) Day 0 Day 1 Day 2 Day 3 Day 4 Day 5
Petri
Dish
Concentration
(pCi/inl)
X 10^  
cells
X 10^  
cells
X 10^  
cells
X 10^  
cells
X 10"^
cells
X 10^ ^
cells
1 0 1.0 0.12 0.74 0.99 1.31 1.46
2 0.5 1.0 0.12 0.29 0.64 1.77 1.29
3 1.0 1,0 0.18 0.56 0.35 1.88 1.46
4 2.0 1.0 0.18 1.59 1.04 2.05 1.48
5 5.0 1.0 0.18 0.44 1.19 1.88 2.35
SL12.3 (SET 2) Day 0 Day 1 Day 2 Day 3 Day 4 Day 5
6 0 1.0 0.12 0.41 1.19 1,10 1.29
7 0.5 1.0 0.12 0.47 0.81 1.80 1.43
8 1.0 1.0 0.12 0.62 0.84 0.66 2.04
9 2.0 1.0 0.12 0.77 0.87 2.39 2.04
10 5.0 1.0 0.18 0.24 0.81 1.48 2.80
SL12.4 (SET 1) Day 0 Day 1 Day 2 Day 3 Day 4 Day 5
11 0 1,0 0.06 2.18 ^ 2.61 3.56 3.16
12 0.5 1.0 0.12 1.24 4.32 6.56 5.43
13 1.0 1.0 0.12 0.92 2.67 3.31 4.86
14 2.0 1.0 0.12 2.24 3.71 4.45 2.66
15 5.0 1.0 0.12 0.35 1.94 2.14 2.63
SL12.4 (SET 2) Day 0 Day 1 Day 2 Day 3 Day 4 Day 5
16 0 1.0 0.12 0.74 0.98 10.3 7.62
17 0.5 1.0 0.12 0.29 0.64 7.61 7.25
18 1.0 1.0 0.12 0.68 4.99 9.09 6.22
19 2.0 1.0 0.06 2.30 7.02 4.16 5.74
20 5.0 1.0 0.18 2.66 7.08 6.73 6.24
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Chart 7.2. Growth curve of SL 12.3 cells (Set 1) in different concentrations of ^4UDR over
5 days
X 10® cells
2.5 -I
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Chart 7.3. Growth curve of SL 12.3 cells (Set 2) in different concentrations of ^^siUDR over 
5 days
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Chart 7.4 Growth curve of SL 12.4 cells (Set 1 ) in different concentrations of
over 5 days
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Chart 7.5. Growth curve of SL 12.4 cells (Set 2) in different concentrations of ^^ l^UDR 
over 5 days
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The above results show that a concentration of 2 |uiCi/ml o f ^^^lUDR results 
in a high percentage of isotope incorporation without loss o f cell viability. 
Five pCi/ml o f ^^^lUDR also resulted in good incorporation but a reduction 
in cell gi'owth in one set of cells studied. Taking into account these results 
and economy of isotope used, a labelling concentration of 2 pCi/ml of 
^^^lUDR was chosen for further study.
Autoradiography
Method:
Preparation o f emulsion fo r autoradiography
Under red safe light in the dark room, the emulsion {Kodak NTB2) was 
diluted 50:50 with distilled de-ionised water and the mixture heated in a 
40^C water bath for thirty minutes without boiling.
Autoradiography
SL 12.3 and SL 12.4 cells at exponential growth were radiolabelled with 
2 jLiCi/ml of ^^^lUDR as described above. A  drop of washed labelled cells 
was smeared onto a glass slide. The slide was air dried for one hour before 
being fixed with freshly prepared chilled acetic acid/methanol (1:3) for
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fifteen minutes. Under red safe light, the lower two-thirds of the slide with 
the specimen was immersed into the prepared emulsion for two seconds. 
The slide was withdrawn slowly and left to drain vertically for five minutes 
and horizontally for thirty mmutes (Figure 7.1) before being stored in a light 
tight microscopic slide box containing a desiccant. The whole box was 
sealed and kept in 4^C for fourteen days.
The slide was exposed to atmospheric temperatuie and humidity for two 
minutes before being immersed mto photographic developer solution 
(Aculux). After five mmutes, the slide was briefly washed in distilled 
deionised water before being immersed into photographic fixer solution 
(Acufix) for five minutes. The prepared slide was then be stained with 
Haematoxylin and Eosin dyes.
Figure 7.1 Steps in preparing an autoradiograph
I
A d ro p  of labe lled  j  
ce lls  t r a n s fe r re d  
o n to  s l id e  ^
D rained  vertica lly
S lide  d ip p e d  into
/
Drii
(40°C water bath)
ried h o r izon ta l ly
K ept in s e a le d  bo x  fo r  14 d a y s  a t  4 C 
▼
Im m e rse d  in to  ‘D e v e lo p e r ’ a n d  la te r  in to  ‘F ixer’ s o lu t io n
▼
S ta in e d  w ith  H aem atoxy lin  a n d  E o s in
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Results
Figure 7.2 show a representative autoradiogram. ^^^lUDR is taken into the 
nucleus and therefore, labelled viable cells appeared to have dark granules in 
their nuclei. Cells which do not take up ^^^lUDR are either dead or remain 
unlabelled. This study confirmed that nuclear labelling had occurred.
Figure 7.2 : Autoradiograph of SL 12.3 cells following labelling with ^^sujDR (Low power)
Unlabelled 
cells
Labelled
cells
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In vivo studies o f  cell d issem ination  and arrest
Methods
Mice
36, eight to ten weeks old inbred female AKR stram mice were used in this 
study. All mice were maintained on a standard mouse diet. All mice were 
given water supplemented with 0.1 % sodium iodide to saturate tlieir tliyroid 
gland three days before injection, thus, preventing thyroid uptake of the 
^^^lUDR
In vivo tracking
SL 12.3 and SL 12.4 cells at exponential growth rate were radiolabelled 
with 2 jLiCi/ml of ^^^lUDR as described above. The cells were pelleted and 
total radioactivity counted before bemg re-suspended to produce an 
inoculum of 10^ cells in 200 pd of sterile phosphate buffer (PBS). The total 
counts per minute o f the pelleted cells were recorded which enabled a count 
per cell to be calculated.
Mice were randomly assigned to be injected with SL 12.3 or SL 12.4 cells 
and a time point to be sacrificed.
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The selected mouse for injection was restrained in a modified bivalved 50 
mis bladder syringe and radiolabelled cells were injected into the mouse via 
the tail vein. Eighteen mice received radiolabelled SL 12.3 cells while the 
other eighteen mice received radiolabelled SL 12.4 cells.
Post injection, the mice from both groups were euthanised at different time 
point as follows:
• six mice at fifteen minutes,
• six mice at one hour
• six mice at tliree hours. I
Autopsies were performed on all the mice and the following tissues and i
I '
organs were harvested, weighed and contained radioactivity counted:
Brain biopsy * Kidneys * Lungs Thymus
Liver * Ovaries Spleen
I* Retroperitoneal lymph nodes
The number of counts per minute for each organ was divided by the wet
tissue weight in grams to give a figure for counts per gram of wet tissue. g
IThis was related to the number of either SL 12.3 or SL 12.4 cells present by T
division by the previously calculated counts per cell.
%
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Results
The mean number o f viable cells in the organs harvested at fifteen minutes, 
sixty minutes and three hours are shown in table 7.3 (a, b and c) and
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graphically in charts 7.6, 7.7 and 7.8. M ean number o f viable cells per gram 
of organs harvested are given in table 7.4 (a, b and c) and shown graphically 
in charts 7.9, 7.10 and 7.11.
:
Table 7.3a: Mean number [Standard Deviation] of viable SL 12.3 and SL 12.4 cells estimated to 
be within each organ at 15 minutes after injection
SL 12.3 (15 minutes) SL 12.4 (15 minutes)
(n= 6  mice) 1 1 = 6  mice
BRAIN 16S4[1101] (0.17 %) 2512 757207(0.25 %)
RIGHT
KIDNEY
10769 [16587] (1.08 %) 17108 7257757(1.71 %)
LEFT
KIDNEY
18991 [21380] {130 %) 14931 7277527 (1.49 %)
RIGHT
LUNG
123714 [255257] (12.37 %) 76796 [107035] (7.68 %)
LEFT
LUNG
98022 [159576] (9.80 %) 50800 7750577 (5.08 %)
LIVER 481494 [610953] (48.15 %) 153511 77627277(15.35 %)
LYMPH
NODES
1788 [1205] (0.18 %) 2593 [3284] (0.26 %)
OVARIES 3063 /27757(0.31 %) 4643 [7745] (0.46 %)
SPLEEN 10625 77742^7 (1.06 %) 408275957/ (0.41 %)
THYMUS 2152 77767/ (0.22 %) nOAl [19069] {1.10 %)
(p-values were obtained using the Wilcoxon Rank Sum Test)
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Table 7.3b : Mean mm ber [Standard Deviation]of m b \e  SL 12.3 and SL 12.4 cells estimated to
be within each organ at 60 minutes after injection
SL 12.3 (1 hour) SL 12.4 (1 hour)
n=6 mice n=6 mice
BRAIN 1517 775527(0.15 %) * 8994 [7676] (0.90 %)
RIGHT
KIDNEY
15566 7270<S57 (1.56 %) 16041 7 7 5 5 5 5 7  (1.60 %)
LEFT
KIDNEY
15263 [24409] (1.53 %) 12016 [8785] {1.20 %)
RIGHT
LUNG
6393 [6574] (0.64 %) 21860 7777607(2.19 %)
LEFT
LUNG
10042 7722^67(1.00 %) 16326 7756557 (1.63 %)
LIVER 120585 [213535] (12.06 %) 55725 [40259] (5.57 %)
LYMPH
NODES
1974 [132] (0.20 %) 2144 72257(0.21 %)
OVARIES 112A [1780] {O .ll %) 11015 7707667(1.10 %)
SPLEEN 11085 7204777(1.11 %) 15187 7702667(1.52 %)
THYMUS 4016 774077 (0,40 %) *13757 7722457(1.38 %)
* ~p<0.05
(p-values were obtained using the Wilcoxon Rank Sum Test)
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Table 7.3c : Mean number [Standard Deviation] of viable SL 12.3 and SL 12.4 cells estimated to
be within each organ at 3 hours after injection
SL 12.3 (3 hours) SL 12.4 (3 hours)
n=6 mice n=6 mice
BRAIN 1979 [85J (0.20 %) 2061 [138] (0.21 %)
RIGHT
KIDNEY
3245 [J585J (0.32 %) 3385 [1874] (0.34 %)
LEFT
KIDNEY
2738 [I008J  (0.27 %) 3443 [1715] {OM  %)
RIGHT
LUNG
7508 [4834] (0.75 %) *4072 74276/ (0.41 %)
LEFT
LUNG
4593 [2002] (0.46 %) 2549 [1100] (0.25 %)
LIVER 13158 755557(1.32 %) 12910 776267(1.29 %)
LYMPH
NODES
1931 7727(0.19 %) 2024 [78]  (0.20 %)
OVARIES 2572 [1139] (0.26 %) 2105 7 7 9 7  (0.21 %)
SPLEEN 3909 72577/ (0.39 %) 3987 775567 (0.40 %)
THYMUS 2406 [606] (0.24 %) 2993 7 9 5 4 7  (0.30 %)
* = p<0. OS
(p-values were obtained using the Wilcoxon Rank Sum Test)
#I
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Chart 7.6. The mean percentage of total viable SL 12.3 and SL 12.4 cells present in
different organs at fifteen minutes
“ ♦"SL  12.3 ceils SL 12.4 ceils
80.00 1
Î3_ijjLj 70.00 -0 
LU-J 60.00 -
1>  50.00 - AFTER 15 MINUTESiH-
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Chart 7.7. The mean percentage of total viable SL 12.3 and SL 12.4 cells present at
different organs at one hour
“♦ “ SL 12.3 cells -S L12.4 cells
25.00 1
20.00  -
AFTER 1 HOUR>  15.00 -
1 0 .0 0  -
ORGANS5.00 '
0.00
Î OJXJcO)c a.
p<0.05 p<0.05
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Chart 7.8 The mean percentage of total viable SL 12.3 and SL 12.4 cells present at
different organs at 3 hours
■SL12.3 cells SL 12.4 cells
1.80 1
1.60  -
ni 1.40 '
AFTER 3 HOURS4  1.20  -
1.00  -
0.80 -
P  0.60 -
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Table 7.4a The mean number [Standard Deviation] of cells per gram of tissues at 15 minutes
after injection
SL 12.3 SL 12.4
T im e 15 minutes 15 minutes
Brail! 6172 9188/702& 5/
Right Kidney 42046 54705 /#0545 /
Left Kidney 622S0 [71317] 42486
Right Limg 553619 [1181070] 548264 /7274^99/
Left Lung 691522 462446 /4^99957/
Liver 21006A [236553] 130353 /"757^52/
Lymph nodes 75426 161547 /7^2638 /
Ovaries 29974 [24158] 64261 /96#57 /
Spleen 52120 20685 /27545 /
Thymus 27802 /2965# / 49939 /6494T/
(p~values were obtained using the Wilcoxon Rank Sum Test)
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Table 7.4b The mean number [Standard Deviation] of cells per gram of tissues at 60 minutes
after injection
SL 12.3 SL 12.4
Time 1 hour 1 hour
Brain 6976 41130 [41611]
Right Kidney 44405 [68349] 65403 /67444/
Left Kidney 64371 [109600] 61164[60083]
Right Lung 61572/6077d/^ 242724/23#955/
Left Lung 193607 /22452^ 404964 [390931]
Liver W919A [166719] 30359/75507/
Lymph nodes 94032 278555 /26g727/
Ovaries 20016 /24259/ * 394082 /42^6g6/
Spleen 66371 /723T7&/ 126253 /97755/
Thymus 50026 [63076] 99505
^ -= p < 0 .0 5
(p-values were obtained using the Wilcoxon Rank Sum Test)
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Table 7.4c The mean number [Standard Deviation] of cells per gram of tissues at 3 hours after
injection
SL 12.3 SL 12.4
Tim e 3 hours 3 hours
Brain 5774 [1286] 6723 /7 964 /
Right Kidney 11926 [8477] 15511 [10312]
Left Kidney 12484/497 77 15375 /64527
Right Lung 43834/373357 29178 /22323 /
Left Lung 54363 [18996] 38580 /32307 /
Liver 9255 /44327 8124/47027
Lymph nodes 130532 /7577737 108475 /7756927
Ovaries 30117 /70376 / 41073 /259027
Spleen 26449 [19443] 22036 /7 36727
Thymus 31143 /265657 16880/773257
(p-values were obtained using the Wilcoxon Rank Sum Test)
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Chart 7.9 Mean number of cells (standard error of mean) per gram of tissue at 15 minutes
after inoculation
Mean number of cells 
per gram of tissue
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Chart 7.10 Mean number of cells (standard error of mean) per gram of tissue at 60 minutes
after inoculation
Mean number of 
cells per gram 
of tissue
Mean of SL 12.3 Mean of SL 12.4
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Chart 7.11 Mean number of cells (standard error of mean) per gram of tissue at 3 hours
after inoculation
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Chapter 8 Molecular Studies
In troduction
Studies tliis far have conJSmied a difference in tiunourigenicity and metastatic 
pattern between these two murine lymphoma clones SL 12.3 and SL 12.4. Such 
variation in tumourigenicity, metastatic potential and pattern may be due to a 
certain subset o f genes, which after either being activated or repressed, favour 
die selective growtii of metastatic cells in organ specific environments, hi 
addition, it is postulated that as die end result, differential expression of a series 
of critical genes allow tumour cells to evade die host’s immune system and to 
“home” to and grow m distant target tissues.
As T and B lymphocytes are found to differ only in about 100 genes 
(Hedrick 1984), it is not surprising that such closely related clones as 
SL12.3 and SL12.4 cell lines might only differ in the expression of a few 
genes. Thus, these cell lines provide an attractive model for the study of 
differential genetic expression that might account for their in vivo metastatic 
behaviour.
T he m olecu lar approach  to study SL 12.3 and SL  12.4 cells
Tliree major approaches to identify specific genes expressed in different cell 
lines are differential screening, subtractive hybridisation and more recently, 
differential display (Sunday 1995). All these approaches involved the basic
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molecular techniques o f messenger RNA (or mRNA) extraction and tire 
synthesis o f complementary DN A (or cDNA).
Messenger Ribonucleic Acids or mRNAs
Wlien a cell produces a protein such as an enzyme or surface receptor, the 
DN A sequence responsible for the protein is used as a template for the 
synthesis o f a complementary strand of nucleic acid called mRNA or 
messenger ribonucleic acid. These mRNAs move from the nucleus to the 
cytoplasm to be translated for protein synthesis in the ribosomes. mRNA, 
therefore, provides valuable information as it encodes the genetic 
infonnation being processed in a cell at any one time.
It is known that cells of liigher organisms contain about 100 000 different 
genes but only about 15 % (15 000) o f these genes are expressed in an 
individual cell (Davidson 1976; Liang 1992). Any mRNAs that represent 
less than 0.5 % of tlie total mRNA population of the cell are classified as 
Tare m RNA’ or Tow abundance m RNA’ (Maniatis 1983). Some of these 
rare mRNA sequences have been found to have short half-life and are not 
expressed all the time.
Using mRNA as a template and in the presence of an enzyme called reverse 
transcriptase, cDNAs (complementary deoxyribonucleic acids) can be 
synthesised. cDNAs have the same sequence as the initial gene segment 
which was expressed by the cell. Therefore, if all mRNAs of a cell line can 
be extracted, it is potentially possible to build a library o f cDNA clones 
which represent the genes being expressed in a cell line at a particular time
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point. Subsequently, comparison of cDNAs between cell lines could, 
theoretically, enable us to isolate cDNAs that are expressed exclusively in 
one cell line or tissue compared with another.
Methods for isolating genes that are exclusively expressed in one cell 
line
/. Differential Screening (Sunday 1995)
mRNAs o f a cell line to be studied are reverse transcribed to their cDNAs.
A cDNA libraiy is then prepared in vectors such as Bluescript or Phage and 
plated onto an agar. The library is plated at a low enough density to visualise 
individual plaques representative as a single cDNA clone. “Lifts” or imprints 
o f the agar-plated cDNAs are made onto nitro-cellulose membranes that are 
then screened with ^^P-labelled cDNA probes synthesised from cell lines of 
interest (Figure 8.1). Clones expressed in both cell lines will be identified as 
labelled plaques whereas plaques representating clones not expressed in the 
comparison cell line will not be labelled.
Despite being technically straightforward, tliis method is relatively 
insensitive. It is good for detecting high abundance mRNAs but rare mRNAs 
are imdetectable because of the low copy number in the probe pool.
Moreover, differential screenmg is very laborious and time consuming as it 
involves hundreds o f duplicate lifts to identify cDNAs that are more strongly 
expressed in one cell line. Limitations lie in the variation of signal intensity 
and high backgi ormd.
:
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Figure 8.1 Differential screening.
Lift 1
Agar plated 
cDNAs from cell 
line A
cDNA plaques on
nitro-cellulose
membrane
cDNA plaques on
nitro-cellulose
membrane
Lift 2
Labelled cDNA probe 
from cell line A
Labelled cDNA probe 
from cell line B
Low abundance cDNA 
(unlabelled plaques)
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IL Subtractive hybridisation
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Subtracted hybridisation is a well-established and sensitive method. A large 
amount o f total RNA ( -  200 jug ) from a cell line to be studied is 
biotinylated and hybridised with single stranded cDNA probes from cell 
lines o f interest. The biotinylated mRNA:cDNA hybrids, thus, represents 
shared sequence expressed by both cell lines. These double stranded hybrids 
can be separated from unbound smgle stranded cDNAs by adding a large 
protein such as streptavidin to the mixture that binds to the biotin. The 
biotinylated sequences can then be extracted with phenol-chloroform where 
the sequences bound to avidin can be found at the interface between 
aqueous and the organic phase and the unbound single stranded cDNAs 
remam in the aqueous phase. These cDNAs can then be isolated and 
inserted into a suitable vector to make a subtracted library (Figure 8.2).
There are number o f known variations to obtain the subtracted library and all 
o f these can detect rare mRNAs (<0.01 % abundance). Flowever, 
subtraction hybridisation has its limitations. The construction of the cDNA 
library requires a large amount o f total RNA and therefore, needs a large 
amount o f cells or tissue. During this multistep process, there is a possibility 
of losing, contaminating or degrading the rare mRNAs.
5#
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Figure 8.2 Subtractive hybridisation
mRNAs from cell line A
cDNAs from cell line B
Biotin
Biotinylated
mRNA
S/ng/e stranded
mRNAicDNA hybrid unbound cDNA
Streptavidin
Binding of avidin to biotin 
E
« i
rrrro-TT-o + Single stranded unbound cDNA
Phenol-chloroform
extraction
Removed Subtracted library
Ligation into vector
^^P-radiolabel to make subtracted
probes to screen cDNA libraries 
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I ll  mRNA Differential Display
A third technique, mRNA differential display was described by Liang and 
Pardee in 1992 (Liang 1992) to try to isolate and characterise genes that are 
differentially expressed in a particular cell line. This techniques involve two 
molecular tools: Reverse Transcription and Polymerase Chain Reaction.
Reverse Transcription-Polymerase chain reaction 
I. Reverse transcription
Reverse transcription (RT) is a process where cDNAs are synthesised from 
mRNAs using an enzyme called reverse transcriptase that is found in 
retroviruses. An oligonucleotide primer is required to be attached to the end 
of the mRNA strand to initiate this process as the enzyme reverse 
transcriptase builds complementary nucleic acid strand by adding 
nucleotides to the primer. Fortunately, most eukaryotic mRNAs end in a 
string of 50-250 adenylate residues (poly-A tail) and as a result, a single 
oligonucleotide prhner with a string of thymidylate residues (poly-T) is 
normally used for most reverse transcription processes.
Once the cDNAs are synthesised, the reverse transcription process is either 
terminated by denaturing the m RNA templates by an alkali treatment that 
does not affect the DNA or by denaturing the reverse transcriptase enzyme 
by heating the mixture to 94^C. Tins leaves a mixture of pure single stranded
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cDNAs that are then used as templates for PCR.
//. Polymerase chain reaction
Polymerase chain reaction or PCR is an in vitro enzymatic method for the 
synthesis o f specific DNA sequences. It involves repetitive cycles of 3 
processes namely template dénaturation, primer annealing and extension of 
amiealed primers (Figure 8.3). Heated to 94^C, DNA strands are denatured 
to allow primers to amieal to them. The sequence of DN A of interest has to 
be known in order to prepare suitable pair o f primers or amplimers to anneal 
and flank the region of the DNA for amplification. In the presence of DNA 
polymerase, nucleotides are then added to the initiating primer of one end. 
The nucleotides are then extended to build a complementary DNA strand.
In PCR, the end primer extension products in one cycle are used as 
templates for the next cycle, thus, approximately doubling the target DNA 
copies in every cycle. Therefore, a 20 cycle PCR would theoretically yield 
2^° amplifications of the tai'get DNAs. This makes PCR a very sensitive 
process which only require a very small amomit o f DNA as the initial 
template. The cycle then repeats itself imtil specified or when all the 
nucleotides and enzyme are exhausted.
The yield of products in PCR depends on the reaction parameters such as 
enzyme, nucleotide, primer and Mg"^ concentrations. Every different DNA 
template requires different reaction parameters to achieve its maximum 
yield. The enzyme originally used in PCR for extending annealed primers 
was the Klenow fragment of E.Coli DNA polymerase I. Unfortunately, this
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enzyme could be inactivated easily during the template dénaturation process 
when the temperature required is about 94^C, thus, requiring fresh enzymes 
to be added for each cycle. The introduction of the thermostable DNA 
polymerase, Taq polymerase, isolated from Thermus aquaticus, transformed 
PCR. It makes PCR simple, robust and easily automated using a thermal 
cycling device. The reaction components (templates, dNTPs and buffers)
can be added to a single tube and the amplification reaction carried out 
simply by cycling the temperatures within the tube.
i
Figure 8.3 A summary of Polymerase Chain Reaction (PCR)
Dénaturation
Annealing of primers 
and nucleotides
Extension of 
nucleotides
Primer 2
Primer 1
Primer 2
Dénaturation
Primer 1
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Chapter 9 mRNA Differential Dispiay
First described in 1992 by Liang and Pardee, mRNA differential display 
essentially displays the products o f reverse transcription and polymerase 
chain reaction side by side on a sequencing gel. mRNAs can then be directly 
compared between cell lines and any mRNAs of interest can be cut out from 
the gel, reamplified and characterised (Liang 1992).
Basic concept of mRNA differential display
Based on the fact that a mammalian cell has 100 000 genes and only about 
15 % (15 000) are expressed, Liang et al., used a pair o f short and relatively 
non specific primers in the polymerase chain reaction. These short primers 
randomly amplify between 50 to 100 subsets of mRNAs of a cell. This 
nmnber being optimal for display on a gel (Liang 1992).
The primers
Liang et al., use an anchoring 3 ’-primer and an arbitrarily chosen 5’primer 
which prime m random (Figure 9.1).
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Figure 9.1 Primers used in differential display. The 3’-primer is an anchoring oligo(dTs) 
and the arbitrarily chosen 5’-primer anneal randomly.
5’primer 3’primer
 —
  "  ■ ■ I
Selection o f the 3 ’-primer
M ost eukaryotic mRNAs have a polyadenylated (poly-A) tail. Therefore a 
3 ’-primer witli oligo(dTs) such as 5 ’-TnC A  would be able to anchor and 
amieal to the 3 ’ end o f the mRNAs containing TG located upstream of their 
poly-A tail (Figure 9.2). By probability, oligo-dTs with extended two bases 
such as 5 ’TiiCA  would recognise and amplify one twelfth o f the total 
mRNA population because there are 12 different combinations o f the last 
two 3 ’ bases, omitting T as the penultimate base.
-i
A
:
-s
I
107 v |
Figure 9.2 Selection of 3’-primer is based on the poly -A tail of mRNAs 
5 ’ 3'
^ ^ ■ ■ ■ t g a a a a a a a a a a a a a a a a a
  A C T T T T T T T T T T T -5 ’
Selection o f the 5 '-primer
To randomly prime, the arbitrarily selected 5’-primer should be veiy short 
such as 6 to 7 base pairs for it to amieal fairly If equently near the end of a 
cDNA strand (Table 9.1). Unfortunately, in experiments, primers shorter 
than 8 bases do not amplify well and primers with 10 bases amplify between 
50 to 100 base pairs. For comparison, specific primers used in standard PCR 
are usually 20  or more base pairs in length.
Table 9.1. Theoretical calculation and experimental data of the number of mRNA species that 
could be amplified by arbitrary primers with different lengths in combination with an 
anchored oligo(dTs) that binds to 1/12 of mRNAs 3’termini 
(From Liang et a!., 1992)
Length of arbitrary 
primer (bases)
Kilobases per 
binding site
Number of mRNAs displayed
Theoretical Experimental
6 4 150 0
7 16 38 0
8 65 10 0
9 262 2 20-30
10 1049 <1 50-100
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Liang et al., used a decamer, LTK3 (CTTGATTGCC), which is located 278 
base pairs upstream of its poly-A tail of murine lymphocyte thymidine 
kinase mRNA as their arbitraiy 5 ’-primer.
PGR parameters
For differential display, the followmg PCR parameters were first described 
by Liang, et a l ,  (Liang 1992):
40 cycles o f dénaturation at 94^0 for 30 seconds, annealing at 42^C for 1 
minute and extension at 72°C for 30 seconds. This is followed by 5 minutes 
o f elongation at 72^0. These parameters were subsequently optimised by 
Liang et al. when the annealing temperature was lowered to 40°C for two 
minutes (Liang 1993) to increase the sensitivity but at a cost o f slight 
increased background.
The concentration o f deoxynucleoside triphosphates (dNTPs) used was 2pM  
as this was found to be the ideal concentration for specific cDNA 
amplification and also optimal for labelling PCR-products with [^^S]-dATP. 
The reaction is carried out in the presence o f 1 X PCR buffer, a pair o f 
primers and Taq polymerase.
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The Display
The process produces a series o f randomly amplified radiolabelled cDNAs 
from which can be separated by polyacrylamide gel electrophoresis (PAGE). 
Inspection of the gel can identify cDNAs expressed in one cell line but not 
m another. cDNAs o f interest can then be cut directly from the gel and 
eluted by boiling. cDNA of interest can then be reamplifred and analysed.
Extraction of Total Cellular RNA from SL 12.3 and SL 12.4 
cell lines
Method
Both SL 12.3 and SL 12.4 cells ( - 1 X 1 0 ^  cells each) were pelleted and 
stored m ice for the whole procedure. 2 mis of a 4M  Guanidinium 
Thiocynate solution (containing 7 jLiPml of 2-mercaptoethanol) was added to 
lyse and denature the cells to allow collection of total cellular RNA (nuclear 
and cytoplasmic RNA). 2-mercaptoethanol was used as an inhibitor to any 
ribonucleases present (Chomczynski 1987).
The total RNAs in the solution o f cellular debris were extracted using 200 pi 
of 2M sodimn acetate followed by 2 mis of water saturated phenol. The total 
cellular RNAs will be present in the aqueous phase of the mixture while 
DNAs and protems are soluble in the phenol phase. The aqueous phase was 
extracted twice with 400 pi of chloroform / iso-amylalcohol solution before 
precipitating the RNAs using isopropanolol at -20^C ovemigjit. This
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Results
The amount and purity of total cellular RNA extracted from SL12.3 and 
SL12.4 cells (Table 9.2)
20 pg of total cellular RNA from SL 12.3 and SL 12.4 cell lines underwent 
electrophoresis in a denaturmg Formamide/Fomaldehyde 1 % agarose gel 
usmg 1 X MOPS (3-[N-morpholino]-propane sulphonic acid-sodium salt) as 
the running buffer and the results (Figure 9.3)
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technique permits recovery of total RNAs from small quantities o f tissues or 
cells and avoids the ultracentrifugation step of the Guanidinium - CsCl 
technique (Chomczynski 1987).
The purity and amount of the extracted RNAs were estimated usmg a 
spectrophotometer, based on the fact that pure RNA absorbs two times the 
amount of light at the wavelength o f 260nm than at 280nm. Therefore a ratio 
o f 260/280 of 2 represents pure RNA. Any contammation with proteins 
reduces this ratio. Furthermore, it is also known that for single stranded 
RNA, the absorbance of 1.0 at 260 mn corresponds to a concentration of 
40pg/ml.
Table 9.2 Total Cellular RNA extracted from SL 12.3 and SL 12.4 cells
RNA R eading 260 nm 280 nm 260/280 C oncentration
12.3 ist 0.180 0.090
2 nd 0.179 0.089
Average 0.1795 0.0895 2.0 7.18 jLig/pl
12.4 ist 0 .121 0.049
2nd 0 .1 2 0 0.048
Average 0.1205 0.0485 2.5 4.82 pg/pl
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Figure 9.3 Electrophoresis of total RNA of SL 12.3 and SL 12.4 cells in 1 % denaturing RNA 
agarose gel
A
* ''v'
18s
28s
SL 12.3 SL 12.4
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Synthesis of first strand cDNA using reverse transcription
(Protocol supplied with the reverse transcription kit from Gibco BRL)
Method
5 pg of total cellular RNA from each cell line was added to 2.0 pi of 25 piM 
T12CA. Sterile distilled deionised water was used to bring die mixture final 
volume to 12.8 pis. The mixture was incubated at 70°C for 10 minutes and tlren 
cooled on ice immediately.
4.0 pis of 5X first strand buffer, 2.0 pis of O.IM DTT and 0.2 pi of 2 inM 
dNTPs were added to the RNA solution and the mixture was spim briefly and 
then warmed at 37°C for 2 minutes. 1.0 pi (200 units) of SUPERSCRIPT 
REVERSE TRANSCRIPTASE (Gibco BRL) was tiien added to tlie solution to 
give a final volume of 20 pis mixture. The solution was fiien heated at 37°C for 
60 minutes before terminated by heating at 94^C for 5 minutes.
Results
cDNA products from reverse transcription underwent electrophoresis in 1 % 
agarose gel with 1 % TBE as running buffer. A  specimen of total cellular 
RNA that was not reversed transcribed was also run in the agarose gel to act 
as negative control. This specimen should have no bands seen unless 
contaminated by cellular DNA (Figure 9.4)
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Figure. 9.4 Electrophoresis of Reverse Transcription products of SL 12.3 and SL 12.4 cells 
(Total RNAs are successfully reversed transcribed to cDNAs as shown by the 
bands. Non reverse transcribed Total RNA acting as controls did not show any 
bands)
Base pairs
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Amplification and radiolabelling of cDNAs using Polymerase 
Chain Reaction
Method
The criteria o f selecting the arbitrary 5 ’end prnner is the same as Liang et., 
al. However, the mRNA of CD 44 was used and a 10-mer sequence was 
chosen 851base pairs upstream o f EcoRI site (Figure 9.5) (Nottenburg 
1989). CD44 was chosen as this adhesion molecule is found commonly in 
metastasismg lymphoma cell lines. LTK3, the 10-mer used origmally by 
Liang et al., was also used for comparison
Figure 9.5 mRNA of murine CD44 (Nottenburg 1989)
GAATTCTGCG CCCTCGGTTG GCTCCGGACG CCATGGACA AGTTTTGGTGG CACACAGCTT 
GGGGACTTTG CCTCTTGCAG TTGAGCCTGG ACATCAGCA GATCGATTTG AATGTAACCT 
GCCGCTACGC AGGTGTATTC CATGTGGAGA AAAATGGCCG CTACAGTATC TCCCGGACTG 
GGCAGCTGA CCTCTGCCAG GCTTTCAACA GTACCTTACC CACCATGGAC CAAATGAAGT 
TGGCCCTGAG CAAGGGTTTT GAAACATGCA GGTATGGGTT ATAGAAGGA AATGTGGTAA 
TTCCGAGGAT TCATCCCAAC GCTATCTGTG CAGCCAACCA CACAGGAGTA TATATCCTCG 
TCACGTCCAA CACCTCCCAC TATGACACAT ATTGCTTCAA TGCCTCAGCC CCTCCTGAAG 
AAGACTGTAC TCAGTCACA GACCTACCCA ATTCCTTCGA TGGACCGGTT ACCATAACTA 
TTGTCAACCG TGATGGTACT CGCTACAGCA AGAAGGGCGA GTATAGAACA ACCAAGAAG 
ACATCGATGC TTCAAACATT ATAGATGACG ATGTCAGCAG GGCTCCACC ATCGAGAAGA 
GCACCCCAGA AGGCTACATT TTGCACACCT ACCTTCCTAC TGAACAGCCT ACTGGAGATC 
AGGATGACTC CTTCTTTATC CGGAGCACCT TGGCCACCAG AGATCGAGAC 
TCATCCAAGG ACTCCAGGGG GAGTTCCCGC ACTGTGACTC ATGGATCCGA ATTAGCTGGA 
CACTCAAGTG CGAACCAGGA CAGTGGAGTG ACCACAACTT CTGGTCCTAT
AGGAGACCTCAGATTCCAG AATGGCTCAT CATCTTGGCA TCTCTCCTGG
CACTGGCTCT GATTCTTGCC GTCTGCATCG CGGTCAATAG TAGGAGAAGG TGTGGGCAGA 
AGAAAAAGCT GTGATCAAC GGTGGCAATG GGACAGTGGA AGACAGGAAA 
CCCAGTGAGC TCAACGGGGAGCCAGCAAG TCTCAGGAAA TGGTGCATTT GGTGAACAAG
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GAACCATCAG AGACCCCAGA CAGTGTATG ACAGCTGACG AGACCCGGAA TCTGCAGAGT 
GTGGACATGA AGATTGGGGT GTAGTGCCTA CGCCATTAAC TTGAAAAGAC 
AGCACGATTG GAAACGTCAT TGAATTC
Sterile distilled deionised water was added to 2 pis of the cDNA specimen 
to give a final volume of 12.9 pis. The cDNA solution was denatured by 
heating to 94°C.
A  mixture o f 2.0 pis 10 X PCR buffer (1 X PCR), 0.2 pi 200 pM  dNTPs 
(2pM ), 2.0 pis 25pM  T ^C A  (2.5 pM ), 0.4pl 25 pM  CD44 or LTIC3 
(0.5pM ), 1.0 pi (5U/pl) Taq Polymerase and 1.5 pis [^^S]dATPaS 
(~0.5pM ) was added to the cDNA solution. The mixture was covered with 
30 pis o f mineral oil before being subjected to the polymerase cham reaction 
parameters as follow: Template dénaturation at 94^C for 30 seconds 
followed by 40 cycles o f 94°C for 30 seconds, 40^C for 2 minutes and 72°C 
for 30 seconds. This was followed by an elongation period o f 72^C for 5 
minutes (Liang 1993). In experiments where a test gel was nm  without 
[^^SjdATPaS, its volume was replaced by 1.5 pis distilled water.
Results
The products of PCR used for the test gel which did not use [^^S]dATPaS 
underwent electrophoresis in a 1 % agarose gel stained with Ethidimn 
Bromide (Figure 9.6). It was found that the random 5 ’-primer based on the 
oligonucleotide CD 44 primed more efficiently tlian LTK3 (Figure 9.6). As a 
result, all subsequent PCRs with [^^S]dATPaS used CD 44 as tlie random
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5’-primer and their products underwent electrophoresis in a DNA denaturing 
polyacrylamide sequencing gel as shown as an autoradiogram in Figure 9.7.
Figure 9.6 PCR products of SL 12.3 and SL 12.4 without psSjdATPaS using either CD44 or 
LTK3 primers
Base pairs
234
271
281
310
603
872
1078
1353
0
SL12.3 SL12.4 
(CD44) (CD44)
SL12.3 SL12.4 
(LTK3) (LTK3)
Lane 1 = 500 ng of standard  m arker <1)X174/HAEIII 
Lane 2 = 10 |il SL 12.3 PCR products + 2 p.1 6X m arker mixture (CD44)
Lane 3 = 10 |il SL 12.4 PCR products + 2 |il 6X m arker mixture (CD44)
Lane 4= 10 |il SL 12.3 PCR products + 2 fxl 6X m arker mixture (Ltk3)
Lane 5 = 10 fil SL 12.3 PC R  products + 2 1^ 6X m arker mixture (Ltk3)
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Figure 9.7 Autoradiogram showing the cDNA ladders of SL 12.3 & SL 12.4 cells using CD44
Base pairs 
310
281
271
234
7 -SL 12.3 SL 12.4
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Four bauds of cDNAs of interest were identified (Figine 9.7):
Band A : Expressed exclusively in SL 12.4
Band B : Expressed exclusively in SL 12.3
Band C : Expressed exclusively in SL 12.3
Band D : Expressed more in SL 12.4
Elution of cDNAs of interest from dried polyacrylamide gel
Method
The gel containing cDNA band A, B, C and D was vacuumed dried onto 
3M M  paper. The dried gel on paper was covered with cling film and had 
one comer marked with radioactive ink for orientation before being exposed 
to autoradiographic fihn.
Havmg developed the autoradiogram, the cDNA of interest seen on the 
autoradiogram were cut out. The autoradiogram was then realigned with the 
dried gel on paper using the radioactive ink markings (Figure 9.8). The 
corresponding areas o f the dried gel on paper were then cut out with a sharp 
scalpel and the piece o f gel rehydrated by immersing in sterile TE buffer, 
The cDNAs m the gel were eluted out by incubating the mixture at 65^C for 
two hours. All tubes were then centrifuged at 13000 RPM  for twenty 
minutes and 5 pis o f the supernatant was used for reamplification.
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Figure 9.8 Cutting dried gel out from 3 MM paper
Radioactive marker
Dried gel on paper
Autoradiographic
film
Autoradiogram
Bands of cDNA 
of interest were 
cut out of the 
autoradiogram
Autoradiogram and 
dried gel on paper 
were realigned
Corresponding 
areas of the gel 
surface were 
cut out
Cut out pieces of gel 
ready for elution
121
122
Chapter 10 Characterisation of cDNAs of interest
Introduction
The isolated cDNAs have to be characterised before subjected to further 
analysis. Their sequence can then be compared to available cDNAs 
databases to identify previously characterised sequences. i.
•I
To allow sequencing of cDNAs o f interest, a reasonable amount o f the 
cDNAs has to be available. The amoimt of cDNAs eluted from the dried gel 
is insufficient but one way of mcreasing the amount is to insert the cDNA 
mto a vector such as a plasmid then allowing bacteria to replicate the vector. I
V;TA Cloning
Introduction
TA clonmg takes advantage o f the nontemplate-dependent activity of 
thermostable polymerases in PCR wliich add a single deoxyadenosine (A) 
nucleotide at the 3 ’-end of duplex molecules o f the PCR product. This 3 ’end 
A-overhangs is used to insert the PCR product into a vector which contains 
a single deoxythymidine (T) nucleotide at the insertion site (Figure 10.1)
■I
•sr
Figure 10.1 Insertion of PCR product into the vector using the overhang 3'-A tail (Insert) and 
the single 5'-T nucleotide (vector)
PCRPraduet
C o p i e d  f ro m I n v i t r o g e n  C a t a l o g u e  1994
The vector used in this study, the plasmid pCR II (Invitrogen), has certain 
genes inserted into it as shown in Figure 10.2
Figure 10.2 pCRII vector with the different genes inserted into it.
pCR^ll
3.9 kb
Feature Function
lac promoter For bacteria expression of the lacZa fragment for a-
complementation
(blue-white screening)
the lacZa fragment Encodes the first 146 amino acids of p-galactosidase. 
Complementation in trans with the O fragment gives 
active 3-galactosidase for blue-white screening
Kanamycin and 
Ampiciilin 
Resistance gene
Selection and maintenance in E.Coli, especially useful 
when cloning products amplified from penicillin resistant 
plasmids.
C o p i e d  f ro m I n v i t r o g e n  C a t a l o g u e  1994
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This vector is designed to have a lacZa fragment, a gene for p-galactosidase 
expression. The insertion site is within tliis fragment so that a vector with no 
insert will have an uninterrupted lacZa fragment and thus, will be able to 
express P-galactosidase. If  the agar medium that the colonies are grown on 
contams galactose, then the bacteria will be able to metabolise galactose 
fonnmg blue colonies.
On the other hand, bacteria which has a vector with an insert will have an 
interrupted lacZa gene fragment. These bacteria cannot express p- 
galactosidase and hence, will be unable to metabolise galactose, forming 
white colonies.
As these vectors also carry amoxycillin and kanamycin resistant genes, they 
allow their host bacteria to grow m agar hnpregnated with antibiotics. This 
helps to elhninate growth of bacteria which does not contam the vector.
Method
The amount of PCR products required could be calculated using the formula 
provided by Invitrogen as below:
X  ng PCR product = ( Y base pair PCR product) X (50 ng pCRII vector)
I
(pCRII vector size in base pair)
= Y base pair PCR product X (50/3900)
(X ng is the amount o f PCR product o f Y  base pairs to be ligated)
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Three times X  ng is used to give a 1:3 vector: PCR product ratio as 
recommended by Invitrogen. The PCR product that was about 500 base pair 
was added to a mixture of 1 pi of 10 X Ligation Buffer, 2 pi pCR II vector and 
1 pi of T4 DNA ligase. Sterile water was added to give a final volume of 10pi. 
All reagents were supphed in the TA cloning kit {Invitrogen). This ligation 
mixture was incubated at 14 -1 5 %  overnight.
The supplied competent cells were added to 2 pi of 0.5 M  
p-mercaptoethanol. Ip l of the hgation mixture was then added to the competent 
cells. The mixture was incubated in ice for 30 minutes, at 42^C for 30 seconds 
and eventually back in ice for another 2 minutes. 450 pi of prewaimed provided 
medium was added to this mixture. The cells were incubated at 37%  for 1 hour 
with constant shaking at 225 RPM.
These cells were spread on an agar plate that contains amoxycillin and X-gal 
(galactose).
Results
Blue and white colonies were grown up as shown in figure 10.3. Blue 
colonies are bacteria with empty vectors (no insert), thus, able to metabolise 
galactose and turn blue. The white colonies, on the other hand, are bacteria 
with insert in vectors, thus, unable to metabolise galactose and turn white.
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Figure 10.3 Agar plate showing white and blue colonies in TA cloning
Blue
colonies White
colonies
A single white colony was transferred to 2 mis o f LB medium and the 
mixture was incubated overnight at 37%  with constant shaking. 1.5 mis of 
this mixture was subjected to mini-prep to extract the vector from the 
bacteria. The 1.5 mis o f bacteria mixture was pelleted and the medium 
aspirated. The pellet was resuspended in 100 pi of Glucose solution (50mM 
Glucose; 25 mM Tris-HCL at pH 8 & 10 mM EDTA at pH 8.0) and 200pl of 
sodium hydroxide solution (0.2 N NaOH & 1 % SDS). The solution was stored 
in ice for 5 minutes before mixing with 150 pi of potassium acetate solution (5 
M potassium acetate & Glacial acetic acid). Having incubated in ice for 5 
minutes, the solution was centrifuged and the supernatant added to equal 
volume of phenol chloroform solution. The mixture was centrifuged and the 
plasmid precipitated using 2 volumes of ethanol.
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The extracted plasmid was sent to Dr. Fox, Alta Bioscience, Birmingham, UK 
for sequencing. The result o f the sequence usmg M l 3 Forward Prnner is as 
shown in Figure 10.4. No result for the sequence was available using the 
M l 3 Reverse Primer.
Figure 10.4 First specimen: Comparing sequence of vector PCR II (& insert) 
and sequence obtained
EcoRI site
T
->
EcoRI site
T
pCRII V ec to r 
S e q u e n c e
: TCA CAC GAC CTT
: NCA CAC NAC CTT
AAQ COG AA I N S E R T TT CGG CTT AAG AGG
AAG ACG
(Arrows indicate missing segment with insert in the ‘white’ colony bacteria)
The whole procedure was repeated using a second white bacteria colony. 
The result o f the sequence using M l 3 Reverse Prnner is as shown in Figure 
10.5, No result for the sequence was available using the T7 Promoter 
Forward Primer.
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Figure 10.5 Second specimen: Comparing sequence of vector PCR II (& insert) 
and sequence obtained
EcoRI site
T
EcoRI site
T
P C R II V ec to r : AGT GTG CTG 
cDNA S e q u e n c e :  AGT GTG CTG
GAA TTC GGC TT AA GCC GAA TTC TGC 
- GAA TTC TGC
(Arrows indicate missing segment with insert in the ‘white’ colony bacteria)
Both specimens showed that the ‘white’ bacteria colonies sampled revealed 
false positives with blunt self-ligation o f the nucleotides of the vectors. This 
self-ligation was unable to complete the lacZa gene fragment, thus, unable 
to express p-galactosidase and metabolise galactose (‘w hite’ colonies).
Furthermore, the inserted PCR product is flanked on each side by EcoRI 
sites. Therefore, treating any vectors with an insert with restriction enzyme 
EcoRI should reveal two distinct bands (insert + plasmid) on Agarose gel. 
Unfortunately, all ‘wliite’ colonies sampled did not reveal any insert. It is 
not surprising as^he self-ligation happened to be around the EcoRI 
restriction site G AATTC as shown in Figure 10.4 and 10.5. Such higli false 
positives were confirmed using another shnilar kit from Invitrogen and 
therefore, no frirther attempts to use TA cloning for this study.
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R eam plification  and d irect sequencing
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introduction
Liang et al., used a pair short prhners, a 10-mer and 13-mers in their 
differential display PCR. Unfortunately, these primers are too small to be 
successfully used as sequencing primers for the amplified-DNA using 
classical procedures. Therefore, to identify an amplified-cDNA, one has to 
insert hr a vector prior to sequencing analysis, which could be time-
consuming and labour intensive. One such technique, TA cloning, has been 
tried and described above.
i
.W enck et ah, (W enck 1995) described a simplified method using extended
.primers for the reamplification of the isolated cDNA bands from a 
differential display sequencing gel. These reamplified cDNAs and the I,
extended primers are also suitable for direct sequence analysis.
Method
W enck et. ah, extended their 5 ’-decamer by adding an extra nine bases 
(GCGAATTCC) at its 5’end to become a 19-mer. An extra of 8 bases 
(CGGATCCC) was also added to the 5 ’ end of the 3 ’-anchored prnner to 
become a 22-mer.
■I
The prhners used in this reamplification were also extended similarly. The 
5’-random decamer o f CD 44 and the 3 ’-anchoring primer are extended as 
below :
CATCTTGGCA (5 ’-random decamer)
3 ’-CATCTTGGCA- CCTTAAGCG -5'
5^-TTTTTTTTTTTTTCA~3 ' ^ ’-anchoring primer)
5 ^  CGGATCCC TTTTTTTTTTTTTCA-3’.
Sterile distilled deionised water was added to 5 pis of the eluted cDNA 
specimen to give a final volmne o f 32.0 pis. The cDNA solution was 
denatured by heating to 94°C.
A  mixture of 5.0 pis 10 X PCR buffer, 2.0 pis 200 pM  dNTPs, 5.0 pis 
25pM  22-mer, 1.0 pi 25 |llM 19-mer, 5.0 pi (5U/pl) Taq Polymerase were 
added to the cDNA solution. The mixture is then covered with 50 pis of 
mineral oil before subjected to polymerase chain reaction for 40 cycles with
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template dénaturation temperature o f 94^C for 30 seconds followed by the 
following parameters: 40 cycles of 94^C for 30 seconds, 40^C for 2 minutes 
and 72^C for 30 seconds. This is followed by an elongation period of 72^C 
for 5 minutes.
Purification of reamplified cDNAs
Method
Before the reamplified cDNA could be sequenced and further analysed, it 
requires to be purified from contaminant such as oligonucleotides and 
dNTPs.
The reamplified cDNAs for tins study were purified using the Promega 
Magic ™  PCR Preps DNA purification kit. 30 pis o f the reamplified cDNA 
was added to the appropriate volume of the Direct purification buffer and 
resms following the protocol Jhom the Pr omega kit. The cDNA would stick 
onto the resins and other contammants such as dNTPs and oligonucleotides 
are then washed away with 80 % isopropanolol. The attached purified 
cDNA can then be eluted out with TE buffer and used for direct sequencing.
Sequencing of cDNAs
I
Unfortunately cDNA B  was lost durmg its purification. Therefore, only 
cDNAs A, C and D  were available for sequencing. Sequencing was 
perfonned by Dr. Fox, Alta Bioscience, Birmingham, UK. All cDNAs were
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sequenced both up and downstream with the 22-mer and 19-mer primers. 
Sequencing using the 19-mer prnner should end with a product flanked by a 
complementary oligonucleotide sequence of the 22-mer primer that was 
originally used: 3 ’-TGAAAAAAAAAAAAGGGATCCG-5’ (Figure 10.6).
Figure 10.6 Sequencing with 19-mers (5’-end primer)
19-mer
TGAAAAAAAAAAAAGGGA TCCG
Sequencing using the 22-mer primer should end with a product flanked by a 
complementary oligonucleotide sequence o f the 19-mer primer that was 
orighially used : GTAGAACCGTGGAATTCGC (Figure 10.7)
Figure 10.7 Sequencing with 22-mer (3’-end primer)
\GTAGAACCGTGGAATTCGC
132
.:3:.
'" S
Figure 10.8 Sequence of cDNA A using 22-mers as the primer
The results o f sequencing of cDNAs A, C and D are shown in figures 10.8 
to 10.13.
*
10 20 30 40
ANGTGGAAAA TTAAAATCAT TCGAAAAGGT TTAGACTGTC 
50 60 70 80
AAGGGTATGT AATGTTTGTG ATCATAACTG GCGAAAATAT 
90 100 110 120
ATCTTCTAAT AGATGGTCAC CAATGGAAAC AAGACACTGG 
130 140 150 160
TTTGTAGAAG AATAGAAATC ACAGTAGAAC CGTGGAATTC
CA
Figure 10.9 Sequence of cDNA A using 19-mers as the primer
10 20 30 40
CNGGNTTCGN NACNTNTNTT TTTCGTTGGT GACCGTCTAT 
50 60 70 80
GTAGAAGATA GNTTTGGGTC AGTTATGTAT CGTGANCATT 
90 100 110 120
ACTNGCCCTT GACTGTCTAC NCCTTTNCGN TNGATTTTNN 
130 140 150 160
TTTNTANNNA TGTGAGAGTT AAAATCTTTC ATCCTGAANA
170
AAAANGNNGG GATCCG
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Figure 10.10 Sequence of cDNA C using 22-mers as the primer
TGGCCCTNNC GTGGAATCCG CACTTCCCAT GATCGTNCAA
TTATNACAAT CGTNATTTGA TNGTGTNTGT TGTANNCTTT
110 120100
CACATNACNC TTGAGAGAAC GATTTATTCA GTTTGTCAAG
150140130
GGAAGTAGTA IGHCGNAAAA CCGNGGAANT CMC
Figure 10.11 Sequence of cDNA C using 19-mers as the primer
TTNNNANGGC CATTACNCNG GGACNGCCGA ACAAATGNAT
CTCNCATTTG TNATNTNAAN NTTNACNNCT TACTCGAACA
110 120100
NNTNCAATNG TNNTATNGAN CCAATCAANG GGAACTGATT
150 160130 140
GTCACTGTGA TTCCTGCCAG AAAAAAANNA AGGGGANCCG
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Figure 10.12 Sequence of cDNA D using 22-mers as the primer
10 20 30 40
GNTCTNNCGT GGATNNGNAN TTTAAAATAT GTATTCATTT 
50 60 70 80
TTCATAAATT ACATGAGATT ATATCACAAA CTATAATAGA 
90 100 110 120
AAATTAACAG ATGACAGTAG ACTTTAAATA GAATTGTTGG 
130 140 150 160
AAAATCTAAT ACTCTTCAGA AAAGATATAT CACCCAGACT 
170 180 190
TTAACAAAAA TATCCTCTGT AGAACCGTGG AATTCGC
Figure 10.13 Sequence of cDNA D using 19-mers as the primer
10 20 30 40
GCNGGNCATT NTGNGGGNNN GGGGTGATAT ATCTTTTCTG 
50 60 70 80
AAGAGTATTA GATTTTCCAN CAATTCTATT TAAAGTCTAC 
90 100 110 120 
TGTCATCTGT TAATTTNCTA TTATANTTTG TGATATAATC 
130 140 150 160
TCGTGTAATC TATGANANAT GAATACATAA TTTANATGTA 
170 180 190 200
TATTTTAATA AAGATTTNTG TGNNAAAAAN ANNGGGACC
CG
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Chapter 11 Comparison sequences obtained with 
Genbank and Embank data
Searching through the Genbank (Genetic sequence database of nucleic 
acids) and Embl (European M olecular Biology Laboratory) (Pearson 1988), 
the following results have been obtained.
Band A : Exclusively expressed in SL 12.4
Usmg the 22-mer primer, the sequence o f band A has the following 
homologies as shown in table 11.1:
Table 11.1 Homologies of Band A ~ 162 nudeotides (nt) (using 22-mer primer)
Databank entries Nucleic acid % Identity Nt overlap
EMiBBPROMB M28681 
GB:BORPROMB M28681
B.burgdorferei promoter region DNA  
(203 nt)
61.5 135
(20-155)
EM:CEUC18B10 U80024 
GB;CELC18B10U80024
Caenorhabditis elegans 
cosmidClSB (21185 nt)
59.8 132
(14910-15042)
EM;CEF59A1 Z81557 
GB:CEF59A1 Z81557
Caenorhabditis elegans cosmid F59A1 
(45300 nt)
64.8 88
(13430-13518)
GB:HSN114B2Z73416 
EM:HSN114B2 Z73416
Hmnan DNA sequence from cosmid N114B2 
(40523 nt)
66.7 84
(35730-35814)
GB:SCYJL109CZ49384 
EM:SCYJL109C Z49384
S.cerevisiae cliromosome X reading 
(6127 nt)
66.7 81
(2300-2381)
EM:HS597370 W74597 
zd77hl2.sl
Soares fetal heart NbHHl (659 nt) 67.6 74
(70-144)
GB:W74597 W74597 
zd77hl2,sl
Soares fetal heart NbHHl9W (659 nt) 67.6 74
(70-144)
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Using tlie 19-mer primer, the sequence o f band A  has the following 
homologies as shown in table 11.2:
Table 11.2 Homologies of Band A ~ 176 nucleotides (nt) {using 19-mer primer)
Databank entries Nucleic acid % Identity Nt overlap
GB:AA020100 AA020100 
mlt49d03.rl
EM:MMAA20759 AA020100 
mh49d03.rl
Soares mouse placenta (265 nt) 75.3 150
(40-190)
EM:XM17896U17896 
GB;XMU17S96 U17896
Xiphophorus maculatus ERCC2/XPD 
gene (16840 nt)
55.9 145
(13740-13885)
GB:CELF28F9 U70850 
EM:CEUF28F9 U70850
Caenorhabditis elegans cosmid F28F9 
(31967nt)
54.7 128
(12980-13108)
GB:CMU68290 U68290 
EM:CMU68290 U68290
Chelonia mydas clone CM45 (618 nt) 
anonymous nuclear DNA sequence
58.3 127
(420-547)
M:RNTFPID 10926 
GB:RATTFPID10926
Rat mRNA for tissue factor in pathway 
inhibitor (1226 nt)
66.7 117
(1070-1187)
EM:MMGS00900 D19510 
GB:MUSGS00900 D19510
Mouse 3'-directed cDNA, MUSGS00900 
(92 nt)
74.4 90
(2-90)
EM:PFFISP L02822 
GB:PFAHSP L02822
Plasmodium falciparmn heat-shock 
protein (2290 nt)
56.8 88
(370-458)
GB:NVU29474 U29474 
GB:NVU29474 U29474
Nasonia vitripennis NATE PI6 LTR 
(1071 nt)
63.4 82
(710-792)
EM:CEF23B2 Z82266 
GB:CEF23B2 Z82266
Caenorhabditis elegans cosmid F23B2 
(43589 nt)
58.9 73
(9380-9453)
GB:AXCELSYN X54676 
EM:AXCELSYN X54676
A. Xylinum gene for cellulose biopsy 
(10094 nt)
66.2 71
(9970-10041)
EM:FIVTYRK06 M 64611 
GB:HYDTYRKINA M 64611
Hydra vulgaris tyrosine kinase mRNA 
(1186 nt)
66.7 63
(100-163)
GB:CELF33G12U41278 
EM;CEF33G12 U41278
Caenorhabditis elegans cosmid F33G12 
(3126 hit)
63.8 58
(21890-21948)
EM:HSU47924 U47924 
GB:HSU47924 U47924
Hmnan chromosome 12pl3 (79787 nt) 66.7 51
(74800-74851)
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Band C : Exclusively expressed in SL 12.3
Using the 22-mer prhner, the sequence o f band C has the followhag 
homologies as shown in table 11.3;
Table 11.3 Homologies of Band C~ 153 nucleotides (nt) (using 22-mer primer)
Databank entries Nucleic acid % Identity Nt overlap
GB:SCYNL319W Z71595 
EM:SCYNL319WZ71595 
EM:SCYNL317W Z71593 
GB:SCYNL317W Z71593
S.cerevisiae cliromosome XIV 
reading frame ORF YNL319w 
(2064 nt)
57.4 115
(1880-1995)
EM:MMSCP2E14X91151 M.musculus scp2 gene exon 14 
(4825 nt)
55.7 115
(440-555)
GB:SCRPD3COS Z46259 
EM:SCRPD3COS Z46259
S.cerevisiae FY1676 RPD3 gene 
(40050 nt)
57.4 115
(21730-21845)
EM;SC9346 Z48784 
GB:SC9346 Z48784
S.cerevisiae chromosome IV 
cosmid 934 (19236 nt)
54.7 106
(19040-19146)
GB:W94205 W94205 zd30g09.rl 
EM:HSW2053 W94205 zd30g09.rl
Soares fetal heart NbHHl9 (461 nt) 58.6 99
(310-409)
EM :FH10292U10292
GB;FHU10292U10292
Fasciola hepatica clone Fas 3-4 tran 
(439 nt)
58.5 82
(300-382)
EM:RNTCBC2 M63794 Rat T-cell receptor beta-chain 
complex (3203 nt)
65.5 55
(2260-2315)
GB:CCGHGX51969
EM:CCGHGX51969
Cyprinus carpio growth hormone 
gene (2838 nt)
63.6 77
(440-517)
EM:CPGCRL13196 Cavia porcellus glucocorticoid 
receptor (2316 nt)
61.0 77
(610-687)
EMiMMDPl X72310 M.musculus mRNA for DRTF- 
polypeptide 1 (DP-1) (1700 nt)
60.5 76
(870-946)
EM:CEC08E8 Z81464 
GB;CEC08E8 Z81464
Caenorhabditis elegans cosmid 
C08E8 (7977 nt)
61.4 70
(84920-84990)
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Using the 19-mer primer, the sequence o f band C has the following 
homologies as shown in table 11.4:
Table 11.4 Homologies of Band C - 160 nucleotides (nt) (using 19-mer primer)
Databank entries Nucleic acid % Identity Nt overlap
EM:SJPARAD28811
GB:SCMPARAD28811
Schistosoma japonicum mRNA 
for paramyosiii 
(3514 nt)
52.7 129
(3320-3449)
EM:SJ11825 U11825 
GB:SJU11825 U11825
Schistosoma japonicum 
structural mus (4022 nt)
53.5 127
(3360-3487)
GB:PVGLND5 X61293 
EM:PVGLND5 X61293
P.vulgaris gln-delta gene for 
plastid-located glutamine 
syntlietase (4695 nt)
53.2 124
(2310-2434)
EM:HS345XF1 Z51487 
GB:HS345XF1 Z51487
H.sapieiis (D12S1701) DNA 
segment containing (CA) repeat 
(373 nt)
53.0 115
(230-345)
GB:R51024 R 51024 yg71b08.sl 
EM:HS024119 R51024 yg71b08.sl
Homo sapiens cDNA clone 
38646 3' (456 nt)
55.0 109
(160-269)
GB:CEF44D12Z68298
EM:CEF44D12Z68298
Caenorhabditis elegans cosmid 
F44D1 (31853 nt)
53.3 107
(24180-24287)
GB:CET19E10Z46795 
EM:CET19E10 Z46795
Caenorhabditis elegans cosmid 
T19E1 (19463 nt)
56.9 102
(14740-14842)
EM:RNCYPLAM14972 Rat cytochrome P-450-LA- 
omega (2462 nt)
53.9 102
(1980-2082)
EM:MMU70033 U70033 Mus musculus sodium calcium 
exchange (3180 nt)
60.7 61
(3060-3121)
GB;HSA1280 Z83307 
EM;HSA1280 Z83307
Human DNA sequence from 
cosmid A1280 (22253 nt)
65.4 52
(10900-10952)
GB:AA048008 AA048008 mj26hl0.rl 
EM:MMAA48008 AA048008 mj26hl0.rl
Soares mouse embiyo Nb 
(915 nt)
70.8 48
(560-608)
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Band D: Expressed more in SL 12.4
Using the 22-mer primer, the sequence of band D has the following 
homologies as shown in table 11.5:
Table 11.5 Homologies of Band D~ 197 nucleotides (nt) (using 22-mer primer)
Databank entries Nucleic acid % Identity Nt overlap
GB;HSU78045 U78045 
EM:HSU78045 U78045
Human collagenase and stromelysin g 
(79788 nt)
54.8 188
(42810-42998)
GB:AMFGENOM LOG 178 
EM:MIAMMFGEN LOG 178
Apis mellifera mitochondrial genome 
(16343 nt)
59.4 180
(16010 - 16198)
EM:TTMII-IILIN M8730G 
GB:TETMIHILIN M87306
Tetrahymena thermophila 
micronuclear linker histone 
polyprotein (3000 nt)
61.0 177
(660-837)
EM;BTCRYIIIAL03393 
GB:BACCRY1IIA L03393
Bacillus thuringiensis insecticida 
(1692 nt)
62.4 170
(550-720)
EM;SDOXIIRFi X95973 
GB;SDOXIlRFl X95973
S.douglasii mitochondrial OXII & R 
(2945 nt)
62.3 167
(100-267)
GBiTRBKPGEN M9428G 
EM:KTKPGEN M94286
Trypanosoma bracei brucei kinetoplast 
maxicircle genes (23016 nt)
59.1 164
(19610-19774)
EM:CEF59G1 U53332 
GB:CELF59G1 U53332
Caenorhabditis elegans cosmid F59G1 
(25642 nt)
60.7 163
(19240-19403)
EM:HVPER1 X96551 
GB:HVPER1 X96551
H.vulgare Perl gene (1994 nt) 62.7 158
(140-298)
EM:STSTHA M29041 
GB:POTSTHAM29041
S. tuberosum patliogenesis-related 
protein (2896 nt)
58.6 152
(2580-2732)
EM:HSAC76 AC000076 00075; 
EM:HSAC76 AC000076 00075;
HTGS phase 3, complete sequence 
(41098 nt)
61.1 149
(17740-17889)
GB:MISCTRNAX06047
EM:MISCTRNAX06047
Yeast mitochondrial tRNA (1847 nt) 62.8 148
(540-688)
GB:BBU62901 U62901 
EM:BBUG2901U62901
Borrelia burgdorferi thdF gene 
(4239 nt)
61.3 142
(430-593)
EM:CEF58G1 Z81556 
GB;CEF58G1 Z81556
Caenorhabditis elegans cosmid F58G1 
(42328 nt)
58.2 141
(27910-28051)
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EM;CET05D4 Z 81U 5
Caenorhabditis elegans cosmid 
(37039 nt)
58.2 141
(27910-28051)
EM:PML1PM62XM97517 Deer mouse (LlPm62) (1825 nt) 61.2 139
(260399)
GB;CYLCPRBCSL M59080 
EM;CHCSRBCS M59080
Cylindrotheca sp. ribulose-l,5-bi 
(2517 nt)
62.7 134
(210-344)
EM:CEC25F6U39742 
GB:CELC25F6 U39742
Caenorhabditis elegans cosmid C25F6 
(43803 nt)
62.6 131
(19690-19821)
GB:CET05D4 Z81115 
EM:CET05D4 Z81115
Caenorhabditis elegans cosmid T05D4 
(32612 nt)
66.4 128
(11890-12018)
EMiPFCOMPIRA X95275 
GB;PFCOMPIRA X95275
P.falciparum complete gene map 
(15421 nt)
60.2 128
(13780-13908)
GB:CET06D8Z49130 
EM:CET06D8 Z49130
Caenorhabditis elegans cosmid T06D8 
(32009 nt)
62.6 123
(22210-22333)
EM:HH43400 U43400 
GB:HHU43400 U43400
Human herpesvims-7 (HHV7) JI 
(65273 nt)
61.5 109
(136480-136589)
GB:PFU16955 U16955 
EM:PF16955U16955
Plasmodium falciparum ATPase 2 
gene (5361 nt)
65.1 106
(5230-5336)
EM'.CFORIDHFR X94372 C.griseus DNA fragment 17kb downs 
(7321 nt)
64.2 106
(6600-6706)
EM:CEB0280U10438
GB:CELB0280U10438
Caenorhabditis elegans cosmid B0280 
(41088 nt)
61.6 99
(10240-10339)
GB:SPAC4G8 Z56276 
EM:SPAC4G8 Z56276
S.pombe chromosome I cosmid c4G8 
(36933 nt)
69.7 89
(29110-29199)
Using the 19-mer primer, the sequence of band D has the following 
homologies as shown in table 11.6:
Table 11.6 Homologies of Band D ~ 202 nucleotides (nt) {using 19-mer primer)
Databank entries Nucleic acid % Identity Nt overlap
EM:SDMT2TRNA X95419 
GB: SDMT2TRNAX95419
S.douglasii mitochondrial 
tRNA pro (932 nt)
59.4 187
(680-867)
EM:PKCYP73AAD82812 
GB:POPC YP73 A A D 828I2
Populus kitakamiensis cyp 73a 
(5167 nt)
53.3 180
(1760-1940)
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GB:YSTMTTGD K03308 
EM:MIYSTGD K03308
Saccharomyces cerevisia 
mitochondria (628 nt)
57.1 177
(380-557)
GB:MISCTRND X04564 
EMiMISCTRND X04564
Yeast mitochondrial gene for 
transf (628 nt)
57.1 177
(380-557)
GB;M1SC36 X00844 
EM:MISC36 X00844
Yeast mitochondrial DNA with 
tRNA-Asp (628 nt)
57.1 177
(380-557)
GB;BMU07224 U07224 
EM ;BM07224U07224
Bmgia malayi a2 (IV) 
basement membrane(13007 nt)
57.2 173
(3780-3953)
GB:YSCMTCG03 L36887 
EM:MISCCG03 L36887
Saccharomyces cerevisia 
mitochondria (6340 nt)
57.6 172
(2070-2243)
EM:HSU66059 U66059 
GB:HSU66059 U66059
Hmnan germline T-cell 
receptor beta (79783 nt)
55.3 170
(42560-42730)
EM;MIEGGU490 U49052 
GB:EGU49052 U49052
Euglena gracilis cytochrome 
oxidase (2502 nt)
56.3 167
(70-237)
EMiRNAMPAOl M38061 Rattus norvégiens glutamate 
receptor (5787 nt)
60.4 164
(4130-4294)
GB:HUMLIMGP L04193 
EM:HSLIMGP L04193
Human lens membrane protein 
(mpl9) (8540 nt)
61.3 163
(1480-1643)
EM:CCPLAS X62578 
GB:CCPLAS X62578
C. caldarium plastid genes 
ompR’ (7462 nt)
56.2 160
(50-210)
EM:MMKPRLRP K03237 Mouse proliferin-related 
protein mRNA (972 nt)
59.7 159
(750-909)
EM:HS253J14Z8077I
GB:HS253J14Z80771
Human DNA sequence from 
PAC 253J14 (79783 nt)
60.1 158
(3350-3508)
EM;MMMAL J02652 Mouse malate NADP 
oxidoreductase mRNA 
(3129 nt)
57.6 158
(1960-2118)
EM:MMMALEN M26756 Mouse malic enzyme mRNAl 
(3071 nt)
57.6 158
(1900-2058)
EM:MISCTGT1 JO 1533 
GBiYSCMTTGTl J01533
Yeast (S.cerevisiae) 
mitochondrial (716 nt)
62.2 156
(150-306)
GB:MISC10 V00691 
EMiMISClO V00691
Two yeast mitochondrial genes 
for tra (690 nt)
62.2 156
(150-306)
EM:HSMED Y00477 
GBiHSMED Y00477
Human bone marrow serine 
protease gene (5292 nt)
60.1 153
(3580-3733)
GB:PFU48228 U48228 
EM:PF48228 U48228
Plasmodium falciparum 5.8S 57.0 151
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ribosome (4639 nt) (4360-4511)
GB;HSDNA11X54282  
EM:HSDNA11 X54282
Human chromosome 11 DNA 
(3750 nt)
56.8 148
(2180-2328)
GB:CEC41C4Z48045 
EM:CEC41C4 Z48045
Caenorhabditis elegans cosmid 
C41C4 (39750 nt)
56.1 148
(16510-16658)
GB:AA212895 AA212895 
mw86e03.rl
EM:MMAA13252 AA212895 mw86e03.rl
Soares mouse NML Mus m 
(496 nt)
93.8 145
(330-475)
EM:MMD382 D78382 Mouse DNA for tob family 
(2338 nt)
59.4 138
(1490-1628)
EM:MMHSP70B M35021 Mouse heat shock protein 70.1 
(hsp7) (3518 nt)
58.7 138
(730-868)
GB;CEF53H4 Z81089 
EM:CEF53H4 Z81089
Caenorhabditis elegans cosmid 
F53H4 (40380)
56.8 132
(32070-32202)
GB;HSPFIOSCX77337
EM:HSPHOSCX77337
H. sapiens gene for phosphate 
carrier (7969 nt)
60.8 130
(2500-2630)
EM:DDPHOSPHC M95783 
GB:DDIPHOSPHC M95783
Dictyosteliiim discoideum 
phosphoin (2788 nt)
60.8 130
(140-270)
EM:MMCD18X14951 M.musculus mRNA for CD 18 
antigen beta (2828 nt)
58.1 129
(2660-2789)
EM;MMHSP68C M 12573 
GB;MUSHSP68C M12573
Mouse heat shock protein 
(hsp68) mR (1330 nt)
61.4 127
(730-857)
EM;HSF91B7 Z80773 
GB:HSF91B7Z80773
Human DNA sequence from 
cosmid F91B7 (42613 nt)
64.7 119
(31770-31889)
EM :S85184S85184 Cyclic Protein-2=cathepsin 
proenzyme (1790 nt)
60.9 115
(1370-1485)
GB:AA116330 AAl 16330 
mp97cl2.rl
EM;MMAA16330 AAl 16330 m p97cl2.rl
Soares 2NbMT Mus muscu 
(163 nt)
95,6 114
(1370-1484)
GB:PEACPD2 M27309 
EM:CHPSD20I M27309
Pea cliloroplast photosystem II 
gene (4078 nt)
64.6 113
(3940-4053)
GB;HUMHPRTB M26434 
EM:FISHPRT8A M26434
Human hypoxanthine 
phosphoribosyltr 
(56737 nt)
60.0 110
(12380-12490)
GB:XV18SRRNX74763
EM:XV18SRRNX74763
X.vesparum gene for 18 S 
ribosomal R (2177 nt)
61.1 108
(200-308)
EM:VFVICG Y00506 
GB:VFVICG Y00506
Vicia faba vicilin gene. 
(5327 nt)
60.2 103
(1420-1523)
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EM:HS25J6 Z84476 
GB:HS25J6 Z84476
Human DNA sequence 
(57949 nt)
65.9 91
(127350-
127441)
GB:HSJI80M12Z82190
EM:HSJ1SOM12Z82190
Human DNA sequence from 
clone J180 (47543 nt)
63.7 91
(126200-
126291)
EM:CEF40B5 U23182 
GB;CELF40B5 U23182
Caenorhabditis elegans cosmid 
F40B5 (22237 nt)
64.4 90
(12640-12730)
EM;HSBFXIII M64554 
GB:HUMBFXIII M64554
Human factor XIII b subunit 
gene (33206 nt)
67.1 82
(10840-10922)
GB.-CELC49H3 U42436 
EM:CEC49H3 U42436
Caenorhabditis elegans cosmid 
C49H3 
(37516 nt)
65.4 78
(34340-34418)
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Chapter 12 Discussion
The studies described have further characterised the SL 12 murme 
lymphoma model and resulted in the detection and characterisation of three 
unique cDNAs expressed in one of the cell lines versus the other.
The SL 12 murine lymphoma model was chosen for study as it shows the 
followmg features: Firstly, the lymphoma model is simple and clean with 
sister clones differmg in their growth patterns, tumourigenicity, surface 
marker expression and metastatic pattern. Therefore, starting with 2 shnilar 
cell lines which were likely to be genetically similar should increased the 
chance of identifying important differences in gene expression.
Secondly, tlie lymphoma model is easy to maintam in tissue culture with a 
hundred percent cloning efficiency. The cell lines are stable witli their 
tumourigenicity mamtained even after multiple passages.
Thirdly, these lymphoma cell Imes which grow m suspension provide an 
ideal system for remtroducing the cells back into the animal model using 
simple access such as tail vein mjection.
Lastly, both SL 12.3 and SL 12.4 cells have an approximate doubling tune 
o f 48 hours in tissue culture and the median latent period for mice to 
deteriorate after tail vein mjection is 17 days (11-24 days) for SL 12.3 cells 
and 56 days (22-56 days) for SL 12.4 cells. Comparing with known tumour 
models, the short doubling time and latent period provide a suitable in vivo
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metastatic model. For example, the doubling time of the murine melanoma 
B16 cell line is 16 hours (Nicholson 1986) and the median doubling time of 
thirteen known human colorectal cell lines is 39 hours (24 to 110 hours) 
(McBain 1984; M orikawa 1988). Furthermore, in one hundred and twenty- 
seven human tmnour cell lines studied, tumours could be harvested in 70 % 
of the cell Imes within two months after subcutaneous inoculation and in the 
remaining 30 % o f cell lines, tumours were harvested after two months of 
inoculation (Fogh 1977).
In vitro properties of SL 12.3 and SL 12.4
In tissue culture, both SL 12.3 and SL 12.4 cells grow in suspension.
146
Morphologically, the SL 12.3 cells, however, tend to be more diffuse whereas
SL 12,4 cells grow in clumps (Figure 5.1 and 5.2). There was no sig i of eitlier
cell line developing attacliment to tlie culture dishes and they are both
anchorage independent. The differing morphology could be explained by the
cell hnes displaying differing cell surface adhesion molecules. For example, in
epithelial cell lines, it is known that cells expressing E-Cadlieiins will bind to
each other whereas cells that do not express or express poorly fimctioning E-
Cadheiins do not. Moreover, inactivation of other adhesion molecules has little
effect on cell-cell interactions as long as tire E-Cadherins adhesion molecules
.are ftinctional (Pignatelh 1992). Lymphoma cell lines do not usually express E- 
Cadheiins but the surface adhesion marker profile is as yet unknown for these 
two cell lines.
're
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Morphological variation o f cellular growth has also been observed in otiier 
tumour models. Out of twelve similar human colorectal cell hnes established 
and characterised by McBain et al, two cell lines have monolayer epitlieliod 
cells, six cell lines have smooth suiface multilayer spheroidal cells, two cell 
lines with tubular chain of cells and the last two cell lines with grape-hke 
clumps. Similar morphological variations have been observed in cell lines 
estabhshed from human breast carcinomas (McBain 1984).
Under tire same growth condition, both SL 12.3 and SL 12.4 cells appeared to 
have a similar exponential growtli rate and doubling time (Figure 5.3).
However, in tlie presence of such wide standard error of mean for each cell 
count, especially for SL 12.4 cells, it is not possible to conclude that tlie growtli 
rate and doubling time are the same for the two cell lines.
Difticulties in counting technique maybe mainly responsible for this variation 
(Figure 5.3) and in particular clumping o f SL 12.4 cells leads to potential 
dilution, pipetting and counting chamber errors. Furtlier studies are required to 
elhnmate these factors such as attempt at mechanical dispersion using repeated 
pipetting or pre-treatment o f cell clumps with Tiypsm.
Also, m view o f the observed difficulties, other approaches should be 
.considered in firrther studies such as the measuring o f DN A produced from 
each Ihie at defined time points. This would allow an indirect comparison of 
growth rate between SL 12.3 and SL 12.4 cells.
' ■ fI
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In vivo properties of SL 12.3 and SL 12.4
The tumourigenicity o f SL 12.3 cells (10^ cells injected intravenously) was 
100 % with the mice deteriorating with a median of 17 days whereas the 
tumourigenicity o f SL 12.4 cells (10^ cells injected mtravenously) was only 
9 % at 8 weeks. The tumourigenicity o f SL 12.4 cells could be mcreased by 
raising tlie number of cells inoculated such that after the mjection of 10^ 
cells 79 % of animals developed tumours but again with a longer latency 
period than SL 12.3 (48 days versus 17 days median). The latency period 
being similar between the 2 inoculae o f SL 12.4 cells.
In the original studies by M acLeod et ah, the tumourigenicity o f SL 12.3 
cells (10^ cells injected intravenously) was 100 % with a latent period 
between 10 to 16 days post inoculation whereas the tumourigenicity of 
SL12.4 cells (10^ cells injected mtravenously) was 43.3 % with a latent 
period between 34 to 79 days post inoculation. (M acLeod 1985).
The tumourigenicity o f SL 12.3 is therefore identical to that reported by 
M acLeod et al., but that of SL 12.4 lower at 1 X 10^ cells. It is possible that 
mice preserved longer than eight weeks could have continued to develop 
tumours but timmg o f sacrifice m the present study was limited by protocol 
and Home Office regulations.
The lower tumourigenicity observed in 10^ SL 12.4 cells maybe due to cells 
imdergoing phenotypic drift revertmg back to a less tumourigenic phenotype 
after repeated passages or storage. One way of regaining back the more 
aggressive phenotype is to reculture cells from organs o f mice that develop
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metastasis following an inoculation o f SL 12.4 cells. However, this may 
potentially give rise to further subclones, thus, complicating the study.
Macroscopic patterns of SL 12.3 and SL 12.4 cells
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On the other hand, the increased tumourigenicity observed after raising the 
number of SL 12.4 cells per inoculmn to 10 cells is probably due to a higher 
number o f viable tumour cells that have survived die tail vein injection and 
immune system to develop metastasis.
:
There were obvious macroscopic differences between the pattern of 
metastasis between the two cell lines. Mice injected with SL 12.3 cells 
characteristically developed massive hepatosplenomegaly with little obvious 
evidence of metastasis at other sites except in one mouse where renal and 
subcutaneous métastasés were apparent.
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In contrast mice injected with SL 12.4 developed less obvious 
hepatosplenomegaly but obvious métastasés mainly in kidneys, ovaries and 
massive retroperitoneal lymph nodes enlargement with occasional 
subcutaneous and brain métastasés. M ost strikingly, the ovarian métastasés 
were up to 1 cm in diameter whereas ovarian enlargement was never seen in
SL 12.3. The pattern of metastasis between 10^ and 10^ SL 12.4 cells was 
not different although o f course die low number o f mice developing 
metastasis following 10^ cells inoculated makes comparison difficult.
Microscopic analysis of SL 12.3 and SL 12.4 cells
In the original studies by M acLeod et al., there were also macroscopic 
differences between SL 12.3 and SL 12.4 cell lines after intravenous 
inoculation of 10^ cells. SL 12.3 cell line produced diffuse splenomegaly 
with occasional hepatomegaly whereas SL 12.4 cell line appeared to 
produce diffuse involvement o f the liver (37 %) and the spleen (58 %) 
(MacLeod 1985).
IIn addition, mice injected with SL 12.4 cells developed extranodal tumours 
such as massive nodules in the kidneys, tumour mass in the thigh muscle and 
around the knee joint, subcutaneous tumour nodules, orbital and 
intracerebral tumours and massive bilateral ovarian tumours in about 95 % 
of anhnals (MacLeod 1985).
I
The metastatic patterns between the current studies and those previously are 
identical for SL 12.3. Where SL 12.4 is concerned, there were some 
variations between the current study and M acLeod’s, in particular liver 
involvement is slightly higher macroscopically and ovarian involvement 
lower but these differences are not statistically significant. Differences might 
have been expected if  there had been variation in the tumour genotype with 
time, as can occur within cells in culture. These results again suggest that the 
cell lines remain stable.
Previous study has shown that all tumour cells including metastatic lesions 
have similar microscopic appearances. Cells were described as large with 
pleomorphic nuclei and were different from the typical AKR spontaneous
150
thymie lymphoma or the lymphomas developed after the primary explant of 
spontaneous lymphoma cells (M acLeod 1985). However, no attempt was 
made to analyse the metastatic patterns microscopically previously.
The macroscopic difference o f lymphoblasts o f SL 12.3 and SL 12.4 cells 
from normal lymphocytes makes the detection o f these cells obvious in most 
tissues. It is, however, difficult to be confident o f the nature of single cells 
and therefore, a cut off of eight or more lymphoblasts was chosen to score 
the slide as positive and any count o f less than five lymphoblasts were 
scored as negative. W hen the scores are between these two limits further 
sections for the same organs were studied. Future studies might increase the 
accuracy usmg immunocytochemistry of protein specific to SL 12.3 and SL 
12.4 cells, however, similar protein is likely to be expressed by other 
lymphocytes. There are no studies as yet identifying the potential marker 
proteins.
This microscopic analysis depends totally on the experience o f the 
consultant histopathologist. To further reduce potential observer bias and 
errors, the observer randomly analysed the tissue sections without any 
information given whetlier the organs were from mice inoculated with SL 
12.3 or SL 12.4 cells. Reproducibility studies were performed without 
observer’s knowledge to check on consistency o f the analysis. The 
sensitivity o f this study could be further increased by performing statistical 
analysis o f the observer as the whole analysis is observer dependent.
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In the current study with SL 12.3 cells, it was found that there was 
commonly diffuse microscopic involvement o f tissues that were not 
macroscopically enlarged. This was particularly apparent in renal, ovarian, 
lung, brain, thymus and retroperitoneal lymph nodes. The tissues commonly 
involved macroscopically in SL 12.3 such as the liver and spleen also 
showed microscopic involvement. Similarly with SL 12.4, diffuse 
microscopic involvement was also seen in liver, spleen, lung and thymus 
even where macroscopic involvement was not obvious.
These results suggest that both SL 12.3 and SL 12.4 cells are distributed to 
all tissues and the macroscopic differences are mainly due to the rapid 
development o f hepatosplenomegaly and early death o f the SL 12.3 
inoculated mice. Wliile there is no detectable difference between the in vitro 
growth rate o f the two cell lines, it is possible that SL 12.3 is growing faster 
m vivo and that in particular the hepatic growth of SL 12.3 is faster than 
SL12.4. This could be either due to SL 12.3 cells expressing cellular growth 
factor receptors for hepatic growth factors or SL 12.4 cells failing to express 
functional growth factor receptors. An alternative explanation might be that 
the mitial hepatic load o f SL 12.3 cells is greater than SL 12.4, a 
phenomenon that may have resulted from hommg of SL 12.3 cells to hepatic 
parenchyma. This possibility was further investigated by in vivo cellular 
tracking studies.
In vivo cellu lar tracking studies
Re-injectmg labelled cells back into an animal model circulation allows the 
study of earlier stages o f metastasis: tumour cell distribution, trapping and
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extravasation. 5-(^^^I)odo-2-deoxynridine (^^^lUDR) has been found to be 
ideal in labelling cells (Fidler 1970; Hart 1981; Kjonniksen 1991) for 
cellular tracking studies as it is incorporated exclusively into DNA of 
actively dividing cells and is released without being re-utilised by other cells 
when the origiually labelled cells died. The concentration o f  ^ ^^lUDR to be 
used is critical. Sufficient ^^^lUDR has to be used to increase the sensitivity
ifor detecting small numbers o f cells in tissues. However, over concentrated serum with ^^^lUDR will be lethal to tlie cells, hi the current study, 2.0 and
5.0 pCFml of ^ ^^lUDR was found to produce optimal cell labelling without 
causing cell deatii (Chart 7.2, 7.3, 7.4 and 7.5). 2.0 pCFml rather than 5.0 
pCFml was used for further study as the concentration producing minimum 
cellular toxicity is to be preferred to the maximum sensitivity for detection and
2.0 pCFml was more economical for isotope.
The percentage of incorporation of ^ ^^lUDR into both cell lines was relatively 
low (6.9 % and 4.8 % for SL 12.3 and SL 12.4 cells respectively) as compared 
to the original study by Fidler (Fidler 1970). Furtliermore, the percentage of 
incorporation is at least 50 % more in one set of cells compared to the other 
(Table 7.1).
i
As all cells were incubated together in the same environment and with the same 
batch of ^ ^^lUDR, the difference in percentage of incorporation observed is 
most likely due to errors in wasliing and pelleting of cells (page 73) before 
being analysed by the gamma counter. These errors miglit be eliminated in 
further studies but in any biological systems there is likely to be variations tliat 
is beyond experimental control.
In the current study, autoradiograms confirmed that the radioactive iodine was 
taken into tlie nucleus of viable cells. This low percentage of incorporation is 
shown tlierefbre to represent true cellular uptake rather tlian background 
contamination.
The current study showed that tumour cells circulated to all organs within 
fifteen minutes o f inoculation but there is no significant difference in cellular 
dissemination in between SL 12.3 or SL 12.4 cells at fifteen minutes, one 
hour or tliree hours. Exceptions were of higher numbers o f SL 12.4 cells 
seen m cerebral and thymus tissues at one hour post mjection and also, 
liigher number o f SL 12.4 cells per gram o f ovarian tissues at one hour but 
these differences were not apparent at fifteen minutes or three hours and 
therefore, it is unlikely that these are true differences explaining the 
distribution o f metastasis.
Tumour cells passed the lungs and start to accumulate in the liver as early as 
fifteen minutes after tail vein injections (15.4% for SL 12.4 cells to 48.2 % 
for SL 12.3 cells in the liver). An hour after inoculation, labelled cells had 
already circulated to all organs but only 1.3 % of the original cells remained 
viable in tissues tliree hours post inoculation. Such rapid disappearance of 
radioactivity in organs could be due to rapid cell death after tail vein 
injection with the radioactive label being excreted from the system.
Pilot studies showed that no radioactivity was detected in mice 24 hours 
after cell injection. Injected in this way, cells may die rapidly and study by 
Fidler (Fidler 1970) has shown that only about 1 % o f cells survived after 24 
hours. The isotopes fr om dead cells are released mto circulation and rapidly
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excreted by the kidneys without being reutilized by other cells. The reason 
why other cells could not reutilize the isotope after the labelled cell died is 
not fully understood.
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iThe percentage o f incorporation of ^^^lUDR in this study is low. This hasreduced the sensitivity and accuracy o f the technique producing wide
variation in tissue counts. As a result, it is difficult to draw any firm
conclusion from these data. However, this study appears to show similar
tissue distribution of SL 12.3 and SL 12.4 following re-injection which is
.against the hypothesis that there is a difference in tissue homing between the
.two cell lines or tliat the phenomenon of homing exists within this model.
.Within the same cell line, there are differences between distribution of cells 
per gram o f tissues within brain, lungs, liver, lymph nodes and ovaries. 
Shnilar differences are seen with both cell Imes implying that the differences 
in tissue distribution are due to mechanical reasons rather than tissue 
specificity or homing. However, low incorporation o f isotope and therefore, 
a reduction in accuracy of the technique means that the conclusion cannot be 
proved on the current data available.
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As the histological studies show widespread microscopic dissemination of 
tumour cells in tissues, it is possible that in this model, components o f both 
Mechanical and Seed and Soil hypothesis could explain the metastatic 
process. It seems that in the earlier stages o f metastasis, the Mechanical 
hypothesis could be applied to explain the difference in the number o f cells 
in different organs. However, despite poor data from the radioactive studies, 
both the macroscopic and microscopic analysis have shown that there are 
differences in the pattern o f metastasis between the two cell lines that could
a
M olecu lar experim ents  
Extraction of Total RNA / mRNA
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■Inot be explained by the M echanical Hypothesis only. The microscopic 
analysis has shown that the presence of tumour cells in tissues is not always 
followed by the formation o f larger macroscopic metastasis. Some cells 
appeal' to stay dormant or probably grow at a slow rate, thus, givmg rise to 
the observed different metastatic patterns between the two cell lines. This 
supports aspects o f the Seed and Soil hypothesis in that there are differences 
or variations in the growth rate of cells in organs according to response to
,local tissue growth factors. On the other hand, failure o f metastasis
■ :
development in tissues maybe due to host immune factors.
Differential display, as a technique, allows us to identify cDNAs that aie 
exclusively expressed in a cell line. It is totally dependent on the amoimt of 
cDNAs sequence amplified. Therefore, the sensitivity o f the technique 
improves with the purity o f mRNAs isolated as the quality o f the luRNAs 
dictates the maximum amount o f sequence information that can be converted 
to cDNA. Any degradation o f RNA samples and DNA contamination leads 
to less reproducible bands resulting in the increase in the number of false 
positives.
High yield and pure undegraded total RNAs could be obtained from cells or 
tissues using the smgle step method of acid Guanidinium Thiocynate- 
Phenol-Chloroform RNA extraction as described by Chomczynski
i
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(Chomczynski 1987). However, despite careful technique, extracted RNA 
samples could occasionally be contaminated with cellular chromosomal 
DNAs (Liang 1993) which could give false positive results. This can be 
prevented by pre-treating the extracted total RNAs with DNase (Liang 
1993) before subjecting to reverse transcription. The purity of total RNA 
specimens can ftirther be assessed by running non-reversed-transcribed 
controls side by side with reversed transcribed products. Any band in the 
non reversed-transcribed controls would then represent samples 
contaminated with cellular chromosomal DNA that are independent of the 
reverse transcription process. The RNA specimens used in this study were 
shown to be free from D NA contaminants as shown in Figure 9.4.
Only 0.5 % to 2 % o f total RNA population is mRNAs. Therefore, for the 
construction o f a cDNA library a reasonable amount o f total RNAs have to 
be extracted before sufficient mRNAs could be used to construct the cDNA 
library. Moreover, the extracted mRNAs has to be free from the degraded 
mRNAs, tRNAs and rRNAs.
One way of extracting mRNAs directly from cellular or tissue samples is to 
use Dynabeads® biomagnetic separation system {Dynal ®)(Dynal). This 
technique makes use o f the concept that mRNAs usually end with 
polyadenylated tails. Mixing dynabeads (beads that is covalently linked to a 
chain o f 25 nucleotides long deoxythymidylates) with the lysates o f cells or 
tissues allows base pairings between the poly-A tail o f mRNAs and oligo 
(dT) residues that are bound to the beads. These bound products were 
removed from the rest o f the mixture by using strong magnet to pull the 
beads. The mRNAs could then be eluted from the oligo-dTs and precipitated
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out for further analysis. This technique is quick and reduces the chances of 
losmg rare mRNAs.
The technique o f differential display is not dependent on selective extraction 
of inRNA. In amplification, the presence of the polyadenylated tail o f the 
mRNAs is used to anchor one of the primers. This has been confirmed by 
Liang et al., that there is no advantage of using mRNAs over total RNAs as 
a template for reverse transcription and polymerase chain reaction in the 
differential display method. The end results o f cDNA bands were nearly 
identical (Liang 1993). This shows that the RT-PCR method is very specific 
for mRNAs even in the presence o f ribosomal and transfer RNA, thus, 
Rirther suggesting that PCR is a highly sensitive but not a quantitative 
reaction (Sunday 1995). Total RNAs are recommended to be used as 
templates as mRNAs can be contaminated with oligo-dTs by the isolation 
method resulting in exogenous priming in the reverse transcription step.
A  comparison o f mRNAs and total RNAs have been used as template for 
the RT-PCR in this series o f study. It was found that fewer bands were 
produced in the mRNAs samples compared to total RNAs samples (Figure 
12.1). One possible explanation is that rarer mRNAs can easily be lost 
durmg its extraction. Therefore, total RNAs rather than mRNAs have been 
used as templates in this study.
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Figure. 12.1 PCR products using either mRNAs or total RNAs as template
mRNAs Total RNAs
Reverse Transcription
Liang et al., (Liang 1992) has shown that for a 20 pi reverse transcription 
reaction, total RNA as low as 0.02 pg (which is equivalent to RNA from 
200 cells) would be sufficient to produce consistent pattern in the differential 
display. Lowering the RNA to 0.002 pg o f RNA caused sparser pattern of 
bands in the display probably due to loss o f detection o f rarer mRNAs. In 
fact, the intensity o f bands displayed is totally independent o f the
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concentration of total RNA between 2 to 0.02 pg, thus, suggesting that 
under PCR conditions the display method is not very quantitative (Liang 
1993).
.The reverse transcription process was carried out in the presence of 2.5 pM  
of anchormg oligo-dTs and 20 pM  dNTPs. The concentration of dNTPs is 
important, as any increase in its concentration would result in excess of 
dNTPs being carried forward to the subsequent PCR reaction, thus, 
producing a poorer yield in DN A amplification.
■ ft.
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The enzymes most commonly used in reverse transcription aie the reverse 
transcriptase from the Moloney murine leukaemia virus (MMLV) or from 
avian myeloblastosis virus (AMV). Reverse transcriptase, like any enzyme, 
is easily degraded if  left for storage too long or imderwent multiple thawing 
and freezing. A  degraded enzyme yields low amount o f cDNAs resulting in 
display failure. This enzyme should be aliquoted for further use to avoid 
repeated freezing and thawing process
H
Polymerase Chain Reaction (PCRl
In these studies, for the polymerase chain reaction we used an anchoring 
3’end primer and a random 5’end primer to amplify all the reversed 
transcribed cDNAs. In general such a pair o f prhner set can amplify and 
display about 50 to 100 cDNA bands.
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The 3 ’end anchoring primer was an oligo-dTs primer consisting of eleven or 
twelve T ’s with two additional non T bases at its 3 ’end such as T 12M N 
(where M  may be dG, dA or dC and N  maybe dG, dA, dT or dC). These 
two additional bases are important as they provide annealing specificity.
It has been found that if  these two additional bases were lacking, such as in 
degraded and old primers, the primer lost its anchoring device resulting in a 
smear being produced as opposed to defined band patterns (Figure 12.2) 
(Liang 1993). This is because the non anchoring 3 ’end primer anneals and 
prime at different sites o f the poly-A tail o f inRNA resultmg in multiple 
transcript. An example of this is shown in figure 12.3 where older primers 
were used wliich may have become degraded and have lost the anchoring 
device. Smearing o f the gel can also be due to the use o f RNA specimens 
that are contaminated with oligo-dTs as in contaminated mRNA after its 
extraction using oligo-dTs.
Figure 12.2 The importance of the anchoring device in the 3'-end primer
■ T G A A A A A A A A A A A A A A A  
iACTTTTTTTTTTTTTTT
Primer with a specific anchoring device results in only one transcript
i
i
i
TGAAAAAAAAAAAAAAA
_  TTTTTTTTTTTTTTTTT 
__________  TTTTTTTTTTTTTTTTT
Primer with no specific anchoring device results in multiple transcripts resulting in a smear
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Figure 12.3 Smearing as a result of old 3’-end primers which have lost their anchoring device
Furthermore, when T^M A  primers were compared with T 12CA primers in 
differential display, it was found that both primers have similar number of 
bands in the display. This suggests that the M  base (where M  may be dG, 
dA or dC) does not provide any specificity as T^A/A, theoretically, should 
produce three times the number o f bands compared to T 12CA. This implies 
that the penultimate base from the 3 ’end of the T ^M N  primer may exhibit 
considerable degeneracy during priming in the reverse transcription step.
However, when the N  base in the T ^ M #  primer (where M  may be dG, dA 
or dC and N maybe dG, dA, dT or dC) is changed, more bands were 
obtained compared to a change only in the ‘M ’ base. This suggests that the 
specificity o f the primer lies in the N  base (Liang 1993) rather than the ‘M ’ 
base. Therefore, instead o f using twelve different anchoring primers to prime 
10 000 mRNA species, only four anchored primers differing in the ‘N ’ base
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are sufficient. It has also been suggested that the longer the anchoring 
primers, the higher the background and fewer discrete bands produced. In 
this study comparison was made using T nC A  and T 12CA primers (Figure 
12.4). T 12CA prhners produced more bands than T nC A  despite having a 
slightly 'nosier' background (Figure 12.4). One explanation for this is that 
the longer primer anchors more efficiently than the T n base primer. Primers 
shorter than T 12 are unlikely to be useful but the background increases as the 
poly-t tail is lengtliened. This has also been shown in other studies (Liang 
1993).
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Figure 12.4 PCR products on an Agarose gel using either TnCA or T12CA anchoring primers 
showing that as the primers are lengthened the anchorage efficiency increases 
but to the detriment to the increasing background
310
603
872
1078
1353
Using TnCA a s  3 -en d  
anchoring primer
Using T 1 2 CA a s  3 ’- 
end anchoring primer
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The specificity and sensitivity o f the polymerase chain reaction are affected 
by the concentration of enzyme, primers and nucleotides, the number of 
cycles and dénaturation, annealing and extension times.
The concentration o f nucleotides and amiealing temperature greatly 
influences the specificity o f the reaction (Erlich 1991; Zimmermami 1996). 
The concentration o f dNTPs is found to be important in both the reverse 
transcription and polymerase chain reaction. Liang et al., found that the 
optimum concentration dNTPs for reverse transcription is 20 |liM  and 2 pM  
for polymerase cham reaction. Lowering the concentration o f dNTPs to 
2pM  improved the specificity o f DN A  amplification and was found to be 
necessary for labelling PCR products to a high enough specific activity with 
[a-^^S]-labelled ATP to provide high resolution on a DNA sequencing gel 
(Liang 1992). Too high dNTPs concentration in the reverse transcription 
caused over-excess dNTPs for the successive polymerase chain reaction. 
This results in direct competition with labelled dATP resulting m poor
labelling o f cDNAs.
ï;S
To reduce excess dNTPs fi*om contaminating subsequent polymerase chain 
reaction, it has been suggested that the reverse transcription products should 
run through cDNA spun columns. These columns, such as those fi-om 
Pharmacia , are pre-packed with Sephacryl S-300 designed to purify 
cDNAs from smaller molecules such as oligonucleotides, nucleotides and 
phenol. However, in this study, this purification step was found not essential 
if  the concentration of dNTPs was restricted to 20 pM  in the reverse 
transcription step. M oreover, in the purification process, the products can
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easily be lost in the columns and not eluted out, thus, reducing the sensitivity 
o f the method.
In a standard polymerase chain reaction, the annealing temperature for 
nucleotides is usually from 50^C to 70 C, depending on the meltmg 
temperature o f the primers, Tm (the annealing temperature is usually about 
50^C below the calculate Tm). In differential display, the Tm o f the 5 '-end 
short random decamer primer is low and, therefore, the annealing 
temperature for the polymerase chain reaction was suggested to be 42°C in 
the origmal studies (Liang 1992). Subsequently, it was found that lowering 
the annealing temperature down further to 40°C and increasing the annealing 
period from one to two minutes was optimum for the display (Liang 1993).
nucleotide is the radioactivity o f choice to label amplified cDNAs. It has 
low energy emission and produces liigh-resolution discrete bands that are 
ideal for display and direct comparison. Other alternatives include using 
and ^^P that are both o f higher energy emissions and therefore, exposure 
time can be reduced. ^^P has lower emission energy compared to ^^P and 
theoretically, produces more discrete and liigher resolution bands than ^^P. 
On the other hand, comparing to both ^^P and ^^P have higher energy 
emissions, thus, producing less discrete bands and the higher backgroimd. 
Furthermore, these radionucleotides have a shorter half life compared to S. 
In these studies, ^^P was originally used to label the nucleotide but die 
background was high and the bands produced were not discrete enough for 
further analysis.
#
The Display
The amplified and labelled cDNAs were displayed on a 6 % denaturing 
polyacrylamide sequencing gel. Any bands smaller than 300 base pairs can 
appear as doublets or triplets (Figure 12.5). The explanation for this is either 
the additional deoxyadenosine added by the Taq DNA polymerase or a 
slight difference in mobility between the two complementary strands on the 
denaturing gel. This phenomenon has been described in other study using 
differential display (Liang 1993).
Figure 12.5 Triplets seen in cDNAs less than 300 base pairs
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The pattern o f inRNAs m the differential display technique has been found 
to be highly reproducible between duplicates experiments ( > 95 % 
reproducibility by counting discrete bands) (Liang 1993), thus, providing a 
good technique to isolate exclusively expressed genes
In tliis study, RNAs extracted from different batches o f SL 12.3 and SL 12.4 
cells that underwent differential display showed high reproducible rates of 
mRNA bands confirming the finding o f Liang 's original work (Liang 1993).
Recovery of cDNA from dried gel
The recovery o f cDNA is important for further analysis and characterisation 
o f the expressed mRNA. It has been suggested that the polyacrylamide gel 
with the displayed cDNAs should not be fixed witli methanol/acetic acid 
solution before drying as tliis makes the recovery o f cDNAs difficult. Liang 
et al., used the Hoefer's gel eluter (Figure 12.6) to recover the cDNA 
segment from the dried gel in their original paper. Briefly, the cut gel/paper 
is inserted and packed into the conical end of the inner elution tube which is 
pre-filled with 300 pi o f TAB buffer. Any bubbles are dislodged and a piece 
o f blotter paper disk is placed into the tube on top of the gel / paper. A 
porous polyethylene plug is placed on top of the blotter paper (Figure 12.6). 
The tip o f the inner elution tip is then cut off before applymg current 
between the two electrodes. The cDNA are then eluted into the 1.5 mis 
eppendorf tube pre-filled with 4 X TAB buffer. Using this teclinique, Liang 
et al., is able to recover 50 % o f the original cDNA. In this current study, 
this method o f band purification and isolation using the Hoefer gel eluter
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was tried but cDNAs were poorly recovered and insufficient for 
reamplification.
A  second technique was therefore used for cDNA band recovery. Besides 
electroelution as above, cDNAs can also be recovered by rehydrating and 
incubatmg the gel / paper in sterile water. The cDNAs are then eluted out 
(Liang 1993; M ou 1994) by boiling. The eluted cDNAs can then be 
precipitated out with sodium acetate and reamplified with PCR. It has been 
shown that elution of cDNA fi'om dried gel is possible in about 90 % and 
reamplification successful in 95 % of cases using these teclmiques (Liang 
1993; M ou 1994). In the current studies, this method produces good cDNA 
band recovery. TE buffer was used m hydration and elution o f the cDNAs in 
dried gel by incubating the paper / dried gel at 65°C for two hours and all 
four bands were successfully eluted.
"  j- T  ' - tv . ;
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Figure 12.6 The Hoefer’s gel eluter
Porous
polyethylene plug
Blotter 
Gel slice
Cut tip off
Electrode cap
Packed inner 
elution tube
1.5 mis
eppendorf tube
Base
300 }.lI 1 X TAE buffer
300 p! 4 X TAE buffer
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Reamplification
Having recovered the cDNA from the gel, it has to be reamplifred and 
purified in order to sequence it. The process o f TA cloning is described in 
Chapter 10. The advantages o f using this method are that once the sequence 
is integrated into the plasmid, the product o f the plasmid and its insert could 
then be replicated in bacteria easily. The cDNA can be directly sequenced 
witlun tlie plasmid as sequencing promoter sites are included in the 
plasm id's design. Also, the plasmids can be frozen down and stored 
indefinitely.
In the current study, despite incorporation of the cDNAs bands o f interest 
withm the plasmid obtaining white colonies the resulting plasmids, on 
testing, were unstable and sequencing revealed that the cDNA had been lost 
with self blunt ligation o f the vector. Possible explanation o f these is that the 
size o f the insert and tertiary structure was not suitable for this method of 
cloning. Alternatively, the TA links necessary for plasmid stability may have 
been weak or the plasmid unstable at the ECoRl sites (See Chapter 10).
Repeated attempts were made varying the conditions for TA cloning. The 
vector: PCR product ratio was varied between 1:1 and 1:3. Studies were 
conducted both decreasing and increasing the number o f PCR cycles and 
finally a different TA cloning kit were used with new batch obligation 
enzymes and vectors. However, the cells still failed to yield plasmids with 
inserts when sequenced. On each occasion sequencing plasmids from 
bacteria o f the 'w hite ' and 'positive' colonies persistently showing no insert 
with the plasmid having been divided at ECoRl site. This was ftirther
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confirmed by adding E coR l restriction enzymes to these 'positive' 
plasmids. If  the insert is present two bands should be seen where the 
enzymes cut out the insert at E coR l sites. These studies repeatedly 
produced only one band representing the plasmid suggesting that the blunt 
ligation at E coR l sites had aheady occurred before the plasmids were 
inserted into the bacteria.
Invitrogen was contacted regarding this problem but provided no frirther 
usefril explanation regarding the observed phenomenon. TA cloning was 
repeated for more than six months until the isolated cDNA spechnen run out.
During the course of these studies, a second method of amplification of 
cDNAs produced by differential display was published (W enck 1995). This 
involves reamplification and resequencmg with longer prhners based on the 
initial primers used in differential display (See Chapter 10). This metliod 
was successfiil and allowed the direct sequencing o f the products.
Sequences were produced for 3 bands isolated from the differential display. 
Band A  was found expressed exclusively m SL 12.4 cells. Band C was 
expressed exclusively in SL 12.3 and Band D was expressed more in SL12.4 
than SL 12.3. Band B that was expressed exclusively in SL 12.3 was 
unfortimately lost during purification.
These sequences were used to search Embank and Genbank for homologies. 
Significant homologies are those that fall into exons o f a gene that have high 
nucleotide overlap and strong identity.
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The tables below detail the results o f the searches with a description of 
likely significance and gene product under the heading homology.
Homologies of Band A ~ 162 nucleotides (nt) (using 22-mer primer)
Nucleic acid % Identity Nt overlap Homology
B.burgdorferei promoter region DNA 
(203 nt)
61.5 135
(20-155)
Promoter region
Caenorhabditis elegans 
cosmid 0 1 8B (21185 nt)
59.8 132
(14910-15042)
Intron
Caenorhabditis elegans cosmid F59A1 
(45300 nt)
64.8 88
(13430-13518)
Gene : F59Al.e 
Product unknown
Human DNA sequence from cosmid 
N114 B2 (40523 nt)
66.7 84
(35730-35814)
Intron
S.cerevisiae clnomosome X  reading 
(6127 nt)
66.7 81
(2300-2381)
Open Reading Frame
Soares fetal heart NbHHl (659 nt) 67.6 74
(70-144)
Expressed sequence tag
Soares fetal heart NbHHl9W (659 nt) 67.6 74
(70-144)
Expressed sequence tag
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Band A (22-mers) has weak homology with an exon in Caenorhabditis 
elegans coding for an unknown protem, F59A1 .e. The other homologous 
sequences detail above are either introns or EST (expressed sequence tags 
which are micharacterised) or reading frames. This sequence could also be 
in the 3 ’-untranslated region.
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Homologies of Band A ^ 176 nucleotides (nt) (using 19~mer primer)
Nucleic acid % Identity Nt overlap Homologous
Protein
Soares mouse placenta 
(265 nt)
75.3 150
(40-190)
Expressed sequence tag
Xiphophorus maculatus ERCC2/XPD gene 
(16840 nt)
55.9 145
(13740-13885)
Gene : ERCC2/XPD
Caenorhabditis elegans cosmid F28F9 
(31967 nt)
54.7 128
(12980-13108)
Intron
Chelonia mydas clone CM45 (618 nt) 
- anonymous nuclear DNA sequence
58.3 127
(420-547)
Intron
Rat mRNA for tissue factor in pathway 
inhibitor (1226 nt)
66.7 117
(1070-1187)
Intron
Mouse 3'-directed cDNA, MUSGS00900 
(92 nt)
74.4 90
(2-90)
Expressed sequence tag
Plasmodium falciparum heat-shock protein 
(2290 nt)
56.8 88
(370-458)
Intron
Nasonia vitripennis NATE P16 LTR 
(1071 nt)
63.4 82
(710-792)
Intron
Caenorhabditis elegans cosmid F23B2 
(43589 nt)
58,9 73
(9380-9453)
Intron
A. Xyliniim gene for cellulose biopsy 
(10094 nt)
66.2 71
(9970-10041)
Intron
Hydra vulgaris tyrosine kinase mRNA 
(1186 nt)
66.7 63
(100-163)
Gene : Tyrosine kinase
Caenorhabditis elegans cosmid F33G12 
(31261nt)
63.8 58
(21890-21948)
Intron
Human chromosome 12pl3 (79787 nt) 66.7 51
(74800-74851)
Intron
■%
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Band A  (19-mer) has weak homology to X. maculatus ERCC2/XPD exon 
and H. vulgaris tyrosine kinase exon. The other sequences detailed above 
are either introns or EST (expressed sequence tags which are 
uncharacterised).
Homologies of Band C ~ 153 nucleotides (nt) (using 22-mer primer)
Nucleic acid % Identity Nt overlap Homology
S.cerevisiae chromosome
XIV reading frame ORF YKL319w
(2064 nt)
57.4 115
(1880-1995)
Open Reading Frame
M.musculus scp2 
gene exon 14 
(4825 nt)
55.7 115
(440-555)
Intron
S.cerevisiae FY1676 RPD3 gene 
(40050 nt)
57.4 115
(21730-21845)
Intron
S.cerevisiae chromosome IV 
cosmid 934 
(19236 nt)
54.7 106
(19040-19146)
Intron
Soares fetal heart NbHHl 9 (461 nt) 58.6 99
(310-409)
Expressed sequence tag
Fasciola hepatica clone Fas 3-4 
trail (439 nt)
58.5 82
(300-382)
Intron
Rat T-cell receptor beta-chain 
complex (3203 nt)
65.5 55
(2260-2315)
Intron
Cyprinus carpio growtli hormone 
gene (2838 nt)
63.6 77
(440-517)
Intron
Cavia porcellus glucocorticoid 
receptor (2316 nt)
61.0 77
(610-687)
Gene ; Glucocorticoid receptor
M.musculus mRNA for DRTF- 
polypeptide 1 (DP-1) (1700 nt)
60.5 76
(870-946)
Gene : Transcription factor
Caenorhabditis elegans cosmid 
C08E8 (7977 nt)
61.4 70
(84920-84990)
Unfinished
175
Band C (22-mer) has weak homology to Cavia porcellus glucocorticoid 
receptor exon and M. musculus transcription factor exon. The other 
sequences detailed above are either introns or EST (expressed sequence tags 
which are imcharacterised).
Homologies of Band 160 nucleotides (nt) (using 19-mer primer)
Nucleic acid % Identity Nt overlap Homology
Schistosoma japonicum mRNA 
for paramyosin (3514 nt)
52.7 129
(3320-3449)
Intron
Schistosoma japonicum 
stracturai mus (4022 nt)
53.5 127
(3360-3487)
Intron
P.vulgaris gln-delta gene for 
plastid-located glutamine 
synthetase (4695 nt)
53.2 124
(2310-2434)
Promoter
H.sapiens (D12S1701) DNA  
segment containing (CA) repeat 
(373 nt)
53.0 115
(230-345)
Intron
Homo sapiens cDNA clone 
38646 3' (456 nt)
55.0 109
(160-269)
Expressed sequence tag
Caenorhabditis elegans cosmid 
F44D1 (31853 nt)
53.3 107
(24180-24287)
Intron
Caenorhabditis elegans cosmid 
T19E1 (19463 nt)
56.9 102
(14740-14842)
Gene : Transfonning protein etc2
Rat cytochrome P-450-LA-omega 
(2462 nt)
53.9 102
(1980-2082)
Intron
Mus musculus sodium calcium 
exchange (3180 nt)
60.7 61 (3060-3121) Intron
Human DNA sequence from 
cosmid A1280 (22253 nt)
65.4 52
(10900-10952)
Intron
Soares mouse embiyo Nb 
(915 nt)
70.8 48
(560-608)
Expressed sequence tag
tr
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Band C (19-mer) has weak homology to Caenorhabditis elegans 
transforming protein exon. The other sequences detailed above are either 
introns or EST (expressed sequence tags which are uncharacterised).
Homologies of Band 197 nucleotides (nt) (using 22-mer primer)
Nucleic acid % Identity Nt overlap Homology
Human collagenase and 
stromelysin g (79788 nt)
54.8 188
(42810-42998)
Intron
Apis mellifera mitochondrial 
genome (16343 nt)
59.4 180
(16010 - 16198)
Intron
Tetrahymena thermophila 
micronuclear linker histone 
polyprotein (3000 nt)
61.0 177
(660-837)
Intron
Bacillus thiiringiensis 
insecticida (1692 nt)
62.4 170
(550-720)
Intron
S.douglasii mitochondrial 
O X II& R (2945 nt)
62.3 167
(100-267)
Intron
Trypanosoma bnicei brucei 
kinetoplast maxicircle genes 
(23016 nt)
59.1 164
(19610-19774)
Intron
Caenorhabditis elegans 
cosmid F59G1 (25642 nt)
60.7 163
(19240-19403)
Intron
H.vulgare Perl gene 
(1994 nt)
62.7 158
(140-298)
Intron
S.tuberosum pathogenesis- 
related protein (2896 nt)
58.6 152
(2580-2732)
Intron
HTGS phase 3, complete 
sequence. (41098 nt)
61.1 149
(17740-17889)
DiGeorge Critical Region of Human 
Chromosome 22
Yeast mitochondrial tRNA 
(1847 nt)
62.8 148
(540-688)
Intron
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Borreiia burgdorferi ÜidF 
geiie (4239 nt)
61.3 142
(430-593)
Intron
Caenorhabditis elegans 
cosmid F58G1 (42328 nt)
58.2 141
(27910-28051)
Intron
Caenorhabditis elegans 
cosmid (37039 nt)
58.2 141
(27910-28051)
Intron
Deer mouse (LlPm62) 
(1825 nt)
61.2 139
(260399)
Intron
Cylindrotlieca sp. ribulose- 
1,5-biphosphate 
carboxylase/oxygenase small 
& large subunit genes 
(2517 nt)
62.7 134
(210-344)
Intron
Caenorhabditis elegans 
cosmid C25F6 (43803 nt)
62.6 131
(19690-19821)
Intron
Caenorhabditis elegans 
cosmid T05D4 (32612 nt)
66.4 128
(11890-12018)
Intron
P.falciparum complete gene 
map (15421 nt)
60.2 128
(13780-13908)
Gene : rpoD
Caenorhabditis elegans 
cosmid T06D8 (32009 nt)
62.6 123
(22210-22333)
Intron
Human herpesvirus-7 
(HHV7) JI (65273 nt)
61.5 109
(136480-136589)
Gene : H8 
Product : Unknown
Plasmodium falciparum 
ATPase 2 gene (5361 nt)
65.1 106
(5230-5336)
Intron
C.griseiis DNA fragment 
17kb downs (7321 nt)
64.2 106
(6600-6706)
Gene : Dihydrofolate Reductase
Caenorhabditis elegans 
cosmid B0280 (41088 nt)
61.6 99
(10240-10339)
Intron
S.pombe cliromosome I 
cosmid c4G8 (36933 nt)
69.7 89
(29110-29199)
Intron
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Band D (22-mer) has weak homology to Plasmodium falciparum rpoD exon, 
H  herpesvirus-7 H8 exon, Plasmodium falciparum ATPase2 exon and C. 
griseus Dihydrofolate Reductase exon. The other sequences detailed above 
are introns.
Homologies of Band D 202 nucleotides (nt) (using 19-mer primer)
Nucleic acid % Identity Nt overlap Homology
S.douglasii mitochondrial 
tRNA protein (932 nt)
59.4 187
(680-867)
Intron
Populus kitakamieiisis cyp 73 a 
gene for cinnamic acid 4- 
hydroxylase (5167 nt)
53.3 180
(1760-1940)
Intron
Saccharomyces cerevisia 
mitochondria Asp-tRNA 
(628 nt)
57.1 177
(380-557)
Intron
Yeast mitochondrial gene for 
transfer RNA (628 nt)
57.1 177
(380-557)
Intron
Yeast mitochondrial DNA with 
tRNA-Asp (628 nt)
57.1 177
(380-557)
Intron
Brugia malayi a2 (IV) 
basement membrane collagen 
gene (13007 nt)
57.2 173
(3780-3953)
Intron
Saccharomyces cerevisia 
mitochondria tRNA- Leu, Gin, 
Lys, Arg, Gly, Asp, Ser2, Arg2, 
Ala, He, Tyr, Asn genes.
(6340 nt)
57.6 172
(2070-2243)
Intron
Human germline T-cell 
receptor beta (267156 nt)
55.3 170
(42560-42730)
Intron
Euglena gracilis cytochrome 
oxidase submiit 1 (2502 nt)
56.3 167
(70-237)
Intron
Rattus norvégiens glutamate 60.4 164 Intron
I
179
receptor (5787 nt) (4130-4294)
Human lens membrane protein 
(mpl9) (8540 nt)
61.3 163
(1480-1643)
Gene : Hmnan lens membrane 
protein
C. caldarium plastid genes 
ompR’, psbD, psbC, rpsl6 and 
groEL (7462 nt)
56.2 160
(50-210)
Intron
Mouse proliferin-related 
protein mRNA (972 nt)
59.7 159
(750-909)
Gene ; proliferin related protein
Human DNA sequence from 
PAC 253 J14 on chromosome X  
(79783 nt)
60.1 158
(3350-3508)
Repeat region
Mouse malate NADP 
oxidoreductase mRNA 
(3129 nt)
57.6 158
(1960-2118)
Intron
Mouse malic enzyme luRNAl 
(3071 nt)
57.6 158
(1900-2058)
Intron
Yeast (S.cerevisiae) 
mitochondrial THR-tRNA-1 
and Val-tRNA-GUR genes 
(716 nt)
6 1 2 156
(150-306)
Intron
Two yeast mitochondrial genes 
for transfer RNA-Val (690 nt)
62.2 156
(150-306)
Intron
Human bone marrow serine 
protease gene (5292 nt)
60.1 153
(3580-3733)
Intron
Plasmodium falciparum 5.8S 
ribosome (4639 nt)
57.0 151
(4360-4511)
Gene ; large subunit RNA
Human chromosome 11 DNA  
(3750 nt)
56.8 148
(2180-2328)
Intron
Caenorhabditis elegans cosmid 
C41C4 (39750 nt)
56.1 148
(16510-16658)
Intron
Soares mouse NML Mus m 
(496 nt)
93.8 145
(330-475)
EST
Mouse DNA for tob family 
(2338 nt)
59.4 138
(1490-1628)
Intron
Mouse heat shock protein 70.1 
(hsp7) (3518 nt)
58.7 138
(730-868)
Intron
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Caenorhabditis elegans cosmid 
F53H4 (40380)
56.8 132
(32070-32202)
Intron
H.sapiens gene for phosphate 
carrier (7969 nt)
60.8 130
(2500-2630)
Intron
Dictyostelium discoideum 
phosphoinositide-specific 
phospholipase (2788 nt)
60.8 130
(140-270)
Intron
M.musculus mRNA for CD 18 
antigen beta (2828 nt)
58.1 129
(2660-2789)
Intron
Mouse heat shock protein 
(hsp68) mR (1330 nt)
61.4 127
(730-857)
Intron
Human DNA sequence from 
cosmid F91B7 (42613 nt)
64.7 119
(31770-31889)
Intron
Cyclic Protein-2=cathepsin L 
proenzyme (1790 nt)
60.9 115
(1370-1485)
Intron
Soares 2NbMT Mus muscu 
(163 nt)
95.6 114
(1370-1484)
Expressed sequence tag
Pea chloroplast photosystem II 
gene (4078 nt)
64.6 113
(3940-4053)
Intron
Human hypoxantliine 
phosphoribosyltransferase 
(56737 nt)
60.0 110
(12380-12490)
Intron
X.vesparum gene for 18S 
ribosomal R (2177 nt)
61.1 108
(200-308)
Gene : 18s RNA
Vicia faba vicilin gene. 
(5327 nt)
60.2 103
(1420-1523)
Intron
Human DNA sequence from 
clone 25J6 (57949 nt)
65.9 91
(127350-127441)
Unfinished
Human DNA sequence from 
clone J180 (47543 nt)
63.7 91
(126200-126291)
Unfinished
Caenorhabditis elegans cosmid 
F40B5 (22237 nt)
64.4 90
(12640-12730)
Intron
Human factor XIII b subunit 
gene (33206 nt)
67.1 82
(10840-10922)
Intron
Caenorhabditis elegans cosmid 
C49H3 (37516 nt)
65.4 78
(34340-34418)
Intron
1
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Band D (19-mer) has weak homology to Human lens membrane exon.
Mouse proliferin related protein exon, P. falciparum rRNA exon, and X. 
vesparum RNA exon. The other sequences detailed above are introns or 
EST (expressed sequence tags which are uncharacterised).
The significant proteins coded by the homologous sequence are tyrosine 
kinase, ERCC2, transforming protein and proliferin-related protein. All these 
proteins are known to play important roles in metastasis.
Tvrosine kinase
Tyrosine kinase catalyses the transfer o f the y phosphate o f adenosine 
triphosphate to the tyrosine residues. This results in confonnational changes 
of the target protein that modulate its activity.
The tyrosine kinase receptor contains an extracellular ligand recognition site, 
a single membrane spanning and cytoplasmic protein kinase domain. The 
primary structure o f this kinase domain consists o f the catalytic core 
embedded within regulatory sequences, that determines the activity of the 
kinase. When bound to ligand, tyrosine kinase phosphorylates the assembled 
proteins, allowing the transmission o f signal from the environment into the 
cell. Tyrosine kinase receptors are essential for normal growth and 
mutations o f the kinase domain could result in uncontrolled cell grovHh 
(Cadena 1992).
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ERCC
The ftmction of ERCC 1 protein is essential for repair o f damaged DNA by 
ultraviolet light and chemicals. E R C C l deficient mice are imable to repair 
DN A damage and cross-links resultmg in accumulation of unrepaired lesions 
and double strands break o f DNAs. This leads to an increased mutation 
frequency and genome instability o f cells (W eeda 1997).
Transforming protein
These are cytoplasmic proteins that could transform a cell to become 
cancerous. An example is v-src, a mutant of the normal cellular protein c- 
src. It is not known how v-src transforms the cells but direct interaction 
between this protein and the cellular plasma membrane is essential before 
the cell become transformed or malignant (Darnell 1990).
Proliferin-related protein
These proteins are expressed by several murine cell lines during active 
gi'owth and found to be in abundance in mouse placenta. Their function as a 
placental hormone is unknown but they are homologous to all the family of 
the prolactin family (Lmzer 1985). As prolactin has been associated with 
tumours such as breast carcinoma (Reynolds 1997), proliferin related protein 
might be important in tumour biology.
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Chapter 13 Conclusions
This thesis investigates the molecular pathology o f metastasis focusing on 
the mechanisms and differential gene expression responsible for the differing 
observed metastatic patterns o f SL 12.3 and SL 12.4 cell lines. The first 
section of this study was to re-establish the metastatic model and to compare 
the growtli patterns and morphology o f the two cell lines. In the second 
section, the pattern o f metastasis o f the two cell lines was analysed both 
macroscopically and microscopically and the cellular dissemination to 
different organs was studied using radiolabelled ^^^lUDR tumour cells. 
Lastly, in the third section, molecular tools such as differential display were 
used to identify, isolate and characterise possible cDNAs being differentially 
expressed by the SL 12.3 and SL 12.4 cell lines.
Section 1
In vitro studies : Tissue culture and growth characteristics
Aim
Tissue culture studies were done to re-establish and to study the growth 
patterns o f the SL 12.3 and SL 12.4 cell lines
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Results
Approaches used 1
Both cell lines were grown in culture and environment as originally
described (MacLeod 1984). Their morphology in tissue culture was d
, ;documented and their growth patterns were determined by daily cellular i
count for five consecutive days.
I I
'ii-
IBoth cell lines grow well in suspension in tissue culture. SL 12.3 cells grow |
■■«'Sdiffusely whereas SL 12.4 cells grow in clumps. Under the same growth 
condition, both cell lines appeared to have similar growth patterns.
Discussion
In tissue culture, both SL 12.3 and SL 12.4 cell lines are stable with a 
hundred per cent cloning efficiency. Despite similar appearance in their 
growth patterns, it was not possible to conclude that the growth rate and |j
doubling time are the same for tire two cell lines as daily cell coimt showed 
wide standard error o f mean for SL 12.4 cells. This variation is mainly due 
to difficulties in counting technique and in particular, clumping of SL 12.4 
cells leads to potential pipetting and counting chamber errors. Further 
studies are required to eliminate these factors such as attempt at mechanical 
dispersion using repeated pipetting or pre-treatment o f cell clumps with 
Trypsin.
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Further studies
In view o f the difficulties and to further compare the growth patterns o f the 
two cell lines, other approaches should be considered such as the measuring 
o f the amount o f DN A produced from each cell line at defined time points. 
This would allow an indirect comparison of growth rate between SL 12.3 
and SL 12.4 cells
Section 2
In vivo studies -  Macroscopic and microscopic studies
Aim
The pattern o f metastasis o f the two cell lines analysed macroscopically 
were compared with the microscopic findings.
Approaches used
SL 12.3 and SL 12.4 cells were injected into the tail vems o f AKR mice to 
mimic circulating metastatic cells. Autopsies were performed on any mice 
showing signs o f distress or surviving beyond 8 weeks. M acroscopic 
findings o f the organs were recorded for comparison with the microscopic 
analysis o f the same organs by a consultant liistopathologist.
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Results
The tumourigenicity o f 10^ SL 12.3 cells was 100 % o f 11 mice compared to 
only 9 % o f 11 mice with 10^ SL 12.4 cells. However, when the SL 12.4 
cells were mcreased ten fold (10^ cells per inoculum), the tumourigenicity 
was increased to 79 %.
Macroscopically, 10^ SL 12.3 cells appeared to produce metastasis mainly 
in the spleen (100 %) and liver (100 %) whereas 10^ SL 12.4 cells injected 
mice developed large ovarian metastasis and retroperitoneal nodes in 
addition to hepatosplenomegaly (78.5 %).
In addition to confirming the macroscopic findings, microscopic analysis 
showed that SL 12.3 and SL 12.4 lymphoblasts are present in organs that are 
not involved macroscopically. Furthermore, the infiltration pattern of the two 
cell lines differs between organs.
Discussion
Unlike SL 12.3 cells, the tumourigenicity of SL 12.4 cells was lower 
compared to original study (MacLeod). It is possible that mice preserved 
longer than eight weeks could have continued to develop tumours but the 
timing of sacrifice in the present study was limited by protocol and Home 
Office regulations.
Another explanation is that the SL 12.4 clone underwent phenotypic drift 
reverting to a less tumourigenic phenotype. One way to regain the more
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The microscopic analysis depends totally on the experience of the observer 
and attempts were made to further reduce any observer bias and errors by
Further studies
i
aggressive phenotype is to culture cells from metastatic deposits of organs f
i 'following an inoculation o f SL 12.4 cells. However, this may give rise to i |
further subclones, thus, confusing the study.
,1
To allow comparison o f metastatic pattern with SL 12.3 cells, SL 12.4 cells 
were increased to 10^ cells per inoculum resulting in an increased in 
tumourigenicity from 9 % to 79 %. This may be due to an increase bolus of
viable cells in circulation that have higher chances to lodge at capillary sites §
and to evade rapid cell death caused by tail vein injection and the immune 
system.
randomisation o f the tissue sections without any information given whether |
the organs were from the mice inoculated with SL 12.3 or SL 12.4 cells. 
Reproducibility studies were performed without the observer’s knowledge to 
check on consistency of the analysis.
Since microscopic evidence o f widespread tumour cells was found, the 
observed metastatic pattern from the macroscopic studies is more likely to 
be due to differing in vivo growth factors and host immune system. The |
t i tsensitivity of this study could be further increased by performing statistical 
.analysis of the observer and by using immunocytochemistry to identify cells 
directly from the slides. Further in vivo studies need to be perfonned to I.f
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study the different growth rates o f SL 12.3 and SL 12.4 in relation to 
differing growth factors and possibly tissue extracts.
In vivo studies -  Cellular tracking studies
Aim
A  cellular tracking study using radiolabelled ^^^lUDR tumorn cells was 
performed to investigate the possibility that the difference in metastatic 
pattern observed is due to the initial load of cells reaching some organs 
being higher, a phenomenon that might result from homing o f tumour cells to 
a specific tissue site.
Approaches used
Daily cell counts were performed for five days on viable cells that were 
incubated with medium containing various concentrations o f ^^^lUDR. 
Having determined the incorporation rate and the optimum dose of ^^^lUDR 
for cell labelling, both the cell lines were labelled and injected into the tail 
vein of mice randomly. The mice were then sacrificed at different time point 
and the harvested organs were washed before analysed with a gamma 
coimter.
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Results
tThe mean percentage o f incorporation o f ^^^lUDR into both cell lines was 
relatively low (6.9 % and 4.8 % for SL 12.3 and SL 12.4 cells respectively) 
and the percentage of incorporation was at least 50 % more in one set of 
cells compared to the other.
There aie no significant differences in cellular dissemination detected
abetween SL 12.3 and SL 12.4 cells at fifteen minutes, one hour and three 
hours. Exceptions were o f higher numbers o f SL 12.4 cells seen in cerebral 
and thymic tissues at one hour post injection and also higher number of 
SL 12.4 cells per gram o f ovarian tissues at one hour but these differences 
were not appaient at fifteen minutes or three hours.
Discussion i
sThe mean percentage o f incorporation of ^^^lUDR was low and this reduced
"Sthe sensitivity and accuracy o f the technique producing wide variation in 
tissue counts. As a result, it is difficult to draw any fm n conclusions from 
the data. However, this study appears to show similar tissue distribution o f 
SL 12.3 and SL 12.4 cells following reinjection which is against the 
hypothesis that there is a difference in tissue homing between the two cell 
lines or that the homing phenomenon exists within the model.
There are differences observed between distribution of cells per gram of 
tissues in brain, lungs, liver, lymph nodes and ovaries within both cell lines
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implying that the differences in tissue distribution are due to mechanical 
reasons rather than tissue specificity or homing. However, these conclusions 
cannot be proved on the current data available as the low incorporation of 
isotope reduces the accuracy o f the technique.
As all cells were incubated together in the same environment with the same 
batch of ^^^lUDR, the difference in percentage of incorporation observed is 
most likely due to errors in washing and pelleting o f cells before being 
analysed by the gamma counter. This could improve with more practice and 
experiment but in any biological systems there are always going to be 
variation beyond experimental control.
Further studies
In vivo cellular tracking can be studied using another approach such as 
fluorescent labelling technique. Molecule such as PKH26 can be used to 
label cells by incorporating into the lipid bilayer o f cytoplasmic membranes. 
The labelled cells can be detected sensitively in various organs using the 
flow cytometry and fluorescence (Johnsson 1997; Horan 1990). Problems, 
however, may still be encountered during this technique if labelling is not as 
high and small number o f cells being present in different organs.
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Section 3
Molecular Studies
Aim
Having shown that SL 12.3 and SL 12.4 cell lines have different metastatic 
patterns, molecular tools are used to isolate and characterise any genes that 
are differentially expressed in a cell line.
Approaches used
Total RNAs extracted from both cell lines were reversed transcribed to
cDNAs. These cDNAs were amplified and labelled with polymerase chain
reaction (PCR) using an anchoring 3 ’-end primer and a arbitraiy 5’-end 
.primer based on CD44 and LTK3 (Lymphocyte thymidine kinase sequence). 
The products were displayed along each other for comparison in a 
polyacrylamide gel. cDNAs o f interest were cut out, reamplified and 
sequenced. Initial reamplification was attempted using the TA cloning 
system without any success. Subsequent reamplification was then carried 
out successfully using PCR and a pair of extended primers. The cDNAs 
were then compared to known sequences in genetic databases.
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Results
Three cDNAs (Band A, C and D) were isolated and sequenced. Band A  was 
exclusively expressed by SL 12.4 cells and has weak homology to 
ERCC/XPD and tyrosine kinase exons. Band C was exclusively expressed 
by SL 12.3 cells and has weak homology to exons coding for glucocorticoid 
receptor, transcription factor and transforming proteins. Lastly, band D was 
expressed more in SL 12.4 cells than SL 12.3 cells and has weak homology 
to exons coding for rpoD, ATPase2, dihydrofolate reductase and proliferin 
related protein.
Discussion
The differential display teclinique was used to isolate cDNAs that are 
exclusively expressed because tliis method was 'state o f the art’ at the time 
this work was produced. The technique is easily reproducible and requires 
very low concentration of RNAs. The gene products can be compared 
directly and cut out for further reamplification. Unfortunately, the difficulties 
lie in reamplification and sequencing as the primers used were too short for 
conventional technique. Attempts to reamplify using the TA cloning system 
failed because false positives were produced as a result o f self blimt ligation 
at EC oR l sites o f the plasmid. Reamplification was, however, succèssfiilly 
performed using the extended prhners that also allowed subsequent 
conventional sequencing technique.
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Further Studies
The three cDNAs isolated merit further study. Northern blot analysis is 
required to confirm their differential expression. Using them as probes, fiiller 
cDNA sequences can be extracted from mouse cDNA libraries for 
characterisation. For further investigation of the role o f this longer sequence 
on the in-vivo and in-vitro growth rates o f the two cell lines and subsequent 
pattern o f metastasis, the gene can be inserted (transfection) into the genome 
o f the other cell line or deleted (knock-out) from the genome of the 
corresponding normal cell in the mice.
Other approaches to identify differential expressed gene (Carulli 1998) such 
as serial analysis o f gene expression or SAGE (Velculescu 1995) and 
representational difference analysis (Lisitsyn 1995) could be applied to this 
model.
Conclusion
Having established the methods, this thesis will be the foundation to fiirther 
studies on the differential gene expression in human trunour model such as 
colorectal cancer. Primary tumours from the left and the right side of the 
colon, despite similar histological appearance, are known to behave 
differently in metastasis clinically. Differential expression of tliese primary 
tumours, liver and nodal metastasis may help in isolating genes that are 
responsible for their different tumourigenicity and pattern o f metastasis.
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